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ABSTRACT 
β-carotene-15,15’-dioxygenase (BCO1) cleaves dietary carotenoids at the central 15,15’ 
double bond, most notably acting on β-carotene to yield retinal. Much work has gone into the 
description of enzymatic carotenoid cleavage activities of the enzyme, but although pleiotropic 
effects of Bco1 loss on lipid and cholesterol metabolism in vivo have occasionally been 
described, few investigators have reported extensively on this. Furthermore, given the 
intersections of lipid metabolism, cholesterol/steroid metabolism, and carotenoid transport and 
distribution, functions of BCO1 within these interdependent realms is of clear physiological 
relevance. Moreover, since observational data in humans have repeatedly demonstrated that 
tomato carotenoid intake is associated with a reduced risk of primary prostate cancer (PCa), 
fundamental knowledge of the role of BCO1 on steroid and lipid metabolism is imperative for 
proper interpretation of epidemiological and experimental data demonstrating a protective role of 
dietary tomato. Thus, using animal models, we sought to: elucidate the carotenoid cleavage-
independent role of Bco1 on circulating testosterone and prostatic androgen signaling; determine 
the impact of Bco1 on lipid, cholesterol, and retinoid metabolism in the liver, a key organ in the 
metabolism and biodistribution of dietary carotenoids; and evaluate the effects of dietary tomato 
feeding in an animal model of PCa and determine its efficacy in preventing disease progression. 
In Chapter 2, using the Bco1-/- mouse model, we sought to probe the effects of Bco1 
ablation on testicular steroidogenesis, serum testosterone levels, and prostatic androgen 
signaling. Male wild-type (WT) and Bco1-/- mice were raised on carotenoid-free AIN-93G diets 
before sacrifice between 10-14 weeks of age. We observed a significant reduction in serum 
testosterone levels due to Bco1-/- genotype, accompanied by significantly reduced weights of the 
prostate and seminal vesicles. This reduction in serum testosterone may have been driven by 
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significant reductions in the expression of a testicular steroidogenic gene (Hsd17b3) and/or 
Leydig cell populations. Concomitantly, we observed reductions in markers of androgen 
signaling, proliferation, and cell cycle progression in the prostate. Together, these data support a 
hypothesis that Bco1-/- mice exhibit reduced testicular testosterone synthesis, concomitant with a 
lowering of circulating testosterone, resulting in depressed prostatic androgen signaling, 
proliferation, and organ weight. 
In Chapter 3, in order to further probe the impacts of Bco1 loss on lipid and retinoid 
metabolism, we again utilized the carotenoid-free Bco1-/- mouse model. We found that, first, 
adult male Bco1-/- mice accumulate 2-6-fold more hepatic retinyl esters than do WT mice and 
that this accumulation is highly dependent on developmental age, as juvenile mice demonstrated 
significant decreases in retinyl esters as a result of Bco1 loss. Additionally, patterns of hepatic 
lipid esterification are altered by Bco1 loss in adult mice, as evidenced by alterations in unique 
fatty acid species, most notably being a two-fold increase in cholesteryl palmitate. Finally, 
PPAR/RXR signaling may explain at least a portion of the hepatic lipid phenotype observed in 
Bco1-/- mice, including the steatosis reported by several independent investigators. In summary, 
we report that Bco1 loss interacts with developmental age to alter hepatic retinyl ester 
accumulation, even when maintained on a carotenoid-free, vitamin A-sufficient diet. This effect 
may in turn result in altered RXR/PPAR signaling and a disruption of hepatic lipid metabolism. 
 In Chapter 4, we sought to determine whether dietary tomato treatments could reduce the 
PCa progression in a mouse model of lethal PCa. This was provoked by the observation that 
although epidemiological studies continue to find strong protection against advanced and lethal 
PCa with increased tomato consumption, no animal studies have examined the effects of dietary 
tomato on castration-resistant prostate cancer (CRPC), which constitutes the late and lethal stage 
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of human PCa. Therefore, we used a mouse model, the transgenic adenocarcinoma of the mouse 
prostate (TRAMP), to probe this gap in the literature. TRAMP mice (n=30/treatment) were 
treated with either control AIN-93G diet (CON) or 10% w/w lyophilized tomato paste (TP) from 
4 weeks of age until euthanization. A third group, modeling adjuvant dietary intervention, 
consumed CON diet from 4 weeks of age until 12 weeks of age, and then 10% w/w lyophilized 
tomato paste from week 12 until euthanization (TP-I). To induce castration-resistant tumors, all 
animals were castrated at 12 weeks of age. Beginning at 10 weeks of age, mice were monitored 
longitudinally with biweekly ultrasound scans for tumor detection and measurement of tumor 
growth rate. Using this experimental design, we have shown for the first time that dietary tomato 
can reduce CRPC progression in an animal model. CRPC tumor volume and rate of CRPC tumor 
growth were significantly reduced nearly 50% by adjuvant dietary tomato intervention following 
surgical castration. In addition, compared to control feeding, adjuvant tomato treatment reduced 
distant gross metastasis to the lungs, and increased gonadal adipose depot and body weights. 
Importantly, CRPC progression was reduced with achievable levels of dietary tomato intake, and 
through the use of a common tomato food source that is already commercially available to 
consumers. These effects should be replicated and extended in future animal studies to assess 
their potential for clinical translation in men with CRPC. 
In conclusion, this work has revealed that BCO1, a key enzyme involved in carotenoid 
metabolism, impacts steroid, lipid, and retinoid metabolism independent of its role in carotenoid 
cleavage. Further work in animal models and humans is needed, but we have shed additional 
light on a somewhat unexamined corner of the carotenoid field. Future work should utilize our 
findings in mice and assess their relevance in humans. Secondly, we have demonstrated that a 
relevant level and source of dietary tomato can reduce cancer progression in a mouse model of 
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human CRPC. This work requires confirmation and further expansion in order to be considered 
for translation to humans. In total, this dissertation has contributed novel findings to our 
understanding of carotenoid metabolism and bioactivity in vivo.  
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CHAPTER 1 
Literature Review 
Introduction 
Carotenoids are ubiquitous in our environment, with over 600 identified in nature 1. Their 
incredible variety is outweighed still by their sheer abundance – chlorophyll is surely the most 
common pigment on planet Earth and yet both it and carotenoids can be measured in deciduous 
leaves on the level of milligrams per gram 2. Carotenoids’ accumulation indicates their 
importance to the photosynthetic process, in which they have been likened to lightning rods, 
dissipating excess energy whenever more has been absorbed than can be safely harnessed 3.  
higher-order plants are the first to mind and the most commonly celebrated for the carotenoid 
content of their fruits and autumnal foliage, unicellular algae are capable of similarly impressive 
feats. Some strains of Dunaliella salina, which thrive in otherwise inhospitably saline conditions, 
produce copious levels of β-carotene to protect against damage by light and oxidative stress 4. In 
fact, 14% of the total D. salina dry biomass present in the appropriately named Pink Lake in 
Victoria, Australia comes from β-carotene 4. Similarly, the colorful bacterial mats surrounding 
the Firehole Pool hot spring in Yellowstone National Park, Wyoming have been shown to 
produce a polar hydroxylated carotenoid thought to be lycoxanthin 5. Whereas some rare species 
in the kingdom Animalia are capable of carotenoid biosynthesis de novo 6, all other animals must 
acquire carotenoids from their diet. Perhaps the most elegant examples of animals’ abilities to 
harness dietary carotenoids have been described in studies of the feather pigmentation and visual 
systems of birds. The colorful plumage displayed by many birds is a result of sequestration of 
dietary carotenoids in feathers, and the sexually dimorphic nature of this coloration (i.e., that 
males often have more brightly and intricately colored plumage) is due to sex-dependent 
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differences in feather carotenoid deposition 7. Additionally, the cone photoreceptors of the avian 
retina possess richly pigmented oil droplets in their inner segment. These oil droplets accumulate 
distinct carotenoid species in a cell-type-specific manner, where they serve as highly 
sophisticated band-specific lenses that fine-tune spatial and color discriminatory visual abilities 8. 
With carotenoids so abundant throughout nature and with the clearly evolved functions that 
various animal species have developed for use of dietary carotenoids, it is no wonder that these 
compounds have been proposed to have bioactivity in humans, notably in lowering the risk of 
chronic diseases such as cardiovascular disease and cancer 9,10.  
 
Carotenoid Structure 
The biochemical actions of carotenoids as a class of compounds, as well as the 
differences in function of individual carotenoid species, depend first and foremost on their 
chemical structure (Fig. 1.1). At their most basic level, carotenoids are members of the terpenoid 
(also known as isoprenoid) family, to which cholesterol and its derived steroids also belong. The 
basic building block of these compounds is the 5-carbon isoprene, or 2-methyl-2,3-butadiene 
(PubChem CID: 6557). Terpene consists of the condensation of two isoprene subunits. 
Triterpenes, like the cholesterol precursor squalene, consist of three terpene (six isoprene) 
molecules, and thus are 30-carbon terpenoid polymers. Carotenoids belong to the tetraterpene 
subfamily and thus normally contain 40 carbons 11 . This basic structure of long hydrocarbon 
backbones with repeating conjugated double bonds gives carotenoids two of their most 
fundamental properties: hydrophobicity and strong absorbance of light, respectively. The basic 
backbone can be modified, however, as is the case with end-group cyclization of lycopene to β-
carotene, or the addition of oxygen-containing functional groups, as is the case with the 
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dihydroxylation of β-carotene to form zeaxanthin 12. These structural modifications can result in 
drastic changes in chemical properties. For example, lycopene is produced from phytofluene in 
tomatoes through the addition of three double bonds by two enzymes 13. This shifts the 
ultraviolet-visible (UV-vis) absorption spectra of the compound from a λmax of 348 nm, invisible 
to the human eye, to 472 nm, producing a deep red pigment. It is also this highly conjugated 
double bond structure that makes lycopene an incredibly effective antioxidant 11,14. Changes to 
the double bond structure of the molecule affect not only chemical properties, but also biological 
functions. β-carotene is a key provitamin A carotenoid, due to its yield of two molecules of 
retinal upon cleavage at the central 15,15’ double bond 15,16. Retinal is then further converted to 
retinol. However, changing the 5,6 double bond β-ring of retinol to a 4,5 double bond ε-ring 
yields α-retinol, which has only half of the vitamin A capacity 17. The in vivo provitamin A 
capacities of β-carotene (two β-rings) and α-carotene (one β-ring, one ε-ring) reflect this 
structural difference. Other structural changes result in alteration of both chemical and biological 
properties. Hydroxylation of β-carotene at the 3 position of one of its two β-ionone rings yields 
β-cryptoxanthin 12. Not only does this result in a more polar molecule - and now classifies it as a 
xanthophyll carotenoid instead of as a hydrocarbon carotene - but it also modifies its provitamin 
A potential 18. Finally, due to the isomerism possible around double bonds and the high degree of 
unsaturation present within carotenoids, many structural isomers are possible for each 
carotenoid. In fact, Olson and Krinsky estimate that the permitted isomerization states of the 
≥600 natural carotenoids allow for over 200,000 unique carotenoid structures 1. Of course, the 
vast majority of these possible isomers are neither abundant nor present in either the human food 
supply or the human body. Selected isomers of certain carotenoids, though, are both present in 
consumed foods and have biological relevance. Lycopene, for example, has many structural 
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isomers that can be measured in human blood samples 19. Broadly, they can be classified by 
cis/trans conformational identify; all-trans lycopene is the “parent” form and the isomer that is 
overwhelmingly found in foods (80 - 90%), whereas at least half of the lycopene in human 
circulation or tissues is in the cis conformation 20,21. Evidence suggests that these cis isomers 
may be more bioavailable than the all-trans configuration 22,23, but isotopic labeling studies 
convincingly show that cis-to-trans isomerization in vivo, and not differential bioavailability, 
likely explains the majority of the differential biodistribution of lycopene isomers 24,25. 
Conversely, it seems that all-trans β-carotene is more bioavailable than the 9-cis form 26, 
demonstrating the complex biochemistry of carotenoid absorption in vivo. 
 
Carotenoid Absorption in the Gastrointestinal Tract 
Prior to any in vivo digestion, aspects of the preparation and delivery of the carotenoid-
containing meal play a large role in eventual absorption – for instance, food matrix 27, heat 
processing 28, and the co-consumption with dietary fat 29 all modulate the bioaccessibility and 
bioavailability of lycopene. In addition, the type of lipid co-consumed with carotenoids may 
impact bioavailability and eventual tissue distribution 30. Although differences in bioavailability 
exist among the carotenoids, regardless of isomeric conformation or even identity, all 
carotenoids share the same mechanisms and routes of digestion and absorption. Following 
ingestion, carotenoids must be: freed from the food matrix through physical, chemical, and 
enzymatic digestion; hydrolyzed from esterified fatty acids, if present; solubilized in lipid 
droplets or mixed micelles; absorbed into the enterocyte via micelle uptake, passive transport, or 
active transport (through SR-BI or CD36); packaged into chylomicrons; secreted into the lymph; 
and united with venous blood for distribution to peripheral tissues 31. Recently, genetic 
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regulation of active transport of carotenoids has been described 32. Through this mechanism, 
vitamin A inhibits intestinal expression of SR-BI via intestine-specific homeobox (ISX), a 
retinoic acid receptor (RAR) target gene. This system functions as a negative feedback loop to 
inhibit the absorption of provitamin A carotenoids and prevent retinoic acid-induced 
hypervitaminosis. However, as lycopene and other non-provitamin A carotenoids are also 
absorbed via SR-BI 33, retinoid signaling through this network serves to inhibit all carotenoid 
absorption, regardless of vitamin A potential. It is for this reason that we and others have utilized 
reduced (but sufficient) levels of dietary preformed vitamin A when examining the absorption 
and metabolism of carotenoids in vivo 34–36. Somewhat ironic, then, is the fact that since 
preformed dietary vitamin A is not absorbed through SR-BI and its uptake is seemingly 
dependent on either facilitated or passive diffusion 37, excess intake causes toxicity. This occurs 
even while the RAR – ISX – SR-BI cascade efficiently inhibits the absorption of provitamin A 
and non-provitamin A carotenoids alike.  
 
Bioaccumulation of Dietary Carotenoids, Particularly those of the Tomato, in Peripheral Tissues 
Distribution of carotenoids to peripheral tissues is achieved through the same route of 
lipoprotein metabolism that is utilized by dietary fatty acids. As carotenoids are effluxed within 
chylomicrons from intestinal enterocytes into the lymph, they bypass the portal circulation and 
hepatic “first-pass” metabolism. After chylomicron remnants return to the liver following 
peripheral off-loading of prandial triglycerides, they are re-packaged as very low-density 
lipoproteins (VLDL) and exported back to the periphery. While in circulation, VLDLs lose 
triglycerides, becoming low-density lipoproteins (LDL), which are the vehicles most responsible 
for delivery of carotenoids to peripheral tissues. In fact, carotenoids do not distribute to various 
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peripheral tissues in equal amounts 30,38–40, which may be explained by the relative tissue 
expression levels of LDL receptor 41. Liver tissue invariably accumulates the largest mass of 
carotenoids, which is not surprising, but other tissues show striking differences. For example, the 
adrenals and testes, both steroidogenic organs, accumulate divergent levels of total carotenoids 
(adrenals high, testes low; 30,39,40). Moreover, the profile of carotenoid distribution is also tissue-
specific – even when provided with higher serum concentrations of phytoene than of lycopene, 
the prostate and seminal vesicles accumulate lycopene but not phytoene 39. It is currently 
unknown what tissue-specific mechanisms of carotenoid uptake mediate these effects, but their 
elucidation would fortify arguments in favor of evolved bioactive functions of these compounds 
in humans.  
 
Carotenoid Metabolism – Carotenoid Oxygenases: the Early Days 
Investigations of carotenoid metabolism have roots as far back as the early twentieth 
century; at that point, scientists were primarily concerned with the identities and metabolism of 
vitamin A and “carotene” 42. Scientists had questioned the logic that “the fat-soluble vitamine” 
and carotenoids were related 43, arguing that raising rodents on diets free of carotenoids produced 
no ill effects, whereas vitamin A-deficient animals suffered well-documented symptoms of 
deficiency 44. However, in 1930, Moore proposed that “carotene” could be converted to vitamin 
A in vivo, thus beginning the modern era of research on provitamin A carotenoids 45. In 1949, the 
work of Thompson, Ganguly, and Kon demonstrated that in addition to the liver, the intestine 
had a capacity for conversion of β-carotene to vitamin A 46. A true watershed moment for 
carotenoid research came in 1965, with the independent discovery by two laboratories of the 
enzymatic cleavage of β-carotene to retinal using crude intestinal and hepatic purifications 47,48. 
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Olson and Hayaishi called their enzyme β-carotene-15,15ʹ-oxygenase, while Goodman and 
Huang provided no suggestion as to naming. Although we now know that the enzyme they 
discovered cleaves other carotenoids in addition to β-carotene 49, modern investigators have 
retained Olson and Hayaishi’s β-carotene-specific nomenclature for the enzyme.  
One year after their initial discovery, Goodman et al. utilized double labeling experiments 
to propose that the enzymatic cleavage mechanism was that of a dioxygenase 50. These results 
were not unequivocal, however, as the authors used 14C and 3H labels, rather than labeled 
oxygen. Concrete assignment of a dioxygenase reaction mechanism would require confirmation 
that the oxygen atoms in the two retinal products originated exclusively from molecular oxygen, 
and not from water. Subsequent work using H218O suggested that the reaction mechanism was a 
monooxygenase cleavage (i.e., one molecule of retinal deriving its oxygen from water and one 
from molecular oxygen), but that study was plagued by methodological issues that likely allowed 
molecular exchange of isotopic oxygen label with the aqueous reaction medium 51. Nevertheless, 
the enzyme was subsequently categorized as a monooxygenase (EC 1.14.99.36) and the enzyme 
became known as β-carotene-15,15ʹ-monooxygenase (BCMO1). However, in 2014, a carefully 
controlled experiment presented the most convincing evidence to date regarding the enzymatic 
mechanism of central β-carotene cleavage, clearly reestablishing the enzyme as a dioxygenase 52. 
The approved human gene symbol (BCO1) provided by the Human Genome Organization 
(HUGO) Gene Nomenclature Committee (HGNC) attempts to avoid the confusion that has 
resulted from the various mechanism-derived names that this enzyme has been given over its 
four decades of study (BCMO1, CMO1, CMO-I, BCDO, BCDO1). For clarity and congruity 
with HGNC standards, the enzyme will therefore be referred to in this document only as β-
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carotene-15,15ʹ-dioxygenase or BCO1, even in cases where primary authors utilized other 
names. 
Following the discovery of BCO1, the Olson group described its substrate specificity, 
demonstrating a preference for the 15,15ʹ central bond, but also arguing that enzyme activity was 
maximal for the β-carotene metabolite β-apo-10ʹ-carotenal 15. This latter claim would be found to 
be inaccurate, as the availability of a highly purified human enzyme 45 years later revealed that 
conversion of β-carotene was much higher than that of equimolar concentrations of β-apo-10ʹ-
carotenal, even accounting for the two-fold difference in provitamin A potential between the two 
substrates 49. Still, other revelations by the Olson group regarding BCO1 have proved prescient, 
such as use of chelating agents to predict that the enzyme requires non-heme iron as a cofactor, 
as well as the realization that intestinal purifications from felines demonstrated no catalytic 
activity 53. Indeed, other obligate carnivores such as the ferret (Mustela putoius furo) are not 
effective converters of β-carotene to vitamin A 54. 
 
Carotenoid Metabolism – Molecular Identification and Characterization of Carotenoid 
Oxygenases 
Despite thorough characterization of tissue purifications of BCO1, its sequence identity 
remained a mystery until the turn of the 21st century. This changed in early 2000, when two 
groups separately reported the cloning of two eukaryotic β-carotene-15,15ʹ-dioxygenases within 
two months of one another 55,56. On par with the 1965 discovery of enzymatic β-carotene 
cleavage by Olson and Hayaishi and Goodman and Huang, this was another seminal moment in 
carotenoid research. However, armed with cDNA sequences and predicted primary protein 
structures, subsequent advances came in greater number and more rapidly. Whereas the original 
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reports identified the sequences of Drosophila 56 and chicken 55 genes, Redmond et al. 
subsequently identified the first mammalian β-carotene-15,15ʹ-dioxygenase in mice 57. Several 
months later, in the same journal, the Blaner group replicated the finding 58. This was followed 
shortly by recombinant expression, purification, and biochemical characterization of the human 
BCO1 enzyme by Lindqvist and Andersson 59. In agreement with the early purifications of 
BCO1 from tissue homogenate supernatant 47,48, investigators consistently found that the cloned 
and recombinant enzymes were present in the cytoplasm, rather than other cellular compartments 
55,57,59.  
Given the function of BCO1 in cleavage of dietary provitamin A carotenoids, obvious 
functions outside of the liver and gastrointestinal (GI) tract were not clear and expression was 
expected to be largely limited to those tissues. Using two unique monoclonal antibodies directed 
against the human enzyme, Lindqvist et al. provided what remains as the most comprehensive 
screen of BCO1 expression in human tissues 60,61. This led to the realization that BCO1 was 
expressed more broadly than previously anticipated. While high levels of staining were indeed 
found in hepatocytes and throughout the GI tract, exocrine epithelia of the pancreas (acinar cells) 
and uterus (endometrium) also demonstrated high levels of BCO1 expression. Interestingly, the 
pancreatic endocrine epithelium (islet cells) does not express BCO1, and other endocrine cell 
types in the adrenals, ovaries and testes stained positively for BCO1, but only weakly to 
moderately. Glandular epithelia in the prostate expressed only low levels of BCO1, and the 
stroma lacked expression altogether. Similarly, stromal cells in the uterus, heart, and skeletal 
muscle all lacked staining for BCO1 or expressed only low levels of the protein. Finally, skin 
and ocular epithelium demonstrated strong BCO1 staining. Three broad themes can be gleaned 
from these data: 1) as expected, BCO1 expression is highest in tissues involved in carotenoid 
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metabolism [GI tract, liver]; 2) generally, epithelial cells strongly express BCO1, with few 
exceptions (e.g., prostatic epithelia); 3) cells of mesodermal origin [stroma, muscle, gonads] do 
not express BCO1 strongly. Epithelial cells are broadly known to be sensitive to retinoid 
signaling - thus, expression of BCO1 in epithelial cells outside of the liver and GI tract may 
provide “backup” capacity for local conversion of β-carotene to retinal in tissues such as the 
retina and epidermis, which have heightened sensitivity to retinoid status. Additionally, although 
testicular Leydig and Sertoli cells displayed only moderate BCO1 staining, they showed stronger 
expression than any other cell type of mesodermal origin examined 60,61. This is consistent with 
the well-established sensitivity of testicular development and function on retinoid status 62–65. 
These results from tissue expression studies suggest that not only does BCO1 function in central 
carotenoid metabolism, but also may have important functions in peripheral tissues. 
Clearly, carotenoid oxygenases play critical roles in the formation and metabolism of 
bioactive carotenoid metabolites. The metabolite of central β-carotene cleavage by BCO1, 
retinal, has bioactivity due to its downstream conversion to retinoic acid, as well as the 
indispensable role of its metabolite 11-cis-retinal in the visual cycle 66. All-trans retinoic acid 
(RA) mediates the classical functions of vitamin A through high-affinity binding to retinoic acid 
receptors (RAR), whereas the RA metabolite 9-cis-RA is an endogenous ligand for the retinoid 
X receptors (RXR) 67–69. Carotenoid oxygenases mediate the production of both of these 
important signaling molecules, as well as other potentially bioactive carotenoid metabolites. 
Studies of BCO1 enzyme kinetics have demonstrated that 9-cis-RA is not formed from central 
cleavage of full-length 9-cis-β-carotene, but rather must result from the isomerization of all-
trans-RA (atRA) to the 9-cis conformation 49. Thus, in conjunction with an as-yet-unidentified 
isomerase, BCO1 regulates production of the RXR ligand 9-cis-RA from β-carotene. Eccentric 
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β-carotene metabolites (i.e., derived from cleavage at bonds other than the central 15,15ʹ bond) 
have previously been identified and it has been proposed that a “stepwise” pathway might exist 
alongside the central cleavage mechanism for the production of retinal from these asymmetric 
metabolites 70. Although its cleavage activity is strictly limited to the central 15,15ʹ double bond, 
BCO1 has been shown to yield retinal and varying-length isoprene fragments from the cleavage 
of β-apo-8ʹ-carotenal, β-apo-10ʹ-carotenal, β-apo-12ʹ-carotenal, and β-apo-14ʹ-carotenal 49. 
When intact, these eccentric carotenoid metabolites – which are naturally present in foods 71 or 
formed from β-carotene through the action of the second mammalian carotenoid oxygenase β-
carotene-9ʹ,10ʹ-dioxygenase (BCO2) 72,73 – antagonize RAR 74 and RXR 75 activity. Thus, 
bioactive carotenoid metabolites are formed and interconverted by the endogenous mammalian 
carotenoid oxygenases, BCO1 and BCO2.  
Bioactivity of carotenoid metabolites is not limited to provitamin A-derived compounds, 
however, as eccentric cleavage products of lycopene have been shown to exhibit bioactivity both 
in vitro and in vivo. BCO2 degrades lycopene in vivo 35 through cleavage at the 9ʹ,10ʹ double 
bond 73,76. Apo-10ʹ-lycopenoic acid inhibited cell cycle progression and activated RARβ 
promoter activity in both normal human bronchial epithelial cells and non-small cell lung cancer 
cells, and reduced lung tumorigenicity in vivo 77. The corresponding aldehyde (apo-10ʹ-
lycopenal) and alcohol (apo-10ʹ-lycopenol) also exhibited bioactive effects in bronchial cells in 
vitro, modulating redox status through glutathione and reactive oxygen species generation 78. The 
same group has also reported that apo-10’-lycopenoic acid reduces high-fat 
diet/diethylnitrosamine-induced liver cancer in mice 79. Interestingly, the metabolite (apo-10ʹ-
lycopenoic acid) and the parent carotenoid (lycopene) may have differential effects in vivo 80 and 
these effects may be dependent on BCO2 genotype 81. Our own group has shown that lycopene 
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and apo-12ʹ-lycopenal both inhibit DU145 prostate cancer cell cycle progression and 
proliferation in vitro 82, suggesting that differential effects of parent and metabolite may be 
highly dependent on structure. Early reports on BCO1 reported that viable substrates must have 
at least one unsubstituted β-ionone ring 59, but others have reported that the enzyme is able to 
cleave lycopene, producing acycloretinal 49,57. In vitro studies using acycloretinal have failed to 
demonstrate effects with physiologically relevant concentrations or that were specific to the 
acycloretinal itself, however (i.e., not also induced by the parent lycopene) 83,84. In summary, 
both BCO1 and BCO2 produce bioactive carotenoid metabolites from provitamin A carotenoids, 
but current data suggest that only BCO2 may be able to directly produce physiologically relevant 
metabolites from acyclic carotenoids like lycopene. Regardless of their source, due to the 
presence of endogenous antioxidants at vastly higher concentrations in vivo (e.g., α-tocopherol), 
it seems that the bioactivity of these lycopene metabolites must be mediated through impacts on 
cellular pathways of molecular biology, rather than through modification of general redox status 
85–87. 
 
Carotenoid Metabolism – Studies In Vivo  
Despite advancement of the field through enzymatic characterization of purified BCO1 
protein, identification of reaction products in vitro, and immunohistochemical assessment of its 
tissue distribution, there remained a desire to experimentally manipulate BCO1 function in vivo. 
Answering that call, Hessel et al. successfully generated the Bco1-/- mouse in 2007 and 
experimentally demonstrated that genomic disruption of Bco1 prevented the conversion of β-
carotene to retinal in vivo 88. The creation of the Bco1-/- mouse model has been of great utility to 
the carotenoid research community and twenty published studies have utilized the strain since its 
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creation in 2007 32,34,36,88–104. It remains, to our knowledge, the only existing animal model of 
disrupted Bco1 function. Ten studies using this strain have replicated the original finding of 
Hessel et al., providing convincing experimental evidence that Bco1 expression is necessary for 
production of retinal from provitamin A carotenoids 34,36,89–93,96,97,99. Coincidentally, only six 
days prior to the original report on the Bco1-/- mouse model, Lindqvist et al. reported a loss-of-
function mutation in BCO1 105 in a woman who had been diagnosed with familial 
hypercarotenemia and hypovitaminosis A nearly 40 years earlier 106. The missense mutation 
resulted in the replacement of a highly conserved threonine residue with methionine and 
decreased enzymatic activity of a recombinant clone by 90% 105. Subsequently, single nucleotide 
polymorphisms (SNPs) in the human BCO1 gene have been shown to modulate the metabolism 
and distribution of provitamin A carotenoids and retinol 107–110, as well as other carotenoids – 
including lycopene 108–112. The combined evidence in these observational and experimental 
reports strongly support a central role for BCO1 in carotenoid metabolism.  
 
Carotenoid Metabolism – Alternative Functions of Carotenoid Oxygenases? 
Carotenoid cleavage is very likely to be the role for which BCO1 has been evolutionarily 
conserved. However, it has become increasingly clear that loss of Bco1 function impacts a 
myriad of physiological endpoints even when mice are fed diets devoid of carotenoids. Evidence 
for this was present even in the very first report on the Bco1-/- model, when it was shown that 
liver steatosis occurred in Bco1-/- mice provided a vitamin A-sufficient, β-carotene-free diet, and 
that high-fat diet feeding further exacerbated this metabolic perturbation 88. Elevations in serum 
free fatty acids were also observed in Bco1-/- mice; uptake of these non-esterified fatty acids into 
tissues is unregulated and may have contributed to the observed phenotype. Dysregulation of 
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lipid metabolism in Bco1-/- mice is not limited to the liver, however, as Lee and colleagues have 
shown that Bco1 loss resulted in elevated cardiac non-esterified fatty acid and ceramide levels, 
alterations in markers of retinoid metabolism, and impairment of cardiac function 102. 
Furthermore, disruption of normal lipid metabolism by Bco1 loss extends throughout the 
lifespan, as reports from the Quadro group have demonstrated altered retinol, cholesterol, and 
lipid esterification in Bco1-/- embryos 101,104. It seems likely that these effects may involve 
alterations in nuclear signaling by the peroxisome proliferator-activated receptor family 
88,99,101,102; these nuclear transcription factors play central roles in lipid metabolism and BCO1 is 
known to be regulated by one member, PPARγ 113. It is unknown whether direct reciprocal 
regulation of PPARγ by BCO1 occurs, but PPARs do heterodimerize with the retinoid-
responsive RARs and RXRs 69, and Bco1 loss has been shown to affect retinoid status even in 
mice provided with adequate dietary levels of preformed vitamin A 101,104. This suggests that 
modulation of BCO1 status may alter mammalian biology not only through the production of 
bioactive molecules from exogenous carotenoids, but also through modulation of cellular 
sensitivity to endogenous levels of nuclear receptor ligands. Clearly, much work is still needed to 
elucidate the impact of BCO1 on mammalian physiology in vivo, especially in “basal” conditions 
devoid of cleavage substrates.  
 
Prostate Cancer – Statistics of Incidence, Staging at Diagnosis, and Mortality 
It is likely that more than 1 in 3 U.S. women and nearly half of American men will be 
diagnosed with cancer in their lifetime 114. More common in males than any other cancer, 
prostate cancer (PCa) singlehandedly accounts for 20 - 30% of all new cancers and is the second-
leading cause of cancer death in this population 114–116. In probabilistic terms, the most recent 
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estimates suggest that 1 in 7 men is likely to be diagnosed with the disease at some point in their 
life 114. Projections for the current year suggest that nearly 181,000 American men will be 
diagnosed with PCa in 2016 and 14% of these men (an estimated 26,160) will die as a direct 
result of the disease 114. Fortunately, 80% of cases are diagnosed when the disease is still 
localized to the prostate gland, a stage at which five-year relative survival is 99% or greater. Data 
from the Surveillance, Epidemiology, and End Results (SEER) database demonstrate that this is 
part of a larger trend, as survival has increased in each of the assessment periods since 1975, 
when overall five-year relative PCa survival was only 68% 114. Although comparable survival in 
men with distant (metastatic) PCa at diagnosis (28%) sharply contrasts with the prognosis of men 
with localized disease, advanced disease at diagnosis comprises only 4% of overall cases, and so 
all-stage survival rates are the same as those for localized cancer 114. 
 
Prostate Cancer – Structure, Function, and Carcinogenesis of the Prostate Gland 
To best understand the malignant transformation, progression, and lethal metastasis of 
PCa, it is necessary to understand the structure, development, and function of the organ in its 
normal, non-neoplastic state. The prostate is an accessory sex organ present only in male 
mammals, which contributes to the composition of semen and critically relies on androgens for 
development and organ maintenance 117. In 1968, McNeal developed an anatomical model of the 
human prostate, describing the presence of peripheral, central, and transition zones, a model 
which is now widely accepted worldwide 118. The peripheral zone occupies 70% of the mass of 
the gland and accounts for nearly 75% of the cancers that arise 119.  In contrast, the rodent 
prostate is distinctly lobular, consisting of the anterior, ventral, dorsal, and lateral lobes; the latter 
two are often grouped together as the dorsolateral lobe (Fig. 1.2). Molecular studies have 
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suggested that the mouse dorsolateral lobe is the closest homologue to the human peripheral zone 
120, although it was the consensus opinion of a National Cancer Institute-directed expert panel, 
convened to assess mouse models of human prostate cancer, that there is not “evidence for a 
direct relationship between the specific mouse prostate lobes and specific zones in the human 
prostate” 121. Regardless, both the human and rodent benign prostrates share general features of 
glandular structure, with ductal branching and two types of epithelial cell - basal and luminal 121. 
Luminal cells, the differentiated cells responsible for secretion of the prostatic components of 
semen into the ductal lumen, are tall columnar cells lining the ducts in a continuous layer and can 
be identified by immunostaining for cytokeratins 8 and 18. Basal epithelial cells line the 
basement membrane (discontinuously in mice and in a continuous layer in humans) and can be 
distinguished histologically by their expression of p63 and the cytokeratins 5 and 14 122,123. The 
mesenchymal or stromal compartment of the prostate is largely composed of smooth muscle 
cells, characteristically expressing smooth muscle actins, desmin, and vimentin 124, although 
morphological differences exist between the human and murine organ. The stromal layer in the 
human prostate is much thicker than that of the mouse, yielding a higher stromal:epithelial cell 
ratio 125.  
Development, growth, and function of the prostate are highly dependent upon androgens. 
Some of the earliest accounts of androgen-regulated growth of the prostate were observations 
that eunuchs had small and underdeveloped prostates. In experiments in animals, castration 
causes regression of the prostate due the apoptosis of the epithelial cell compartment 126. This 
regression is rapid, as it can be detected within one day and can result in a loss of two-thirds of 
epithelial cells within one week 127. The involution of the prostate is fully reversible and 
repletion of androgen status with exogenous testosterone results in rapid proliferation of 
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epithelial cells and reestablishment of a gland of normal size 128. Circulating androgens control 
the development of the prostate and are supplied almost entirely by the testes, even during the 
fetal period 129,130. One of the first androgen-driven responses of the developing prostate is the 
elevated expression of the homeobox gene Nkx3.1 in the fetal urogenital sinus epithelium (UGE) 
131. Nkx3.1 expression is also dramatically reduced (~8-fold) following castration of adult mice. 
In contrast to other homeobox gene families, the Nkx family of genes controls tissue-specific 
organogenesis; loss of Nkx2.1 is embryonically lethal and results in the absences of the thyroid 
gland and lung parenchyma 132, whereas loss of Nxk2.5 results in an embryonic-lethal disruption 
in heart development 133. Nkx3.1 maps to chromosomal position 8p21, a locus that frequently 
suffers a loss of heterozygosity in PCa 134. Additionally, Nkx3.1-/- mice exhibit epithelial 
hyperplasia, which increases in severity with age 135,136, suggesting that Nkx3.1 plays a key role 
in androgen-driven establishment and maintenance of differentiated prostate structure and 
function.  
 
Paracrine Androgen Signaling in Prostatic Development and Carcinogenesis 
In contrast to androgens’ direct pro-differentiative influence on Nkx3.1 in the epithelia, 
many androgenic effects in the prostate are mediated through stromal-epithelial interactions. In a 
series of elegant and seminal experiments starting in the 1970s, Cunha et al. began to describe 
the central role played by stromal-epithelial paracrine signaling in prostatic organogenesis and 
function. Using tissue recombination approaches, they demonstrated that 1) stromal signals 
control epithelial differentiation and function, and 2) functional androgen receptor (AR) in the 
stroma is necessary for prostatic differentiation, morphogenesis, and proliferation. When ventral 
prostate fetal urogenital sinus mesenchyme (UGM) was combined with UGE from a mix of 
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dorsal and ventral prostate lobes, the tissue recombinant formed differentiated prostate glandular 
ducts that displayed molecular signatures characteristic of only the ventral prostate 137. In direct 
contrast, mixed UGM from the dorsal and ventral lobes combined with adult ventral epithelium 
formed tissue recombinants with molecular signatures characteristic of not only the ventral lobe, 
but also the dorsal and anterior lobes 138. Fascinatingly, prostatic UGM recombined with adult 
bladder epithelium also resulted in the formation of differentiated prostatic tissue. However, it 
seems that this effect is limited to cell types of similar embryological origin – recombination of 
UGM with epithelia from other anatomical locations, such as the salivary gland and esophagus, 
only form differentiated epithelia reflective of their site of origin and cannot be “reprogrammed” 
as prostatic tissue 139. Regardless, despite the aforementioned anatomical differences of the 
prostate between species, it appears that the paracrine signals involved in prostatic development 
and differentiation are widely conserved: in almost all combinations of UGM and UGE or adult 
bladder epithelium from human, mouse, rat, or rabbit sources, differentiated glandular prostatic 
tissue arose 140.  
Androgenic control of this paracrine signaling system was demonstrated by use of 
stromal or epithelial tissue from Tfm mice, which carry an X-linked AR mutation that results in a 
premature stop codon and severe decrease (~10%) in androgen responsiveness 141. In these 
experiments, as previously demonstrated, UGM and UGE from wild-type animals recombined to 
form functional and differentiated glandular prostatic-like tissue. However, when mesenchyme 
from Tfm mice (lacking a functional AR) was recombined with wild-type UGE, vaginal-like 
morphology resulted, demonstrating a need for stromal AR function in prostatic differentiation 
142. Additionally, using the reciprocal combination (Tfm epithelia and wild-type stroma) in this 
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and another paper 143, Cunha et al. crucially demonstrated that epithelial AR function was not 
necessary for prostatic morphogenesis, given a functional stromal AR.  
Clearly, androgen signaling supports prostatic development, differentiation, and 
proliferation to yield the normal functions of a healthy organ. However, androgenic stimulation 
has been alleged to play key roles in the malignant transformation, progression, and metastasis of 
PCa 144. How the normal androgen signaling program in the prostate becomes corrupted is 
clearly of interest to cancer biologists and nutritionists concerned with identifying dietary 
strategies for PCa prevention. As in the normal prostate, stromal-epithelial interactions are 
involved in malignant transformation and carcinogenesis. Ricke et al. 145 demonstrated this using 
tissue recombinants of mouse stroma and human benign prostate epithelia grafted into castrated 
athymic host mice, which were then treated with testosterone and estradiol for two to four 
months to stimulate proliferation and carcinogenesis. When the investigators combined wild-type 
stroma and either wild-type benign epithelia or benign epithelia with AR knocked-down through 
small hairpin RNA, they observed the development of large invasive tumors. Conversely, loss of 
AR in the stroma (using stroma from AR-knockout mice) prevented the malignant 
transformation when recombined with wild-type benign human prostate epithelium. Using a 
different paradigm, the authors recombined wild-type mouse stroma with mouse epithelium from 
Pten and Tp53 double heterozygote mice (Pten+/-, p53+/-) and implanted grafts into castrated or 
intact athymic mice. In castrated animals, the recombinants were histologically benign and 
similar to recombinants with wild-type epithelium. In intact animals, however, carcinogenesis 
occurred. Data such as these demonstrate that stromal androgen-mediated signaling is necessary 
for malignant transformation of prostatic epithelium, even with diminished function of major 
tumor suppressor genes.  
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In support of this hypothesis, Ricke et al. found that testosterone treatment increased 
stromal expression of major paracrine peptides such as fibroblast growth factor (FGF) 2, FGF7, 
FGF10, transforming growth factor β (TGF-β), and hepatocyte growth factor (HGF). 
Demonstrating that androgen-dependent paracrine signaling can also enhance progression of 
previously transformed PCa cells, in an in vitro co-culture model using human-derived cancer-
associated fibroblasts (CAFs), the human PC3 PCa cell line grew more slowly and displayed less 
invasive potential when co-cultured with CAFs that had AR knocked down with siRNA, 
compared to control CAFs 146. Knockdown of AR also resulted in a significant decrease in CAF 
mRNA expression of several paracrine growth factors, including FGF-7, FGF-10, HGF, TGF-
βII, insulin-like growth factor (IGF) 1, and stromal cell-derived factor 1 (SDF1). The sum of the 
studies above shows that whereas androgens are necessary for the development and 
differentiated normal function of the prostate, abnormal androgenic stimulation can both induce 
malignant transformation and also enhance cancer progression.  
 
Relationships between Circulating Hormone Levels and Prostate Carcinogenesis 
First, it is important to note that differences between human and rodent endocrinology 
exist. In humans, up to half of the androgen available to the prostate gland is the product of local 
conversion of adrenal steroids, with the remainder directly supplied as testosterone from the 
testes 147. This is in contrast to the endocrinology of rodents, which do not produce much of the 
androgen precursors dehydroepiandrosterone (DHEA) or androstenedione (AE) 148, relying 
instead on gonadal testosterone for androgenic stimulation of the prostate. This species-specific 
difference owes itself to divergent adrenal expression and activity of cytochrome P450 17A1 
(CYP17A1). In both humans and rodents, CYP17A1 possesses dual enzymatic functions: the 
 21 
17α-hydroxylation of 21-carbon steroids, as well as 17,20-lyase activity to produce the 19-
carbon androgens 149. Whereas the human adrenal gland utilizes the 17α-hydroxylation capacity 
of CYP17A1 to provide substrate (17α-OH-progesterone) for the eventual formation of cortisol, 
the major human glucocorticoid, it also harnesses CYP17A1’s lyase activity to convert 17α-OH-
pregnenolone to the 19-carbon androgen precursor DHEA. Rodents, on the other hand, do not 
express CYP17A1 in the adrenal gland 150. The major glucocorticoid produced by the rodent 
adrenal gland is corticosterone, rather than cortisol, and it produces very little of the androgen 
precursors DHEA or AE 150,151. Once circulating testosterone (or DHEA or AE in humans) 
reaches the prostate, it is free to diffuse into prostatic cells, where it is converted to 
dihydrotestosterone (DHT) by 5α-reductase, type 2 (SRD5A2) 152–154. DHT is 10-fold more 
potent than testosterone, primarily due to a 10-fold lower rate of dissociation from the AR, and 
thus a much higher overall affinity 154. Once bound to DHT, AR dimerizes, is phosphorylated, 
translocates to the nucleus, and binds AR response elements on AR-target genes (AREs), recruits 
transcriptional co-activators, and initiates gene transcription patterns collectively referred to as 
“androgen signaling” (reviewed in 155,156). 
Circulating androgens or androgen precursors, produced by the testes in mice and both 
the testes and adrenals in humans, have long been investigated as risk factors in the development 
of PCa. In fact, the recognition that PCa was responsive to manipulation of systemic androgen 
levels (via castration) won Charles Huggins a 50% share of the 1966 Nobel Prize in Physiology 
or Medicine for work he had done in the 1940s 157. In 1990, the first prospective analysis of PCa 
risk relative to endogenous sex hormone levels suggested that men in the highest tertile of serum 
AE levels compared to the those in the lowest tertile were at a roughly 2-fold increased risk of 
total PCa 158. In 1996, another prospective study found no relationships between individual 
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hormones and PCa risk, but when adjusted for concentrations of other circulating hormones, 
testosterone was positively associated with overall PCa risk 159. A meta-analysis of three studies 
(including the 1996 study) found an association between endogenous levels of testosterone and 
PCa risk 160. However, subsequent studies, including a large pooled analysis of 18 prospective 
studies, found no effect of any endogenous sex hormone and PCa risk 161. Some investigators 
expressed concerns about exposure to exogenous testosterone, whether through dietary 
supplements 162,163, illegal anabolic steroids 164, or pharmacological agents to treat age-related 
hypogonadism 165. Clearly, much confusion was present in the literature. Moreover, it had 
remained difficult to align the demographics of PCa incidence (highest incidence in aging males 
concomitantly experiencing declining androgen levels) with a model that proposed elevated 
androgen levels to be a causative factor.  
A unifying theory arrived in 2006, when Morgenthaler proposed the saturation model 166. 
Further refined in 2009, the saturation model posits that both the prostate’s exquisite sensitivity 
to castration as well as its ambivalence to high levels of endogenous testosterone can be 
explained by recalling the basic biochemical principles of high-affinity ligand-receptor binding 
167. With castration, the androgen-dependent prostate rapidly and dramatically experiences 
apoptosis-mediated involution, as reviewed above. With systemic testosterone repletion, through 
the high-affinity binding of DHT to prostatic AR, the prostate is sensitive even to minute 
changes in circulating testosterone concentration, as long as concentrations remain near castrate 
levels. As intracellular DHT concentrations rise along with higher serum concentrations of 
testosterone, the prostate begins to approach a boundary to its androgen-induced response – the 
limited number of available AR binding sites become increasingly occupied by high-affinity 
DHT ligand. At a certain point of tissue DHT concentration, within the low nM range 168, all 
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binding sites are occupied and additional androgen achieves no further androgen-mediated 
response. In support of the saturation model, pharmacological inhibition of testosterone-to-DHT 
conversion forces the AR to bind lower-affinity ligand testosterone, receptor saturation does not 
occur, and prostatic growth tracks with serum testosterone across a wide range of concentrations 
169. Thus, without the need for novel mechanisms, the saturation model simultaneously describes 
the established effects of castration and testosterone repletion on androgen-dependent prostatic 
growth, while also explaining the lack of association observed between PCa and high 
endogenous levels of testosterone. 
 
Prostate Cancer Epidemiology – Factors that Modulate Risk 
Beyond the coarse-grained summary of PCa incidence and survival presented earlier, 
observational data have identified risk factors that significantly increase a man’s risk of PCa 
diagnosis, or which may put an individual at higher risk of developing lethal disease. Factors that 
modulate these risks can be broadly classified into two groups: non-modifiable and modifiable.  
A truly defining characteristic of PCa may be the “dose-response” in incidence observed in 
relation to age. Based on population-level statistics, whereas the percent likelihood of developing 
PCa before the age of 50 is less than 1%, the probability of a PCa diagnosis between the ages of 
60 to 69 alone is >5%, and is 10% for all years at or above the age of 70 114. These statistics are 
borne out in autopsy studies, which consistently find that histological evidence of PCa tracks 
strongly with age at death from other causes. Indeed, at the upper end, 87% of men 81-95 years 
of age showed histological evidence of prostatic adenocarcinoma 170. Surprisingly, even men in 
their 3rd decade of life (20-29 years of age) exhibit focal pre-neoplastic or neoplastic lesions 171, 
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demonstrating that although this is commonly perceived as a disease of older age, its etiology 
may be traced to events or conditions present at earlier stages of life. 
Like the inevitable aging process, family medical history and racial background are 
factors that are not modifiable for the management of disease risk. Positive diagnosis in African-
American men is 50-66% more common than in Caucasians and they are 200% more likely to 
die from PCa 172. In contrast, Japanese and Chinese men in their native country enjoy low rates 
of PCa; strikingly, however, immigrants to the U.S. from these countries experience an elevated 
risk for PCa that increases in concordance with the length of their American residence 172–174. 
Racial background thus seems to interact with environmental factors to modulate risk of PCa. 
While it follows, then, that a family’s history of PCa is necessarily intertwined with its ethnic 
history, medical histories can still be independent predictors of PCa risk, even across groups with 
diverse ethnic backgrounds. Men with an immediate relative with PCa (i.e., in a father, brother, 
or son) or even a second-degree relative (cousin, uncle, grandfather) may have up to a three-fold 
increased risk of developing PCa themselves 172,175. Additionally, whereas PCa is very rare in 
men below 50 - 55 years of age (≤1%), a positive family history can raise their risk probability to 
nearly 50% 173. Of course, underlying the contribution that family histories provide to PCa risk 
are the inherited genetic variations that presumably mediate disease etiology. A thorough 
discussion of this entire body of literature is beyond the scope of the current review, but of note 
are studies that have investigated polymorphisms in genes governing steroid hormone 
metabolism. As PCa is in many ways governed by endocrine factors 144, it seems logical that 
polymorphisms in genes controlling androgen 176–178 and estrogen 179 metabolism may modulate 
disease risk. Moreover, a polymorphic polyglutamine sequence in the human androgen receptor 
(AR) may alter PCa risk 180 and its prevalence in the African-American population may account, 
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at least in part, for the increased PCa risk observed in that population 181. However, it must be 
noted that hereditary factors account for only ~9% of PCa cases 172, and thus it seems that 
environmental factors or spontaneous genomic lesions may account for most of the observed 
PCa burden. 
At the behest of the U.S. Congress, Doll and Peto estimated in 1981 that 35% of cancers 
could be attributed to dietary factors – albeit with a confidence interval of 10 - 70% 182. Thirty-
five years later, others have proposed that a more accurate number may be closer to 20%, but 
that Doll’s and Peto’s estimates “generally have held true” 183. Of course, dietary components 
may either increase or decrease risk. Indeed, the 2007 World Cancer Research Fund/American 
Institute for Cancer Research joint report declared that foods containing lycopene, foods 
containing selenium, and selenium supplementation at a dose of 200 µg/day were associated with 
“probable decreased risk” of PCa, whereas diets high in calcium were linked to a “probable 
increase in risk” 184. This judgment was based on synthesis of many observational individual 
studies, but individual cohort or case-control investigations have also proposed an increased risk 
of PCa with high levels of α-linolenic acid 175, calcium 175,185, whole milk 186, phosphorous 185, 
and total energy 175 intakes. Other dietary components, such as fiber 187, soy 174,188, cruciferous 
vegetables 188,189, and total vegetables 189,190, have been associated with decreased risk of total or 
aggressive prostate cancer. Notable though, and of interest to our research, has been the repeated 
observation that dietary lycopene or tomato products are associated with reduced risks of both 
total and lethal PCa.  
 
 
 
 26 
Prostate Cancer Epidemiology – Tomatoes, Lycopene, and Prostate Cancer 
The first study to propose an inverse relationship between dietary lycopene and PCa dates 
to 1995, when a landmark study of 47,894 men found that estimated lycopene intake was 
associated with a 31% reduced risk of prostate cancer diagnosis 173. Internally consistent with 
this, tomato products (which provide >80% of U.S. lycopene intake 191), but not 41 of the other 
42 fruits or vegetables investigated, were significantly associated with lower rates of PCa. 
Furthermore, lycopene was unique among carotenoids in its protective effect, suggesting that the 
finding was not simply indicative of a biomarker for intake of vegetables or other potentially 
healthful foods, but rather that it may have communicated some truth about a meaningful 
biological relationship. Indeed, subsequent studies have repeatedly found an inverse association 
between dietary lycopene or tomato intake and PCa 175,192–195. Often, the strongest protective 
effects of lycopene have been found in relation to advanced PCa 173,175,192–194,196. Furthermore, 
meta- or combined analysis of studies has further supported a protective effect of lycopene and 
tomato intake 195,197. Some researchers have suggested that dietary recall methods are inadequate 
for accurate estimation of dietary composition 198,199 and although methods for self-reported 
estimation of dietary carotenoids have been validated 200, some authors’ concerns remain. 
Allaying this concern, then, should be studies in which direct measurements in the serum have 
revealed inverse associations between elevated levels of circulating lycopene and risks of total or 
lethal PCa 201,202.  
Cancer is a complex disease, driven by many possible foundational and driver mutations, 
inhibitory and progression factors, environmental agents, and inherent variability in the patient’s 
own physiology. Diet, too, is intricately complicated; dietary patterns may vary widely or not at 
all between assessments, varying food composition may confound similar outcomes of food item 
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intakes, and interactions between food components may cloud mechanistic insight. Given these 
challenges, it is not surprising that some observational studies have not reported significant 
associations between dietary lycopene/tomato exposure and PCa. Moreover, aspects of trial 
design may have biased several reports against detection of differences in PCa incidence or 
advanced disease. One trial in particular, the Prostate Cancer Prevention Trial (PCPT), was a 
placebo-controlled clinical trial to test the effect of a pharmacological inhibitor of androgen 
metabolism, finasteride, on prevention of primary prostate cancer 203. A nested case-control 
study was performed within the PCPT to assess if dietary lycopene/tomato or serum lycopene 
could prevent prostate cancer. In two publications, Kristal et al. reported that dietary or 
supplemental lycopene did not modulate prostate cancer risk 204 and that serum concentrations of 
lycopene were not associated with lower risk of PCa 205. Notably, the authors of this report made 
the following statement regarding the impact they interpreted from their findings: 
 
“Scientists and the public should understand that early studies supporting an association of 
dietary lycopene with reduced prostate cancer risk have not been replicated in studies using 
serum biomarkers of lycopene intake. Recommendations of professional societies to the public 
should be modified to reflect the likelihood that increasing lycopene intake will not affect 
prostate cancer risk.”  
 
– Kristal A.R. et al., Cancer Epidemiol Biomarkers Prev; 20(4); 638–46, 2011 
 
Such a statement would indeed be prudent if confronted with new and convincing 
evidence demonstrating an obvious futility of dietary lycopene or tomato in the prevention of 
PCa; however, their data do not, in fact, provide said convincing evidence. First, in clarification, 
“early studies supporting an association of dietary lycopene with reduced prostate cancer risk” 
indeed have been replicated in studies using serum biomarkers of lycopene intake 201,202. 
Secondly, the PCPT, from which Kristal et al. obtained data for their nested case-control study, 
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is quite unique in design and requires careful analysis. Men 55 years of age or older were 
enrolled into a placebo or finasteride (5 mg/day) study arm, with intent-to-treat for seven years 
203. Monitoring of PCa in these men was accomplished through yearly digital rectal exams 
(DREs) and measurement of prostate-specific antigen (PSA), which is a prostatic-specific 
seminal protease that is released into the circulation as a result of neoplastic, but also non-
cancerous, insults 206. PSA screening has become a topic of fierce debate in the PCa community 
and only more so following the U.S. Preventative Services Task Force’s 2008 and 2011 
decisions to recommend against all PSA screening due to concerns of harms from over-diagnosis 
and overtreatment vs. limited perceived benefit 207,208. Indeed, many clinicians have balked at the 
recommendation 209–211. Analysis of PSA screening is beyond the current scope of this review, 
but nevertheless, its inclusion on the PCPT trial protocol is an important detail. Abnormal DRE 
or PSA findings in PCPT yearly screenings prompted needle core biopsy and evaluation of 
prostatic pathology; 571/1,934 (29.5%) men in the placebo group who underwent biopsies in this 
fashion were diagnosed with PCa. Cancers diagnosed in this fashion can be classified as “for-
cause”, as they were identified in response to subjects’ clinical presentation. Following the 
seven-year study period, men in the PCPT who had not been diagnosed with PCa were given the 
option of receiving biopsies, whether or not their clinical presentation would have called for 
biopsy while on study; 576/3,820 (15%) of men in the placebo group who underwent these 
biopsies were subsequently diagnosed with PCa. These PCa diagnoses can be classified as “not 
for-cause” – they were identified not on the basis of clinical presentation, but as a byproduct of 
greatly elevated biopsy screening at the end of the PCPT trial. Strikingly, nearly two times as 
many men in the PCPT placebo group were screened “not for-cause” as “for-cause” (3,820 vs. 
1,934), resulting in an overrepresentation of indolent, low-grade, localized, and asymptomatic 
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PCa diagnoses within the PCPT trial 212. Surely, these “for-cause” and “not for-cause” cancers in 
the PCPT do not represent the same tumor phenotype. Similarly, the latent and focal lesions 
identified in 20-30-year-old men in autopsy studies are surely not of the same phenotype as those 
presenting as clinically urgent tumors in men over the age of 60. Thus, when Kristal et al. 
combine “for-cause” and “not for-cause” diagnoses and conclude that lycopene does not protect 
against PCa risk 205, they ignore this critical dichotomy present within the PCPT trial population. 
Indeed, their own data show that higher levels of serum lycopene in both quartile-based and 
continuous variable analyses provide a significant protective effect against “for-cause” cancers, 
but not “not for-cause” cancers; however, this was not reflected in their conclusions 205. A 
separate re-analysis of the data from Kristal et al. by Giovannucci concurs with this 213. A similar 
analytical approach draws into question the conclusions made from their analysis of dietary 
tomato and lycopene intake in the PCPT trial 204. These are significant limitations to the 
conclusions drawn. Other studies finding no link between PCa and lycopene/tomato intake or 
serum lycopene have also drawn their study populations from large longitudinal DRE/PSA-based 
screening trials (e.g., the Prostate, Colorectal, Lung, and Ovarian [PLCO] Cancer Screening 
Trial) 214,215. Although the PLCO and other trials did not utilize the unique end-of-study biopsy 
protocol that the PCPT did, reliance on PSA screening resulted in the diagnosis of many more 
low-grade, indolent cancers than would have otherwise been detected 208. Without careful 
accounting for this PSA-bias, effects of dietary lycopene on clinically relevant cancers are likely 
to be “washed out” by the abundance of screening-detected cancers. Giovannucci convincingly 
argued this point in 2011 213 and Wei and Giovannucci provided a thorough analysis of this 
problem in 2012 216. 
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 To summarize the body of epidemiological evidence linking lycopene/tomato intake and 
PCa, multiple reports, from multiple laboratories, suggest that tomato or lycopene intake is 
inversely associated with total PCa incidence. Moreover, lycopene or tomato intake appears to be 
linked most strongly with a lower risk of aggressive or lethal PCa, suggesting that 
lycopene/tomato may inhibit cancer progression. As cancer etiology and the composition of a 
human diet are both incredibly dynamic and complex ecological problems, it is not surprising 
that variability exists in the observational literature. Moreover, bias present within trial datasets, 
like the PCPT, has clouded or obscured relationships between dietary tomato/lycopene and PCa 
where they do or may exist. Whether dietary lycopene/tomato prevents the formation of initial 
carcinogenic lesions, inhibits the progression of extant lesions to clinically relevant and life-
threatening stages, or both, are answers unavailable to the techniques at the disposal of 
observational investigation. Experimental studies, past and present, have used these questions as 
a foundation for inquiry.  
 
The Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) Model 
The transgenic adenocarcinoma of the mouse prostate (TRAMP) model was developed in 
the 1990s in the lab of Norman Greenberg as a model of human prostate carcinogenesis 217. The 
model relies on prostate epithelium-specific expression of the simian virus 40 large and small T 
antigens (SV40 Tag), driven by the androgen-regulated rat probasin promoter, which directs 
transgene expression to the dorsal and ventral prostate lobes. The viral large T antigen inhibits 
the tumor suppressors p53 and Rb, two genes commonly lost in human PCa, whereas the small t 
antigen inhibits protein phosphatase 2A, a negative regulator of the pro-proliferative MAP kinase 
pathway. The result of these effects is prostatic hyperplasia and neoplasia in the TRAMP mouse 
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as early as 10 weeks of age. In subsequent papers, the Greenberg group documented progression 
of this model through primary disease, metastasis 218, and castration-resistant disease 219,220. 
Additionally, they developed a histological pathology grading system for the model 221, which 
has been modified by Clinton and colleagues 222. To date, the TRAMP model has been used 
extensively – over 440 original articles appear on PubMed as of March 17, 2016. Several aspects 
of the TRAMP model make it an appropriate model of human PCa and especially CRPC. The 
model demonstrates a progression from early low-grade hyperplasia through to metastasis, 
resembling development of the human disease. Castration initially induces prostatic or tumoral 
regression before selecting for castration-resistant disease, and some tumors exhibit AR 
mutations 223, as in humans (reviewed in 224,225). Despite many similarities to the human disease, 
as with any animal model, the TRAMP model is not a perfect representation of human PCa. A 
commonly voiced concern over use of this model has been the presence of a neuroendocrine 
phenotype within some tumors. Some authors have claimed that malignancies in the TRAMP 
model are primarily of neuroendocrine phenotype and in fact are of neuroendocrine origin 226, 
but we and others feel that this is an extreme view. Studies of human PCa demonstrate that focal 
neuroendocrine differentiation is present in 45%-50% of tumor biopsies (as determined by 
synaptophysin immunoreactivity) and correlates with increasing Gleason score 227,228. In the 
TRAMP model, similarly, many poorly differentiated tumors display focal synaptophysin 
immunostaining, but this occurs very rarely in less severe lesions 229. Additionally, the fact that 
early prostatic intraepithelial neoplasia (PIN) lesions do not display synaptophysin staining 
contradicts arguments in favor of a neuroendocrine origin of disease in TRAMP mice. It seems 
that in the TRAMP model, as in human PCa, foci of neuroendocrine differentiation may be a 
natural function of disease progression. 
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Dietary Tomato or Lycopene in Animal Models of Prostate Cancer 
This section will focus only on the use of rodent models for the investigation of PCa 
prevention by dietary tomato and lycopene. Use of available animal models for more general 
investigation of human PCa has been thoroughly reviewed elsewhere 224,230–232. Additionally, 
despite much work that has been done on the effects of tomato carotenoids on PCa cell lines in 
vitro, these studies will not be addressed in depth here. Readers interested in summaries of in 
vitro reports of lycopene bioactivity are directed to the reviews by Holzapfel et al. and van 
Breemen and Pajkovic 233,234. 
Although the TRAMP model is now the most common animal model for investigation of 
PCa, other models preceded its introduction. To our knowledge, the first report of the use of 
tomato or lycopene in an animal model of prostate carcinogenesis was a report in 2001 by Imaida 
and colleagues 235, but they failed to observe a preventative effect of lycopene on PCa incidence 
in their model of carcinogen-induced general carcinogenesis. Subsequently, our own group, 
using a carcinogen + testosterone model designed to specifically induce prostatic carcinogenesis, 
observed a significantly increased proportion of survival in rats fed tomato paste (10% w/w, 13 
mg/kg diet), but not a ~10-fold higher dose of purified lycopene 236. This was the first 
experimental report to show a protective effect of tomato feeding in vivo and, importantly, the 
source and level of tomato inclusion were chosen to approximate realistic intakes in humans.  
Furthermore, this study suggested a synergistic effect of compounds within the whole tomato, 
which was not matched by feeding of single purified bioactive compound (lycopene).  
However, subsequent studies would provide conflicting data: Pannellini et al. 
demonstrated that a 10% tomato paste diet reduced cancer incidence in TRAMP mice 237, 
whereas Konijeti et al. reported no effect on TRAMP carcinogenesis with a 12.8% tomato paste 
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diet, but a significant reduction in cancer incidence (-35%, p < 0.002) in mice fed purified 
lycopene 238. The reasons for these inconsistencies are unclear, as molecular endpoints (prostatic 
lycopene levels, serum growth factors, and markers of DNA damage) did not differ between the 
lycopene- and tomato paste-fed animals groups in the Konijeti report. Venkateswaran et al. 
demonstrated that lycopene in combination with vitamin E and selenium reduced carcinogenesis 
in the Lady model (which is a less-aggressive derivative of the TRAMP model) 239, and that 
lycopene was an essential component of this antioxidant mixture for prevention of 
carcinogenesis 240. Our own lab has published two studies on the effects of tomato feeding in 
TRAMP mice. In the first, 10% tomato powder feeding significantly reduced PCa incidence by 
nearly 40%, and by 55% when combined with a 2% soy germ diet 241. This combinatorial effect 
was less than additive, however, which might have been explained by the reduced carotenoid 
bioavailability observed when co-feeding soy 40. In contrast, Conlon et al. failed to demonstrate a 
protective effect of 10% tomato feeding in TRAMP mice 242. Despite the fact that the tomato diet 
provided by Conlon et al. contained ~20-fold lower levels of lycopene than was fed by Zuniga 
(24 µmol lycopene/kg vs. 500 µmol lycopene/ kg diet, respectively), prostatic accumulation in 
the anterior prostate of the Conlon study was actually higher (0.4 ± 0.1 nmol/g) than was 
accumulation in the tumors of the Zuniga study (0.25 ± 0.05 nmol/g). Serum concentrations were 
practically identical, at 0.66 ± 0.15 µM and 0.67 ± 0.07 µM, respectively. This suggests that, due 
to tissue saturation, vastly different dietary exposures may not have mediated the difference in 
effect. However, whereas the Zuniga study initiated feeding at weaning, the study by Conlon et 
al. was designed to assess whether tomato diet intervention at 8 weeks of age (during the window 
of SV40Tag-induced transformation) would be effective. It is possible that in primary TRAMP 
prostate cancers, there exists a critical window for intervention before neoplastic transformation 
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and while the Zuniga study intervened within this window, the treatment initiated by Conlon et 
al. was too late. Examining this question, we have demonstrated that markers of early prostate 
carcinogenesis are evident at 10 weeks of age in the TRAMP mouse and that although initiation 
of tomato and lycopene diets after weaning similarly impact gene expression, the effects are 
modest when compared to manipulation of TRAMP genotype or castration status 243. 
Nonetheless, tomato and lycopene feeding both reduced mRNA expression of the DHT-
biosynthetic enzyme 5α-reductase, as well as two AR coactivators (SREBP and paxillin) 243, 
suggesting that tomato intake may impact PCa carcinogenesis through modulation of androgen 
status. A later intervention (e.g., at 8 weeks as in Conlon et al.) would thus likely be at a distinct 
disadvantage in preventing early carcinogenic transformation and later PCa progression.  
Other studies have utilized tumorigenesis models to demonstrate a protective effect of 
lycopene or tomato on PCa progression in vivo. Siler et al. showed that purified dietary lycopene 
induced necrosis in the Dunning transplantable tumor and modulated expression of genes 
involved in paracrine androgen signaling 244. Our own lab has demonstrated that tomato feeding 
in combination with dietary broccoli reduced Dunning tumor weights, increases apoptosis, and 
inhibited proliferation 245.  
Animal models have provided crucial opportunities for experimental testing of 
hypotheses generated by observational studies. Many studies have demonstrated efficacy of 
purified lycopene and/or tomato, but have not provided clarification as to what components of 
tomatoes may contribute to the occasionally differential impacts of purified lycopene and whole 
tomato. More studies focused on specific mechanisms are needed, but studies to this point have 
suggested that lycopene and/or tomato may alter androgen metabolism or signaling within 
tumors. Additionally, as efficacy has been demonstrated in both carcinogenesis and 
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tumorigenesis studies, lycopene and/or tomato may impact prostate cancer at multiple levels, 
preventing both initial lesions as well as disease progression. 
 
Development, Treatment, and Prevention of Castration-Resistant Prostate Cancer 
Whereas treatment for mild, primary disease is often radiation or prostatectomy (removal 
of the prostate), advanced cancers that progress after primary treatments fail require alternative 
treatment strategies. Androgen deprivation therapy (ADT), accomplished through 
pharmacological blockade of androgen synthesis or ligand binding (and formerly by surgical 
castration) is currently the first-line therapy for these aggressive cancers 155. Since the prostate 
and prostatic neoplasms are initially dependent on circulating androgens, tumors often regress 
following ADT, but the disease recurs as castration-resistant prostate cancer (CRPC) in 80% - 
90% of patients. CRPC is an advanced and lethal form of recurrent PCa that has a median 
survival of only 2.5 years 246. CRPC development is facilitated by the selection via evolutionary 
pressure of existing “androgen-independent” clonal populations 247, acquisition of novel-function 
androgen receptor (AR) mutations 248–250, or the capacity for local de novo androgen synthesis 
251–254. Medical oncologists have long been searching for ADT regimes that will delay CRPC 
occurrence and prolong survival, whether through testing of new temporal 255 or pharmacological 
246 schemes of treatment. However, as with primary PCa, dietary approaches may hold great 
promise in the prevention of disease progression. In fact, others have argued that the protective 
effects of lycopene and tomato intake on primary PCa may actually be through the reduction of 
disease progression and therefore clinical symptoms 213. Supporting this, a prospective study in 
1,202 men with PCa from the Health Professionals Follow-up cohort found that high 
consumption of tomato sauce after diagnosis was linked to lower rates of PCa progression 196.  
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Aims of Dissertation 
 Much has been discovered regarding the metabolism of tomato carotenoids and their 
protective effects against PCa incidence and mortality, but much still remains to be clarified. In 
particular, although BCO1 is known to play a key role in the metabolism of dietary carotenoids, 
it also appears to impact aspects of physiology independent from carotenoid cleavage. In order to 
fully understand how human genetic variation in BCO1 may impact carotenoid metabolism – and 
potentially modulate relationships between dietary lycopene and PCa risk – a more thorough 
understanding of the cellular and physiological role of BCO1 is necessary. Specifically, 
elucidating the impact(s) of BCO1 on prostatic physiology and hepatic lipid metabolism will be 
important to understanding the complex interplay between carotenoid metabolism and prostatic 
disease. Secondly, although much epidemiological and animal work has focused on the effects of 
dietary tomato carotenoids on primary PCa, little is known about the effects on CRPC, which 
represents the lethal phase of the disease. Therefore, the aims of this dissertation are the 
following: 
 
1. Elucidate the impact of Bco1 loss on prostatic physiology, with a focus on androgen 
responsiveness, 
 
2. Determine the impact of Bco1 loss on lipid, cholesterol, and retinoid metabolism in the 
liver, a key organ in the metabolism and biodistribution of dietary carotenoids, and 
 
3. Evaluate the effects of dietary tomato feeding on an animal model of CRPC and determine 
its efficacy in preventing disease progression. 
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Figure 1.1. Structures of major dietary carotenoids and biologically active retinoids.   
A all-trans lycopene, B all-trans ζ-carotene, C all-trans phytofluene, D all-trans 
phytoene, E tetra-cis (7,9,7ʹ,9ʹ) lycopene, F 5-cis lycopene, G all-trans β-carotene, H 
all-trans retinal, I all-trans retinol, J all-trans retinoic acid, K 11-cis retinal, L 9-cis 
retinoic acid, M α-carotene, N lutein. 
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Figure 1.2. 
  
 
 
Figure 1.2. The anatomies of the adult human (left) and adult mouse 
(right) prostates. Reproduced from 256.  
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CHAPTER 2 
Serum testosterone and prostatic androgen receptor signaling are reduced in 
mice lacking the carotenoid cleavage enzyme β-carotene-15,15’-dioxygenase 
 
Abstract 
 β-carotene-15,15’-dioxygenase (BCO1) cleaves dietary carotenoids at the central 15,15’ 
double bond, most notably acting on β-carotene to yield retinal. However, Bco1 ablation also 
impacts diverse physiologic endpoints independent of dietary carotenoid feeding, including 
expression of genes controlling androgen metabolism. Using the Bco1-/- mouse model, we sought 
to probe the effects of Bco1 ablation on testicular steroidogenesis, serum testosterone levels, and 
prostatic androgen signaling. Male wild-type (WT) and Bco1-/- mice were raised on carotenoid-
free AIN-93G diets before sacrifice between 10-14 weeks of age. Bco1 gene ablation 
significantly decreased serum testosterone concentrations and altered prostatic homeostasis. 
Organ weights of the prostate and seminal vesicles were significantly lower in Bco1-/- than in WT 
mice (-18% and -29%, respectively). Serum testosterone levels in Bco1-/- mice were significantly 
reduced by 73%. Bco1 ablation reduced Leydig cell number and decreased testicular mRNA 
expression of Hsd17b3 while increasing Hsd17b2 expression, suggesting a possible inhibition of 
testicular testosterone synthesis. Immunofluorescent staining of the androgen receptor (AR) in 
the dorsolateral prostate lobes of Bco1-/- mice revealed a modest decrease in AR nuclear 
localization and analysis of prostatic H&E morphology suggested decreases in gland size. These 
findings were supported by a reduction in immunofluorescent labeling of the proliferation 
marker Ki67 in Bco1-/- prostates. Expression analysis of 200 prostate cancer- and androgen-
related genes suggested that Bco1 loss significantly disrupted prostatic androgen receptor 
signaling, cell cycle progression, and proliferation. This is the first demonstration that Bco1 
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ablation impacts murine prostatic cell proliferation and androgen receptor signaling, further 
supporting the role of this gene in processes more diverse than carotenoid cleavage. 
 
Introduction 
 Experimental evidence demonstrating that β-carotene is a precursor to vitamin A, and 
therefore serves as a provitamin, dates to the late 1920s. However, elucidation of the mechanism 
of action of this conversion remained a mystery until 1965, when two independent reports 
demonstrated the enzymatic cleavage of β-carotene to retinal and retinol using extracts of rat 
liver and intestine 1,2. Additional studies over the next several decades determined the 
characteristics and specificity of this new enzyme 3, identified iron as a required cofactor 4, and 
proposed central cleavage metabolites as the main reaction products 5. Still, the molecular 
identity of this crucial enzyme remained unknown for 35 years, until the cloning of the 
Drosophila ortholog of human BCO1 in 2000 6. Biochemical characterization of recombinant 
mammalian enzymes 7,8, tissue-specific expression in humans 9, and description of mutational 
events 10 followed in short order. The mechanism of its enzymatic activity was debated for an 
additional 14 years, until careful double-labeling experiments confirmed that BCO1 is a 
dioxygenase 11. Genomic research has now identified single nucleotide polymorphisms (SNPs) in 
the human BCO1 gene, which result in altered accumulation of dietary carotenoids, including β-
carotene 12–14. 
 Meanwhile, carefully controlled studies in mice lacking functional copies of this enzyme 
demonstrate the importance of BCO1 in carotenoid cleavage. These mice experience dramatic 
accumulation of β-carotene and are unable to generate vitamin A when fed a diet providing β-
carotene as the predominant or only source of vitamin A 15,16. However, these mice often present 
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additional phenotypes independent of their dietary vitamin A status, including altered lipid 
metabolism 15, impaired lipid, cholesterol, and retinol esterification 17, cardiac dysfunction 18, 
elevated insulin and leptin levels 19, and changes in expression of genes controlling steroid 
metabolism 20. A preponderance of evidence now suggests that whereas central cleavage of 
provitamin A carotenoids to yield retinal represents the main evolutionary function of BCO1, 
this enzyme likely plays a broader role in an array of physiological processes. Given the 
demonstrated effect of Bco1 ablation on the expression of genes responsible for steroid 
metabolism 20 and our group’s longstanding interest in the role of dietary carotenoids in prostate 
carcinogenesis 21,22 – which is driven by androgens – we questioned the extent to which Bco1 
ablation and dietary tomato carotenoids may alter androgen biology in male mice. Therefore, in 
this report, we have assessed the impact of homozygous genomic Bco1 deletion and short-term 
dietary lycopene or tomato feeding on serum concentrations of sex steroids (testosterone and 
estradiol), testicular morphology, genes controlling testicular steroid and cholesterol metabolism, 
prostatic morphology, prostatic androgen receptor signaling, and prostatic cell proliferation. 
 
Materials and Methods 
Animals and study designs  
All animal procedures were approved by the University of Illinois Institutional Animal 
Care and Use Committee.  
Generation of Bco1-/- animals has been described previously 15. C57BL/6J x 129/SvJ F1 
cross and C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice 
were housed in shoebox cages in a temperature- and humidity-controlled facility with ad libitum 
 70 
access to water. Mice were acclimated to powdered AIN-93G diet for two to three weeks before 
exposure to experimental diets. 
Three studies were completed to investigate the effects of tomato carotenoid feeding and 
Bco1 loss on prostatic and androgen biology. Study 1 and Study 2 examined interactions 
between Bco1 status and short-term tomato carotenoid feeding, whereas Study 3 was designed to 
investigate only Bco1 genotype effects. 
 The experimental design for Study 1 has been described previously 23. Nine- to twelve-
week-old male wild-type (WT; C57BL/6J x 129/SvJ F1) or Bco1-/- mice were randomly assigned 
to one of two study arms, consisting of a tomato powder (TP) or lycopene (LYC) diet group and 
their respective control diet group (Appendix Fig. A.1). TP diet consisted of powdered, 
modified AIN-93G diet with 10% w/w tomato powder (Futureceuticals, Momence, IL). LYC 
diet consisted of powdered, modified AIN-93G diet with the addition of 0.1% w/w water-soluble 
beadlets containing purified lycopene (10% w/w, DSM, Basel, Switzerland). Control diets for the 
TP and LYC diets consisted of powdered, modified AIN-93G (CON) and powdered, modified 
AIN-93G + 0.1% w/w placebo beadlets (CON+P), respectively. Diets were formulated to be 
isocaloric and balanced for levels of protein, fat, carbohydrates, and fiber (Appendix Table 
A.1). Mice (n = 25 per genotype/diet) consumed the experimental diets ad libitum for four days, 
after which they were fasted for three hours, asphyxiated with CO2, and blood collected via 
cardiac puncture. Tissues were collected, frozen in liquid nitrogen, and stored at -80 ˚C until 
analysis.  
 Study 2 was designed to replicate Study 1, with slight modifications. Ten- to thirteen-
week-old male WT (C57BL/6J) and Bco1-/- mice were randomized onto one of three powdered 
AIN-93G-based diets: 10% w/w tomato powder + 0.1% w/w placebo beadlets (TP+P), 0.1% w/w 
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lycopene beadlet (LYC), or control diet + 0.1% w/w placebo beadlets (CON+P) (Appendix Fig. 
A.1). Inclusion of placebo beadlets in the control and tomato diets allowed statistical comparison 
across all three diet groups. Tomato powder and beadlet sources were the same as in Study 1. 
Mice (n = 15 per genotype/diet) consumed the experimental diets for four days ad libitum and 
were euthanized in the same manner as in Study 1. One testicle per mouse was fixed in 10% 
neutral-buffered formalin for 24 h, whereas all other tissues were frozen in liquid nitrogen and 
stored at -80 ˚C until analysis. 
 In Study 3, Ten-week-old WT (C57BL/6J) and Bco1-/- mice (n = 10 - 11/genotype) 
consumed CON+P diet for four days ad libitum and were euthanized in the same manner as in 
Study 1. Only the CON+P diet was fed in Study 3 (Appendix Fig. A.1), as this study was 
designed to examine only the effects of Bco1 ablation. One lobe of the anterior, dorsolateral, and 
ventral prostate per mouse was fixed in 10% neutral-buffered formalin for 24, whereas all other 
tissues were frozen in liquid nitrogen and stored at -80 ˚C until analysis.  
In all three studies, mice were euthanized between 13:00 and 16:00 U.S. Central Time to 
control for diurnal variation in hormone levels. Designs of all three studies are shown in 
Appendix Fig. A.1.  
 In Study 1, the LYC diet provided 248 nmol lycopene/g diet, whereas TP diet provided 
204 nmol lycopene/g diet, 10.1 nmol phytoene/g diet, 2.6 nmol phytofluene/g diet, and 0.8 nmol 
beta-carotene/g diet. In Study 2, LYC diet contained 185 nmol lycopene/g diet whereas TP+P 
provided 214 nmol lycopene/g diet, 24.6 nmol phytoene/g diet, 14.6 nmol phytofluene/g diet, 
and 1.9 nmol beta-carotene/g diet Appendix Table A.1. All diets were reduced in vitamin A 
content to 1500 IU retinyl palmitate/kg in order to ensure intestinal carotenoid absorption while 
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not resulting in vitamin A deficiency 15,16. Diets were formulated every one to two months and 
stored in the dark at 4 ˚C. Fresh diet was provided to animals each study day. 
Serum testosterone and estradiol analysis 
Serum steroids were extracted with diethyl ether and lipids were removed with a biphasic 
hexane-methanol extraction. Briefly, 150 µL of serum was spiked with approximately 1000 cpm 
of tritiated testosterone (Perkin-Elmer, Waltham, MA) and vortexed for 3 minutes with 6 mL 
diethyl ether (Sigma, St. Louis, MO). The aqueous phase was frozen in dry ice-cooled methanol 
and the ether extract was removed and evaporated. Hexane and methanol (1.5 mL each; Sigma) 
were added to each tube and vortexed for 3 minutes. The hexane and methanol layers were 
allowed to separate for 30 minutes and the bottom methanol layer was removed and dried. 
Samples were reconstituted in phosphate-buffered saline + 1% w/v gelatin. 15 µL was removed 
for scintillation counting and calculation of extraction efficiency, which averaged 75% for both 
the testosterone and estradiol assays. In Study 2, serum testosterone was quantified with a 
radioimmunoassay (RIA) kit (TKTT1 Coat-A-Count Total Testosterone, Siemens, Malvern, PA) 
per manufacturer’s instructions, but with a customized standard curve. In Study 3, due to 
manufacturer’s discontinuation of the RIA, serum testosterone was measured using a coated-
plate ELISA, per manufacturer’s instructions (Arbor Assays, Ann Arbor MI). Inter-assay %CV 
was 14% for the RIA; intra-assay %CV was 5% for the RIA and 17% for the ELISA. Serum 
estradiol was quantified with an RIA (KE2D1 Double Antibody Estradiol, Siemens) per 
manufacturer’s instructions, but with a customized standard curve. 
Gene expression 
Total RNA was extracted from pooled prostate (Study 1) and dorsolateral prostate (Study 
2) using RNEasy Mini spin columns (Qiagen, Valencia, CA) according to manufacturer’s 
 73 
instructions. cDNA was synthesized using the High-Capacity Reverse Transcription Kit (Life 
Technologies, Grand Island, NY). qPCR was carried out with SYBR Green chemistry (Life 
Technologies) on an ABI 7900 HT qPCR platform (Life Technologies), using pre-designed 
primer assays (Cyp17a1, Hsd17b2, Hsd17b3, Scarb1, Hmgcr, Vim, and Actb; SA Biosciences, 
Valencia, CA) or custom-designed oligonucleotide primers (Integrated DNA Technologies 
(IDT), Coralville, IA) (Appendix Table A.2). Oligonucleotide primers were validated for 
specificity and amplification efficiency.  
 NanoString nCounter technology was used for prostatic gene expression analysis on a 
custom-designed 200-gene codeset (Appendix Table A.3), which has been described previously 
24. RNA was extracted from the dorsolateral prostates of mice from Study 3 as described above 
and 100 ng total RNA was used directly for gene expression analysis 25. Data were subjected to 
global normalization (global mean fold-change = 1.06; 95% confidence interval: 0.97, 1.14). 
Transcripts with expression below negative control group means were excluded from further 
analysis. A heat map was constructed in the nSolver Analysis Software by subjecting Z-scored 
samples (columns) and genes (rows; labels not shown) to Ward’s minimum distance linkage 
within Pearson’s correlation hierarchical clustering.  
Protein expression 
 Tissues were lysed in RIPA buffer with the addition of Halt Protease Inhibitor Cocktail, 
EDTA-Free (Pierce Thermo Scientific, Rockford, IL), and protein quantified using the BCA 
assay (Pierce Thermo Scientific). After SDS-PAGE and transfer onto PVDF membranes (0.45 
µm Immobilon-P, Millipore), blots were blocked with 5% nonfat dry milk and probed for 
Cyp11a1 (sc-18043, Santa Cruz Biotechnology, Dallas, TX; 1:200 dilution) with GAPDH 
(#5174, Cell Signaling Technology, Danvers, MA; 1:4000 dilution) as the loading control. 
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Androgen receptor (#06-680, Millipore; 1:500) was measured relative to histone H3 (#4499, Cell 
Signaling; 1:2000) as the loading control. HMG-CoA reductase expression was probed (sc-
33827, Santa Cruz; 1:1000) with GAPDH as the loading control. Detection was with donkey 
anti-goat (sc-2020, Santa Cruz; 1:5000) and goat anti-rabbit (#7074, Cell Signaling; 1:2000) 
HRP-linked secondary antibodies, SuperSignal Molecular Weight Protein Ladder (Pierce 
Thermo Scientific), and Amersham ECL Prime Western Blotting Reagent (GE Life Sciences, 
Pittsburgh, PA) on an ImageQuant LAS 4000 imaging station (GE Life Sciences). Relative band 
densitometry was performed in ImageJ software (Rasband, W.S., ImageJ, U. S. National 
Institutes of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/) by integration of 
intensity profile area-under-the-curve. 
Histology 
 Testes from Study 2 and prostate from Study 3 were fixed in 10% neutral-buffered 
formalin for 24 hours, transferred to 70% ethanol until embedding in paraffin blocks, and cut 
into five-micron sections. Cross-sectional testicular sections were stained with periodic acid-
Schiff-hematoxylin (PAS-H) and prostatic sections were stained with hematoxylin and eosin 
(H&E). Staining was done in the Comparative Biosciences Histology Laboratory at the College 
of Veterinary Medicine, University of Illinois at Urbana-Champaign. Slides were digitized with a 
NanoZoomer 2.0-HT slide scanner (Hamamatsu, Bridgewater, NJ) equipped with an Olympus 
Uplansapo 10X objective (Tokyo, Japan). Images were captured with NDP View software 
(Hamamatsu). 
 A blinded evaluator with expertise in comparative pathology (Matthew A. Wallig, Ph.D., 
D.V.M.) assessed testicular and prostatic pathology. Testes were graded on the basis of 
seminiferous tubule contraction/dilation and the vacuolation, apoptosis, necrosis, and size of 
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Sertoli and Leydig cells (score 1 = <5% affected, 2 = 5-25% affected, 3 = 26-50% affected, 4 = 
51-75% affected, 5 = >75% affected). Prostates were graded on the basis of gland size (score 0 = 
normal, 1 = slight decrease, 2 = decrease, 3 = marked decrease) and abundance of glandular 
secretion (score 0 = 0% decrease, 1 = <20% decrease, 2 = 20-40% decrease, 3 = >40% decrease). 
Testicular morphology (seminiferous tubule number, total tubule size, tubule lumen area, 
and tubule epithelial area) was measured in Fiji using the following method: 1) representative 
frames of H&E-stained testicular sections were captured at 10x optical magnification; 2) 
circumference of individual seminiferous tubules which were no less than 80% within frame was 
manually traced and total tubule area [lumen + epithelium; ta] calculated in µm2; 3) lumen 
circumference of individual seminiferous tubules was manually traced and lumen area [la] 
calculated in µm2; 5) epithelial cell layer area [ea] of individual seminiferous tubules was 
calculated as  !" = !" − !"; 6) seminiferous tubules measured in this fashion were counted; 7) 
TA, LA, and EA were calculated as the averages of ta, la, and ea, respectively, across all counted 
seminiferous tubules; 8) Leydig cells were counted and expressed as cell count/1000 µm2 TA. All 
calculations were subsampled across 6 - 7 seminiferous tubules/frame and 2 - 3 frames/slide. 
Averages for an entire slide (i.e., animal/experimental unit) were used for statistical analysis.  
Immunofluorescence imaging 
Formalin-fixed, paraffin-embedded prostatic sections from Study 3 used for 
immunofluorescence imaging. Background Punisher blocking agent (Biocare Medical, Concord, 
CA) was used to reduce non-specific binding. Sections were probed for AR or Ki67 with primary 
(AR: 1:100, Millipore; Ki67: 1:600, #9129, Cell Signaling) and secondary antibodies (DyLight 
488, 1:200, #111-487-03-03, Jackson ImmunoResearch Laboratories, West Grove, PA). Nuclei 
were stained with 4',6-diamidino-2-phenylindole (DAPI, 1:1000, #32670, Sigma-Aldrich). 
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Negative controls were created for each sample by omission of the primary antibody; non-
specific staining was revealed to be minimal (data not shown). Slides were imaged on a Zeiss 
LSM 700 confocal microscope at the Core Facilities of the University of Illinois Carl R. Woese 
Institute for Genomic Biology.  
 Nuclear AR staining was scored on a qualitative three-point scale; a score of 1 indicating 
predominantly diffuse cellular AR localization with the absence of punctate nuclear staining, and 
a score of 3 corresponding to predominantly nuclear staining, at times with cytoplasmic 
exclusion. Scores from subsample images (2 - 4/prostate lobe/mouse) were averaged and 
rounded to the nearest integer. A similar approach has been demonstrated previously 26. 
 Ki67 quantitation was performed on 20x confocal images in Fiji using a thresholding-
watershed cell counting method (Fiji. Nuclei Watershed Separation. Available from 
http://fiji.sc/Nuclei_Watershed_Separation. Accessed Nov 2, 2015). 
Statistical analysis 
 Data are presented as mean ± SEM. With the exception of the NanoString gene 
expression analysis, all data were analyzed with two-way ANOVA and results were considered 
statistically significant at p ≤ 0.05. Data were transformed logarithmically when normality 
assumptions were violated. Individual group variances were used in place of the pooled variance 
when homogeneity of variance assumptions were violated. In Study 1, the CON/TP and 
CON+P/LYC study arms were analyzed as separate 2x2 factorial designs. Where appropriate, 
data were blocked by study cohort, assay batch, or sacrifice order. ANOVA analysis was done in 
SAS v9.3 (SAS Institute, Cary, NC). For NanoString expression analysis, calculations of fold 
regulation by Bco1-/- genotype  (relative to WT) were done within the NanoString nSolver 
Analysis Software (NanoString Technologies, Seattle, WA). Pairwise T-tests were considered 
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significant at α = 0.005. False discovery rate (FDR) at α = 0.005 was estimated to be FDRhat = 
0.060 (95% confidence interval: 0.053, 0.068) using the method of Storey 27,28. 
 
Results 
Effects of dietary tomato or lycopene 
  Short-term tomato or lycopene feeding had no effect on most of the endpoints measured. 
As a result, only main effects of Bco1 genotype in animals fed the CON+P diet will be addressed 
in this chapter, with two exceptions. Testicular expression of 3-hydroxy-methylglutaryl-
coenzyme A reductase (HMG-CoA reductase) protein and testicular mRNA expression of 
steroidogenic acute regulatory protein (Star), were impacted by tomato or lycopene feeding, 
effects which were modulated by Bco1 genotype. Those results are displayed in Appendix A 
(Appendix Fig. A.4A-D) and interpreted in the discussion. Data of outcomes with dietary 
treatments, rather than the genotype-only data presented in this section, are displayed in 
Appendix A and referenced throughout. 
Prostate and seminal vesicle weights are decreased in Bco1-/- mice 
We observed no effect of Bco1 ablation on body weight or testicular weight (Fig 2.1C, 
D; Appendix Fig. A.2C, D). Bco1 ablation reduced prostate weight as a percentage of total body 
weight (%BW). Total prostate %BW was significantly decreased by 18% in Bco1-/- mice 
compared to WT (p < 0.001, Fig. 2.1A), an effect replicated in a second independent trial (-14%, 
p < 0.001, Appendix Fig. A.2E).  
The seminal vesicles, like the prostate, are dependent upon androgens for growth; 
similarly, Bco1-/- mice were found to have statistically significant decreases in seminal vesicle 
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%BW, compared to WT (-29%, p < 0.001, Fig. 2.1B). A second study confirmed these 
observations (-18%, p < 0.001, Appendix Fig. A.2F). 
Serum testosterone is decreased in Bco1-/- mice 
 Given the significant reductions in the weights of the prostate and seminal vesicles, we 
measured circulating concentrations of the sex steroids testosterone and estradiol. Serum 
testosterone levels were significantly lower in Bco1-/- mice than in WT mice, as measured by 
RIA (3.9 ± 0.3 nM vs. 14.6 ± 5.4 nM, respectively, p < 0.05; Fig 2.2). This observation was 
replicated in a second independent trial, as measured by ELISA (4.1 ± 0.9 nM in WT vs. 2.5 ± 
0.5 nM in Bco1-/-, p < 0.001; Appendix Fig. A.3B). Serum concentrations of estradiol, as 
measured by RIA, were unchanged by genotype (99.3 ± 5.0 pM in WT vs. 100.7 ± 4.8 pM in 
Bco1-/-, Appendix Fig. A.3C, D).  
Bco1 ablation alters testicular morphology and reduces Leydig cell number 
Morphological assessment of testicular sections from WT and Bco1-/- mice (Fig. 2.3C) 
revealed an increase in total seminiferous tubule area as a result of Bco1 ablation (Fig. 2.3A). 
Pathological grading corroborated this finding, suggesting a modest increase in tubule dilation in 
Bco1-/- mice compared to WT mice (data not shown). Necrosis, apoptosis, vacuolation of Sertoli 
or Leydig cells, and alterations in Leydig cell size were all determined to be minimal/normal 
(data not shown). The increase in seminiferous tubule area was driven by expansion of the 
epithelial compartment, rather than an increase in tubule lumen area (Fig. 2.3A). Counting of 
Leydig cells (normalized to tubule area) revealed a 44% decrease in Leydig cell number in  
Bco1-/- mice, compared to WT (Fig. 2.3B). 
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Testicular androgen biosynthetic capacity at the mRNA level is reduced in Bco1-/- mice 
Testicular Leydig cells obtain cholesterol substrate for testosterone synthesis via 
lipoprotein import or through de novo synthesis. Seven key mediators of testicular cholesterol 
acquisition (de novo and selective uptake), steroidogenesis, and androgen metabolism were 
assayed to determine the effects of Bco1 ablation on testicular steroidogenic potential (Fig. 2.4). 
No differences in expression of genes or proteins controlling testicular de novo cholesterol 
synthesis (Hmgcr transcript, HMG-CoA reductase protein), cholesterol uptake (Scarb1), 
cholesterol transport (Star), or general steroidogenesis (CYP11A1 protein, Cyp17a1 transcript) 
were observed. However, transcript levels of Hsd17b3, which encodes an enzyme responsible for 
the final reduction of androstenedione to testosterone 29, were significantly decreased by Bco1 
ablation (69% of WT, p < 0.01). Conversely, the enzyme produced by the Hsd17b2 gene 
catalyzes the reverse reaction, converting testosterone back to its less active precursor 30; 
testicular Hsd17b2 mRNA expression was significantly upregulated 34% (p < 0.05) in Bco1-/- 
mice (Fig. 2.4).  
Prostatic androgen receptor signaling and markers of cellular proliferation are reduced in Bco1-/- 
mice 
 Concurrent observations of decreased prostatic weight and reduced serum testosterone 
concentrations suggest that Bco1 ablation may alter prostatic biology through androgen-
dependent pathways. We explored this hypothesis by examining prostatic androgen receptor 
(AR) expression and subcellular localization, the expression of AR-target genes, and the 
expression of genes controlling apoptosis, cell cycle progression, and cellular proliferation.  
We performed confocal fluorescence microscopy to evaluate the effect of Bco1 ablation 
on prostatic AR nuclear localization. Representative confocal microscopy images are shown in 
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Fig. 2.5Ai, ii, vi, and viii, demonstrating a modest reduction in nuclear AR staining in 
dorsolateral prostate sections from Bco1-/- mice, compared to WT. As seen in Fig. 2.5Aiii and 
2.5Aviii, Bco1 ablation reduced qualitative scores of nuclear localization. Moreover, 
morphological assessment of H&E-stained dorsolateral prostate sections (Fig. 2.5Aiv, ix) 
revealed a similar shift, resulting in smaller gland structures in Bco1-/- mice, compared to WT 
(Fig. 2.5Av, x). These effects were limited to the dorsolateral prostate, and were not observed in 
the ventral or anterior prostate lobes (data not shown).  
Although Bco1 loss appeared to decrease nuclear localization of the AR, total levels of 
AR mRNA or protein were unchanged (Fig. 2.5B, Appendix Fig. A.7). 
Due to the morphological changes we observed in the prostates of Bco1-/- mice, we 
assessed proliferation through immunofluorescent labeling of Ki67 protein. Ki67 labeling (as a 
percentage of total nuclei) was reduced by nearly half in the dorsolateral prostate of Bco1-/- mice 
(1.85% ± 0.19% in WT vs. 0.98% ± 0.11% in Bco1-/-, p < 0.001) and trended lower in the 
anterior prostate (2.56% ± 0.78% in WT vs. 1.01% ± 0.17% in Bco1-/-, p = 0.09) (Fig. 2.5C). 
We hypothesized that the reduced prostatic weight and proliferation in Bco1-/- mice 
resulted from decreased prostatic AR signaling, potentially impacting the expression of genes 
involved in growth and proliferation. Therefore, using a previously described custom NanoString 
gene expression array 24, we measured the dorsolateral prostate expression of 200 genes involved 
in androgen synthesis, AR signaling, apoptosis, cell cycle progression, proliferation, and prostate 
carcinogenesis. Bco1 ablation significantly (p < 0.005) modulated 13 genes of the 200-gene 
codeset (Fig. 2.6B and Table 2.1). The entire dataset is presented in Appendix Table A.3. 
Among the 13 genes significantly altered were genes involved in proliferation (Ki67, -44%; 
Pcna, -12%), G2 to M cell cycle progression (Aurkb, -54%; Ccnb2, -51%), apoptosis (Bax, -
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18%), and cell-cell communication, intracellular signaling, or gene transcription (Kras, -89%; 
Tgfb2, -59%; Met, +66%; Esr2, +60%; Vegfa, +51%). To further elucidate prostatic pathways 
and biological processes potentially regulated by Bco1-/- genotype, the heat map of the entire 
200-gene code set (Fig. 2.6A) was visually inspected to identify signatures of differential 
regulation. Three gene clusters, assembled during heat map creation through minimum-distance 
clustering based on gene expression correlation, were identified as displaying potentially 
differential regulation due to Bco1 status. The 36 genes contained within these three clusters, 
along with their fold change, raw p-values, and gene ontology functional classifications 31,32, are 
presented in Table 2.1.  
To support our NanoString gene expression data, we used qPCR to measure the mRNA 
expression of an androgen-induced gene, Msmb, and a stromal marker not responsive to 
androgen, Vim. As expected, Msmb expression was significantly decreased (66% ± 10% of WT), 
whereas Vim expression remained unchanged by Bco1 knockout (Fig. 2.6C, Appendix Fig. 
A.8).  
 
Discussion 
 This work sought to investigate the effects of disrupted Bco1 function on androgen status 
and prostatic androgen receptor signaling in mice. We observed a reduction in serum testosterone 
levels due to Bco1-/- genotype, accompanied by reduced weights of the prostate and seminal 
vesicles. This reduction in serum testosterone may be driven by a reduction in testicular 
steroidogenic genes and/or reduced Leydig cell populations. Concomitantly, we observed 
reductions in markers of androgen signaling, proliferation, and cell cycle progression in the 
prostate. Together, these data support a hypothesis that Bco1-/- mice exhibit reduced testicular 
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testosterone synthesis, thereby lowering circulating testosterone, resulting in depressed prostatic 
androgen signaling, proliferation, and organ weight. 
 Both the prostate and seminal vesicles, as male sex accessory glands, are dependent upon 
androgens for growth and homeostasis. As clearly demonstrated by rodent castration studies, 
removal of circulating testosterone induces involution of the organ 33. In fact, prostatic regression 
after androgen deprivation is such a well-characterized response that it has been directly 
implemented as an assay to investigate the activity of putative AR agonists 34. Seminal vesicular 
response to androgen is very similar to that of the prostate 35. Rodent castration studies report 
reductions in prostate weight between 40% and 80% 36–38, and reductions in seminal vesicle 
weight of approximately 70% 36. Our results (-14% to -18% in total prostate weight, -18% to  
-29% in seminal vesicle weight) are more modest than found in castration studies, but this is 
expected, as the reductions in serum testosterone observed in our mice (-39% to -73%) are not as 
severe as reductions achieved by castration (-90% to undetectable levels; 39–41). However, since 
testosterone serves as a substrate for local prostatic synthesis of the most active androgen, 
dihydrotestosterone (DHT) 30, and prostatic DHT levels in mice correlate significantly with 
serum testosterone across a >100-fold range of concentrations 41, it is likely that both castration 
and Bco1 ablation serve to reduce the amount of testosterone available for local DHT synthesis 
in the prostate.  
 In men, it is estimated that up to half of the androgen in the prostate is derived from local 
conversion of adrenal steroid precursors, whereas the remainder is supplied directly as testicular-
derived testosterone 42. Rodents, however, secrete very little adrenal androgen precursors and the 
prostate in these species relies on testicular testosterone for virtually all androgenic activity 43,44. 
Testicular steroidogenesis is a multistep process that is dependent upon several key enzymes for 
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acquisition of cholesterol substrate. Whether cholesterol is synthesized de novo through the rate-
limiting step of HMG-CoA reductase (gene name Hmgcr), or is imported from circulating HDL 
via scavenger receptor class B, type 1 (SR-B1, gene name Scarb1), steroidogenic acute 
regulatory protein D1 (StAR) transports cholesterol across the outer mitochondrial membrane to 
the inter-membrane space for side-chain cleavage by the rate limiting enzyme for all steroid 
synthesis, CYP11A1 29. HMG-CoA reductase is well-known to be regulated both 
transcriptionally and translationally 45,46, whereas testicular levels of Scarb1 and Star are 
primarily under transcriptional control by cAMP-mediated, hormone-stimulated signaling 47,48. 
Expression of Scarb1 and Hmgcr mRNA, and HMG-CoA reductase protein, were not altered by 
the main effect of genotype (Fig. 2.4). However, we did observe a significant interaction in 
testicular HMG-CoA reductase protein expression between diet and genotype, such that dietary 
lycopene depressed expression in WT mice, but elevated expression in Bco1-/- mice (Appendix 
Fig. A.4B). A similar, but non-significant, trend was observed when mice were fed tomato 
powder (Appendix Fig. A.4A). This was an intriguing result, as other groups have found 
lycopene to reduce HMG-CoA reductase activity in cultured macrophages 49 and that several 
plant-derived terpenes (the chemical family to which lycopene and all carotenoids belong) 
reduced translation of Hmgcr transcript 50. Additionally, testicular Star mRNA expression was 
significantly reduced by a main effect of tomato feeding and a main effect of Bco1 ablation 
significantly increased expression across both the CON and TP diets (Appendix Fig. A.4C). 
However, this genotype effect did not reach significance in the CON+P-fed (Fig. 2.4) and LYC-
fed groups (Appendix Fig. A.4D).  
On one hand, these results suggest that 1) short-term tomato carotenoid feeding may alter 
expression of enzymes controlling cholesterol substrate acquisition for testicular steroidogenesis, 
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2) these may represent primary targets of lycopene action, and 3) Bco1 status may modify the 
effects of tomato carotenoid feeding. In opposition to such a hypothesis, however, is the 
observation that the effects seen are small and very likely not physiologically relevant. Indeed, 
when levels of testicular cholesterol were measured, levels of total (Appendix Fig. A.5A-B) and 
free (Appendix Fig. A.5C-D) cholesterol were unaltered by either Bco1 genotype or dietary 
treatment. Paradoxically, levels of esterified cholesterol were lower in Bco1-/- mice than in WT 
mice (Appendix Fig. A.5E-F), despite a lack of effect on the mRNA expression of two enzymes 
controlling cholesterol esterification, Soat1 and Soat2 (Appendix Fig. A.6A-D), and the 
increased expression of a third, Lcat (Appendix Fig. A.6E). Perhaps a longer period of dietary 
exposure to tomato carotenoids would induce greater and more consistent differences across the 
endpoints in testicular cholesterol metabolism that we measured here. Alternatively, the minor 
alterations in testicular cholesterol metabolism observed in this study may be secondary to 
perturbations in other organs, such as the liver. Regardless, the present data clearly do not 
support the hypothesis that Bco1 ablation or short-term tomato carotenoid feeding reduce serum 
testosterone through direct modulation of testicular cholesterol uptake, esterification, or de novo 
synthesis. 
In mice and humans, subsequent to cholesterol side-chain cleavage by CYP11A1, the 
cholesterol-derived sterol backbone is transported to the ER, where CYP17A1 catalyzes the 
production of several possible intermediate steroids, which are dedicated to sex steroid synthesis 
29. No differences in expression (Cyp11a1 protein, Cyp17a1 transcript) were detected for either 
of these enzymes, suggesting that decreases in serum testosterone in Bco1-/- mice are likely due 
to alterations specifically in androgen biosynthesis, rather than impacts at earlier stages of 
testicular steroidogenesis.  
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The final step of testosterone synthesis involves the reduction of the inactive androgen, 
androstenedione, to testosterone via 17β-hydroxysteroid dehydrogenase, isoform 3 (gene name 
Hsd17b3) 29,51. The importance of this enzyme in testosterone synthesis is made clear by 
observations that mutations in the human HSD17B3 gene result in male pseudohermaphroditism 
and an inability to produce testosterone 52. Conversely, Hsd17b2 catalyzes the reverse, oxidative 
reaction, converting testosterone back to inactive androstenedione 53. Relative to WT, transcript 
levels of Hsd17b3 were decreased 32% by Bco1-/- genotype, whereas Hsd17b2 was induced by 
34%. Using a basic ratio operation, we can calculate an Hsd17b3 / Hsd17b2 value of 0.51 
(0.68/1.34), suggesting that, at the transcript level, capacity for inactivation of testosterone to 
androstenedione is roughly double the biosynthetic capacity. However, this is a simplistic model, 
not accounting for the absolute level of expression for each gene: although Hsd17b3 is highly 
expressed in the testes, Hsd17b2 is not. In our data, average Hsd17b3 Ct was 22.6 and average 
Hsd17b2 Ct equaled 29.0; the absolute difference between these two values, and thus the 
exponential difference in transcript abundance of the two genes, is 6.4 Ct units. Computed, this 
corresponds to >84-fold difference in transcript abundance (26.4 = 84.4). Threshold values and 
cycling parameters were set equal for the two genes, and the difference in expression of the 
housekeeping gene, Actb, was <1-fold. Both primers were validated for amplication efficiency 
(data not shown). Therefore, we propose that although both Hsd17b3 and Hsd17b2 were 
significantly modulated by Bco1 ablation to putatively alter testosterone biosynthetic capacity, 
due to absolute transcript abundance, the observed decrease in serum testosterone was likely due 
to inhibition of Hsd17b3, whereas catabolic Hsd17b2 contribution was likely negligible. 
However, the mechanism by which Bco1 ablation impacts expression of Hsd17b3 and Hsd17b2 
in the testes remains to be determined. 
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In the testes, testosterone is produced by Leydig cells 54, as they express all of the 
necessary enzymes required for androgen synthesis 29,55. Experimental evidence demonstrates 
that reductions in Leydig cell number, through either apoptosis or necrosis, result in reduced 
testosterone production 56–58. Thus, we examined the testes of WT and Bco1-/- to determine 
whether altered morphology or decreased Leydig cell populations may help to explain the 
observed reduction in serum testosterone. We found that loss of Bco1 increased total 
seminiferous tubule area, driven by an increase in seminiferous epithelial area, rather than lumen 
area. Additionally, Leydig cell number, normalized to tubule area, was lower in Bco1-/- testes 
than in WT testes. Leydig cell counts were normalized to tubule area, rather than total area or 
tubule count, because variation in tubule diameter necessarily alters tubule packing density, and 
therefore, the volume of interstitial space where Leydig cells reside. No overt differences in 
Leydig apoptosis or necrosis were observed between groups. It may seem apparent that the 
observed reduction in serum testosterone levels would be a consequence of diminished Leydig 
cell number, it is not clear whether the reduction in Leydig cells is causative or a simply 
associated with other morphological changes in the testes. In addition, although expression of 
Hsd17b3 was reduced, other steroidogenic enzymes were unchanged, such as Cyp17a1 and 
CYP11A1, and yet others were induced (Star and Hsd17b2) - suggesting that a decrease in 
Leydig cell number did not reduce steroidogenic capacity en bloc.  
The testicular seminiferous epithelium consists predominantly of germ cells 
(spermatogonia, spermatocytes, spermatids, and spermatozoa), with the much less-common 
somatic Sertoli cells present on the basal perimeter 59. While it has been shown that global AR 
loss results in altered Sertoli cell number in the adult mouse testes 60, due to the small number of 
Sertoli cells normally present, such changes are not likely to impact seminiferous epithelium 
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thickness directly. Rather, perturbations in germ cell development can meaningfully influence 
composition and size of the epithelium. Typically, upon inhibition of testosterone secretion or in 
mice lacking functional AR, investigators have observed drastically reduced populations of 
spermatocytes and spermatids 61. In contrast, we observe reductions in serum testosterone in 
conjunction with a 24% increase in seminiferous epithelial area. Analysis of germ cells in 
testicular sections revealed a moderate decrease in spermatocyte apoptosis, which may explain 
these results, although the cause of this effect remains unclear. This study was not designed to 
allow for a comprehensive assessment of spermatogenesis and fertility, so firm conclusions 
would be improper at this point. Focused work in this area would be required to fully address 
questions regarding the impact of Bco1 genotype on spermatogenesis and fertility.  
Androgens mediate their actions at target tissues (such as the prostate) through specific 
binding to the AR and subsequent transcriptional regulation of genes containing androgen 
response elements (AREs). Unliganded AR exists as a monomer primarily localized to the 
cytoplasm 62. Upon ligand binding, AR undergoes a conformational change, dissociates from 
cytosolic chaperones, translocates to the nucleus, dimerizes, binds androgen response elements 
(AREs) on AR-target genes, and recruits transcriptional machinery to initiate a transcriptional 
program collectively referred to as ‘AR signaling’ 63,64. Genes activated in this AR signaling 
program serve to, among other functions, maintain epithelial differentiation, stimulate release of 
stromal-derived growth factors, and inhibit epithelial apoptosis 65–67. Translocation of ligand-
bound AR from the cytoplasm to the nucleus during AR signaling is thus a necessary step in 
androgen-dependent maintenance of the prostate; this process can serve as one marker of 
prostatic androgen status 62,68. WT animals displayed both nuclear and cytoplasmic AR staining 
within dorsolateral prostate luminal epithelia, but many Bco1-/- sections lacked the punctate 
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nuclear AR localization characteristic of active AR signaling. Ablation of Bco1 thus induced a 
downward shift in qualitative nuclear AR staining scores. This qualitative analysis suggests 
modest effects of Bco1 ablation on dorsolateral prostate nuclear AR localization, rather than 
drastic “on/off” regulation; such an effect aligns with the modest reductions seen in prostatic 
organ weight and serum testosterone levels. Similar methods of qualitative nuclear staining 
scoring have been previously used to describe modulation of nuclear AR localization within the 
rat prostate during castration and DHT administration 26. AR mRNA and total protein expression 
remained unchanged, suggesting that any androgen-regulated effects on the dorsolateral prostate 
of Bco1-/- mice may have been due to diminished AR activation, and not reduced expression of 
the receptor. This supports the hypothesis that Bco1 ablation impacts prostatic androgen status 
through depression of testicular testosterone synthesis, rather than through direct perturbation of 
the prostate. Indeed, in humans, BCO1 is not highly expressed in the prostatic epithelium, but 
greater expression is seen in both testicular Sertoli cells and the testosterone-producing Leydig 
cells 9.   
Previously, in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model of 
prostate cancer, our group has found that castration significantly reduced prostatic mRNA 
expression of cell growth and proliferation markers (Mki67, Aurkb, Ccnb2, Ccne2, Foxm1, and 
Birc5), which, with the exception of Foxm1, were also upregulated by TRAMP genotype during 
early carcinogenesis 24. Additionally, Wan et al. 24 reported that castration, as expected, 
modulated classical androgen-regulated genes, including down regulation of Nkx3.1 and 
induction of Igfbp3. We have obtained very similar results in the dorsolateral prostates of Bco1-/- 
mice. Msmb is an androgen-regulated gene known to be strongly repressed by castration and 
induced by testosterone repletion 69–72; in single-gene qPCR analysis, Bco1-/- genotype 
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significantly reduced Msmb expression, suggesting that Bco1 ablation impacted prostatic 
androgen receptor signaling. NanoString analysis revealed that markers of cell growth and 
proliferation (Pcna, Mki67, Aurkb, Ccnb2) were significantly reduced (p < 0.005), with several 
others (Aurka, Birc5, Ccne2, Foxm1) inhibited at 0.005 < p <0.05 (Table 2.1). Moreover, Wan et 
al. reported that prostatic Ki67 protein expression (gene name Mki67), as measured by 
immunofluorescent staining, was reduced by castration, but induced in early carcinogenesis 24. 
Similarly, we found that Bco1-/- genotype significantly reduced Ki67 labeling in the dorsolateral 
prostate, and trended towards a reduction in the anterior prostate. Although the fold-change 
differences were predictably higher in the castration and cancer model used by Wan et al., our 
results here show that Bco1-/- genotype not only mimicked decreases in proliferation seen with 
castration (both at the level of gene and protein expression), but also inhibited the expression of 
genes that are induced during early carcinogenesis. 
 Unexpectedly, Bco1 mRNA expression was increased 8.2-fold (p = 0.0001) in Bco1-/- 
mice compared to WT mice (Table 2.1). When this genetically engineered mouse model was 
created, disruption of Bco1 gene function was achieved through homozygous replacement of 
exons 2 and 3 of the Bco1 gene (approximately 8.8 kb) with IRES-lacZ and a neomycinR cassette 
15. This was confirmed by PCR genotyping (see also Appendix Fig. A.9). Mice of this strain do 
not express BCO1 protein 15 and they accumulate intact β-carotene when fed tomato powder 16, 
consistent with a lack of BCO1 cleavage function. However, the Bco1 probe used in this 
NanoString array targets 100 nt within exons 9 and 10 (see footnote † at Appendix Table A.3) – 
a portion of the gene that was not modified during generation of this model. The increased 
mRNA transcript expression detected with this specific Bco1 probe is likely a feedback response 
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to the absence of functional BCO1 protein. Bco1-/- genotype of mice in this study was confirmed 
by PCR (Appendix Fig. A.9).  
 After unguided visual inspection of the NanoString heat map (Fig. 2.6A), three gene 
clusters were identified as being potentially differentially regulated by Bco1-/- genotype (Table 
2.1). All 13 genes that were significantly regulated by Bco1 ablation (p ≤ 0.005) were included 
within these three clusters, representing 36% of the 36 total genes in the three clusters combined. 
In contrast, a random sample of 36 genes from the entire 200-gene code set would be expected to 
contain ~7% significant genes (13 / 200), or only 2 - 3 genes. The fact that these three clusters 
not only contained all of the significantly regulated genes in the entire analysis, but also 
represented a >5-fold enrichment of significantly regulated genes (36% / 7% = 5.1), suggests that 
they are the most biologically informative group of genes examined. Gene ontology 
classifications from the PANTHER database 31,32 demonstrates that cluster 1 predominantly 
contains genes involved in the regulation of proliferation, cell cycle regulation, and apoptosis, 
whereas clusters 2 and 3 contain genes implicated in cell-cell-communication, intracellular 
signaling, and gene transcription (Table 2.1). 
 
Conclusions 
Together, these data suggest that lowered prostatic AR activation, mediated by reductions 
in serum testosterone due to Bco1 ablation, results in decreased AR signaling within the prostate, 
reduced cellular proliferation, and a decreased rate of growth of the prostate. Moreover, the gene 
and protein expression patterns observed in Bco1-/- mice demonstrate a similar, although less 
dramatic, phenotype as that observed after castration. Previous work in mice shows that 
adiposity 73, diet-induced obesity 15, hepatic steatosis 15, adipocyte gene expression 15,73, 
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cholesterol esterification 17, triglyceride and phospholipid metabolism 17, serum insulin, leptin, 
and cholesterol 19, and cardiac lipid metabolism 18 are all impacted by Bco1 loss. In conjunction 
with this previous work, our findings continue to build a convincing argument for the existence 
of functions of BCO1 that are independent of carotenoid cleavage. Eleven studies 12–14,74–81 have 
investigated the impact of single nucleotide polymorphisms (SNPs) in the human BCO1 gene. 
These SNPs are common (most with a minor allele frequency between 0.25 and 0.50) and have 
been shown to impact carotenoid metabolism and distribution. However, only three of the studies 
74,77,78 investigated endpoints other than carotenoid metabolism and distribution. Greater 
understanding of the consequences of Bco1 ablation in this model may not only help to uncover 
new aspects of carotenoid metabolism, but it may inform the scientific community of the 
potential physiologic repercussions of natural genomic variation in the human BCO1 gene. This 
report adds novel data to the growing body of evidence demonstrating that, although cleavage of 
dietary carotenoids seems to be the major function of BCO1, its pleiotropic roles in mammalian 
physiology may extend far beyond carotenoid metabolism. 
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Figures 
 
Figure 2.1. 
           
                      
 
 
Figure 2.1. Bco1-/- loss reduces seminal vesicular and prostate weight as a percent of body 
weight. Total prostate (A), seminal vesicle (B), testes weight (C), as percent of total body weight 
(%BW). Body weight (D). Data are presented as group mean %BW ± SEM. n = 15, ***p < 
0.001.  
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Figure 2.2. 
 
            
Figure 2.2. Serum testosterone is reduced by Bco1 ablation. Data are presented as means ± 
SEM; n = 11-13. *p < 0.05.  
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Figure 2.3. 
   
   
 
 
Figure 2.3. Bco1 ablation increased seminiferous tubule total and epithelial areas (A) and 
decreased Leydig cell number (B). Representative images are shown in (C). Leydig cells (filled 
arrowheads) reside in the interstitial space between seminiferous tubules, often alongside blood 
vessels (asterisks). Cells within the seminiferous tubules include Sertoli cells (open arrowheads) 
and spermatocytes (filled arrows).  *p ≤ 0.05.  
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Figure 2.4. 
 
Figure 2.4. Bco1 ablation does not significantly affect testicular protein expression of HMG-
CoA reductase (HMG-CoA R) or CYP11A1, and does not alter mRNA expression of Hmgcr, 
Scarb1, Star, or Cyp17a1. Expression of Hsd17b3 is significantly decreased, while Hsd17b2 
expression is induced by Bco1 ablation. HMG-CoA reductase and CYP11A1 protein expression 
was measured by Western blot and Hmgcr, Scarb1, Star, Cyp17a1, Hsd17b3, and Hsd17b2 
mRNA expression was determined by qPCR. Data are presented as means ± SEM, n = 6 - 10,   
*p < 0.05, **p < 0.01. 
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Figure 2.5. 
 
 
 
 
Figure 2.5. Bco1 ablation alters prostatic morphology, AR localization, and proliferation, but 
does not impact AR expression. Bco1 ablation impacts nuclear AR localization within the 
dorsolateral prostate lobe (Aii, Avii), as well as alters dorsolateral prostate morphology (Aiv, 
Aix). Qualitative grading of immunofluorescent androgen receptor nuclear staining demonstrates 
a shift from high or moderate nuclear localization (score = 3 or 2) in WT mice (Aiii) to weak 
nuclear localization (score = 1) in Bco1-/- mice (Aviii). Qualitative grading of prostatic 
morphology reveals a shift from predominantly normal glandular size (score = 0) in WT mice to 
markedly decreased size (score = 3) in Bco1-/- (Av, Ax). Data in (Ai, Aii, Aiii, Avi, Avii, Aviii) 
are representative of 2 - 4 images in n=3 - 4 mice per genotype; data in (Aiv, Av, Aix, Ax) are 
representative of n = 9-10 mice/genotype. AR mRNA and protein expression is unchanged in 
Bco1-/- mice (B). Data are presented as means ± SEM; n = 11 - 14 for qPCR and n = 5 for 
Western blotting (WB). AR mRNA expression was normalized to Rpl19 and histone H3 (HH3) 
was used as a loading control for WB. Bco1 loss reduces Ki67 protein (as detected with 
immunofluorescent labeling) in the dorsolateral prostate (C); ***p < 0.001, n = 4 - 6. AP: 
anterior prostate; DLP: dorsolateral prostate; VP: ventral prostate. 
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Figure 2.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Prostatic androgen- and proliferation-related expression is altered in Bco1-/- mice. 
NanoString quantitative gene expression analysis for 200 proliferation-, androgen- and cancer-
related genes WT or Bco1-/- mice (n = 8 - 9) displayed in a heat map (A) and volcano plot (B).  
Z-scored samples (columns) and genes (rows; labels not shown) were subjected to Ward’s 
minimum distance linkage within Pearson’s correlation hierarchical clustering (A). Absolute 
log(fold-change) values of 0.25 and 0.50 approximately equal absolute fold-change values of 1.8 
and 3.2, respectively (B). qPCR-based single gene expression of Msmb and Vim in the prostates 
of mice (C); n = 7 - 14, *p < 0.05 vs. WT.  
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CHAPTER 3 
Loss of β-carotene-15,15’-dioxygenase alters  
hepatic vitamin A and lipid metabolism in mice  
Abstract 
 Dietary provitamin A carotenoids are converted to retinol by β-carotene-15,15’-
dioxygenase (BCO1). Much work has gone into the description of enzymatic carotenoid 
cleavage activities of the enzyme, but although pleiotropic effects of Bco1 loss on lipid 
metabolism in vivo have occasionally been described, few investigators have reported 
extensively on this. We sought to describe the effects of Bco1 loss on hepatic vitamin A status, 
lipid composition, and gene expression profile. Additionally, we describe phenotypic effects of 
Bco1 loss on organ weight across the lifespan. We found that vitamin-A sufficient, chow-fed 
adult (20 - 22 weeks of age) male Bco1-/- mice accumulate > 2-fold more hepatic vitamin A than 
wild-type (WT) controls, an effect driven exclusively by retinyl ester accumulation. Notably, 
Bco1 status significantly interacts with age across a wide range of developmental stages (<9 – 71 
weeks of age) to alter hepatic retinyl ester accumulation in a highly age-dependent fashion. 
Furthermore, Bco1-/- mice experience alterations in hepatic lipid metabolism, including a 2-fold 
increase of cholesteryl palmitate. Levels of this cholesteryl ester correlate with total vitamin A 
content, and gene expression analysis suggests that a retinoid – Pparg – Slc27a4 mechanism may 
increase palmitoyl-CoA levels to drive cholesteryl palmitate synthesis. Additionally, PPAR/RXR 
signaling may explain at least a part of the hepatic lipid phenotype observed in Bco1-/- mice, 
including the steatosis reported by several independent investigators. In summary, we report that 
Bco1 loss interacts with developmental age to alter hepatic retinyl ester accumulation, even when 
maintained on vitamin-sufficient diet. This effect may in turn result in altered RXR/PPAR 
signaling and a disruption of hepatic lipid metabolism. Investigators should be aware of retinoid 
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and lipid perturbations present in the Bco1-/- strain when using this mouse model to study the 
metabolism and distribution of lipophilic carotenoids and retinoids.  
 
Introduction 
In 2007, Hessel et al. were the first to describe the effects of genomic Bco1 ablation in a 
mammal 1. They reported that the Bco1-/- genotype abolished retinol production in mice fed β-
carotene as the major source of vitamin A; these data validated the hypothesis that BCO1 was the 
primary enzyme responsible for conversion of provitamin A carotenoids to retinol. Of the 68 
articles that have cited the Hessel paper (per PubMed as of 2/27/16), nearly all have cited it 
purely in relation to its biochemical function in carotenoid cleavage. Although retinol production 
from provitamin A carotenoids clearly seems to be the conserved evolutionary role for the 
enzyme, the Hessel paper also reported that Bco1-/- mice experience perturbations in hepatic lipid 
metabolism, even when provided adequate dietary levels of pre-formed vitamin A. Later reports 
also pointed to disruptions of lipid metabolism in Bco1-/- mice 2–5.  
These results, suggesting that Bco1 loss alters physiology through a mechanism not 
reliant on its function in β-carotene cleavage, are important for the interpretation of data arising 
from use of this model. If the loss of BCO1 function truly impacts biological outcomes 
independently from cleavage of dietary provitamin A carotenoids, studies on single nucleotide 
polymorphisms (SNPs) in the human BCO1 gene (which are common, with minor allele 
frequencies between 0.25 and 0.50) should take these broader effects into account. Of the 11 
studies that have investigated the effects of BCO1 SNPs 6–16, only 3 have investigated endpoints 
other than carotenoid metabolism and distribution 7,11,15 and only one explicitly examined 
markers of lipid status 7. Even in studies limited in scope to carotenoid metabolism and 
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distribution, it would seem important to acknowledge and account for potential changes in lipid 
metabolism, as carotenoids are lipophilic compounds that are absorbed and transported along 
with exogenous and endogenous lipids. 
As the “central hub” of mammalian metabolism, the liver is responsible for regulation of 
anabolism, catabolism, and peripheral distribution of lipids. Previous reports have described 
effects of Bco1 loss on hepatic lipid metabolism, but have either not investigated alterations in 
metabolism to the depth of individual lipid species 1, or have done so only in embryonic, and not 
adult, mice 3,4. Therefore, our goal was threefold: 1) in adult mice, describe the effects of Bco1 
loss on the composition of hepatic lipid pools at the level of individual fatty acid species, 2) 
investigate changes in gene expression which may be responsible for such alterations, and 3) 
report any changes in gross organ weight across the lifespan of Bco1-/- mice, as these key 
phenotypic data are currently missing from the literature. If scientists are to truly understand the 
role of BCO1 in the metabolism and distribution of the lipophilic dietary carotenoids, it is critical 
to elucidate its impact on lipid metabolism, especially in the liver. 
 
Materials and Methods 
Animals and study designs  
All animal procedures were approved by the University of Illinois Institutional Animal 
Care and Use Committee.  
Generation of Bco1-/- animals has been described previously 1. C57BL/6J x 129/SvJ F1 
cross (WT) mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and used in all 
experiments. Mice were housed in shoebox cages in a temperature- and humidity-controlled 
facility with ad libitum access to water. For the studies described, we have focused our studies 
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only on male mice, although the importance of expanding these investigations to female mice in 
the future is acknowledged. 
Two studies were completed. Study #1 investigated the effects of Bco1 loss on hepatic 
retinyl esters, composition of distinct lipid pools, and expression of genes governing lipid and 
cholesterol metabolism in mice fed a chow diet. In this study, male Bco1-/- mice (n = 8) were 
weaned from the breeding colony at 3 weeks of age onto a standard rodent chow (Harlan Teklad, 
Indianapolis, IN) and sacrificed at 21 – 22 weeks of age (one mouse was 36 weeks of age). Male 
WT mice (n = 8) were received from Jackson Laboratories at 4 - 8 weeks of age and consumed 
chow diet until sacrifice at 20 weeks of age. Tissues were harvested, weighed, frozen in liquid 
nitrogen, and stored at -80 ˚C until analysis. Chow pellets were replenished weekly. Study #2 
was designed to probe the effects of Bco1-/- genotype hepatic vitamin A status in mice 
consuming a nutritionally defined (vitamin A-sufficient, carotenoid-free, and semi-purified) diet. 
In addition, the interaction of Bco1-/- genotype with age was assessed through evaluation of WT 
and Bco1-/- mice at ≤9, 9, 31, 51, and 71 weeks of age. In this study, male Bco1-/- mice (n = 
8/age) were weaned from the breeding colony at 3 weeks of age onto a powdered, semi-purified 
AIN-93G-based diet and sacrificed at ≤9 (range, 5 - 8), 9, 31, 51, or 71 weeks of age. Male WT 
mice (n = 8/age) consumed the semi-purified diet upon arrival at 4 - 8 weeks of age until 
sacrifice at the same ages as Bco1-/- mice. Tissues were harvested, frozen in liquid nitrogen, and 
stored at -80 ˚C until analysis. The diet in Study #2 was devoid of carotenoids and contained 
1,500 IU retinyl palmitate/kg, which is sufficient to prevent deficiency 1,17. Composition of the 
diet in Study #2 was identical to the CON diet described in Chapter 2 of this dissertation.  
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Hepatic retinyl ester and free retinol analysis 
 Briefly, 100 – 150 mg of liver tissue was homogenized in a 1:1 mixture of PBS:absolute 
ethanol + 0.1% BHT (w/v). Retinyl acetate (1 µg) was spiked into homogenates for calculation 
of extraction efficiency. To preserve retinyl esters, samples were not saponified. The samples 
were extracted three times with 5 mL hexane, the nonpolar supernatant was separated by 
centrifugation (5 min @ 1056 x g, 4 ˚C), transferred to a new tube, and dried in a centrifugal 
evaporator (Savant, Thermo Scientific, Waltham, MA) and with compressed argon. Extracts 
were stored at -20 ˚C for <48 h before analysis. 
An HPLC system consisting of an Alliance e2695 separations module and 2998 
photodiode array (PDA) detector (Waters, Milford, MA), with column cooling set to 22 ˚C and 
sample cooling at 4 ˚C, was used for all analyses. The HPLC conditions for free retinol and 
retinyl ester separation were modified from a previously published method 18. A three-
component gradient method was composed as follows: mobile phase A: acetonitrile/H20/glacial 
acetic acid, 90/10/2; mobile phase B: acetonitrile/methanol, 90/10; mobile phase C: 
tetrahydrofuran, 100%. Separation was performed on a Supelco® Supelcosil LC-18 250 mm x 
4.6 mm x 5 µm analytical column (Sigma-Aldrich, St. Louis, MO) over a total run time of 36.2 
minutes, at 0.79 mL/min flow rate, and using the following linear gradient profile: 0 – 6.27 min 
at 100% A, 6.27 – 9.06 min to 100% B, 9.06 – 16.72 min to 60% B/40% C, 16.72 – 20.90 min 
hold at 60% B/40% C, 20.90 – 27.87 min to 100% B, 27.87 – 36.23 min back to 100% A. 
Retinyl palmitate, free retinol, and the retinyl acetate internal standard were identified by 
comparison to authentic standards (Sigma-Aldrich) and quantified using an external standard 
curve. Seven additional peaks surrounding the retinyl palmitate peak were identified as putative 
retinyl esters (retinyl laurate, retinyl linoleate/retinyl palmitoleate co-eluted peaks, retinyl 
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myristate, retinyl pentadecanoate, retinyl oleate, retinyl heptadecanoate, retinyl stearate) based 
on comparison to chromatograms from the published literature of retinyl esters positively 
identified using mass spectrometry 19. As all retinyl esters share the same chromatophore, the 
putative retinyl esters were quantified using the retinyl palmitate standard curve.  
Hepatic lipid analysis 
 Total hepatic lipids were extracted with the method of Folch et al. 20. For TLC-GC lipid 
analysis, internal standards (50 µg) for cholesteryl esters (C15:0; Sigma-Aldrich), 
phosphatidylcholine (C17:0, Avanti Polar Lipids, Alabaster, AL) and triglycerides (C17:0, 
Sigma-Aldrich) were added before extraction. Extracts were separated into cholesteryl ester 
(CE), phospholipid (PL), triglyceride (TG), and free fatty acid (FFA) pools on channeled 
Uniplate Silica Gel G (500 µm gel thickness) thin-layer chromatography (TLC) plates (Analtech, 
Newark DE), resolved with 80:20:1 petroleum ether:ethyl ether:acetic acid. Lipid bands were 
visualized under UV light with dichlorofluoroscein, scraped into new tubes, and derivatized to 
fatty acid methyl esters (FAMEs) with 3 mL methanolic HCl and 0.5 mL benzene at 75 ˚C for 90 
minutes. FAMEs were extracted with 1.8 mL petroleum ether after addition of 2mL K2CO3, 
dried under argon, and analyzed via gas chromatography (GC). GC analysis was performed on a 
GC-2010 Plus instrument (Shimadzu Corporation, Kyoto, Japan) equipped with a flame 
ionization detector set to 250 ˚C. Separation was achieved on a DB-FFAP 15 m x 0.1 mm x 0.1 
µm column (Agilent Technologies, Santa Clara, CA). FAMEs were identified by comparison of 
retention times to 20 authentic standards and quantified as a percent of total fatty acids, as 
previously demonstrated 21.  
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Gene expression 
Total RNA was extracted from liver tissue of animals in Study #1 using RNEasy Mini 
spin columns (Qiagen, Valencia, CA) according to manufacturer’s instructions. cDNA was 
synthesized using the High-Capacity Reverse Transcription Kit (Life Technologies, Grand 
Island, NY). qPCR was carried out with SYBR Green chemistry (Life Technologies) on an ABI 
7900 HT qPCR platform (Life Technologies), using pre-designed primer assays (Scd1, Fasn, 
Rpl19; SA Biosciences, Valencia, CA) and pre-designed PCR arrays (“PPAR Targets” and 
“Lipoprotein and Cholesterol Metabolism” arrays, SA Biosciences). Relative expression (to 
Rpl19) was calculated using the 2-ΔΔCt method. For analysis of the two PCR arrays, identical 
PCR cycling and threshold parameters were used, raw Ct data were combined into one dataset 
analyzed together relative to the mean of Actb and B2m expression, which was averaged across 
both arrays.  
Statistical analysis 
 Data are presented as mean ± SEM. Statistical analysis was done in SAS v9.3 (SAS 
Institute, Cary, NC). With the exception of the qPCR array analysis, all data were analyzed with 
two-way ANOVA and results were considered statistically significant at p ≤ 0.05. Repeated 
measures analysis was used to probe the effects of age in Study #2. Letters denoting statistical 
significance were assigned using a SAS macro that has been previously described 22. Data were 
transformed logarithmically when normality assumptions were violated. Individual group 
variances were used in place of the pooled variance when homogeneity of variance assumptions 
were violated. Correlations were calculated with PROC CORR and considered significant at p ≤ 
0.05. For qPCR array analysis, pairwise T-tests for each gene were calculated in Excel and 
considered significant at p ≤ 0.005.  
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Results 
Effects of Bco1-/- genotype on body and organ weight throughout the lifespan of male mice 
In Study#1, Bco1 loss did not alter the body or liver weights of adult (20 - 22 weeks old) 
chow-fed mice (Fig. 3.1A, B). Significant effects of genotype were observed in spleen and brain 
weights, both of which were reduced in Bco1-/- mice, compared to WT (Fig. 3.1C). At this age, 
weights of lungs, kidney, testes, and seminal vesicles were not affected by genotype. Prostate 
weights were not recorded in this study. In mice of <9, 9, 31, 51, or 71 weeks of age fed a semi-
purified, vitamin A-sufficient, carotenoid-free diet (Study #2), significant main effects of 
genotype and age were observed, as well as significant genotype*age interactions (Fig. 3.1D-I). 
Due to the significant effects of age on body weight (Fig. 3.1D), raw organ weights in Study #2 
were normalized to body weight and expressed as a percent of total body weight. Significant 
genotype*age interactions were observed in the liver (Fig. 3.1E), brain (Fig. 3.1F), testes (Fig. 
3.1G), seminal vesicles (Fig. 3.1H), and kidneys (data not shown). As in Study #1, a significant 
main effect of genotype reduced brain weight (Fig. 3.1F). Prostate weights were not recorded in 
this study. In every organ collected other than the heart (liver, lung, spleen, kidney, brain, testes, 
seminal vesicles), a significant main effect of age was observed. Weight of the heart, as a percent 
of body weight, trended lower in Bco1-/- mice at 51 and 71 weeks of age, compared to age-
matched WT mice (Appendix Fig. B.1). However, heart tissues were not collected in the <9 and 
9 week-old groups, and no statistically significant interaction or main effects of genotype and 
age were observed.  
Bco1 loss alters hepatic vitamin A accumulation 
 BCO1 has a well-established role in mammalian vitamin A metabolism. Therefore, we 
measured hepatic retinyl ester and free retinol levels, as the liver is the main storage depot for 
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this vitamin. In Study #1, in which mice did not consume a nutritionally defined diet, Bco1 loss 
increased hepatic retinyl ester levels more than two-fold (Fig. 3.2A). As expected, retinyl 
palmitate, identified by comparison to an authentic standard, was by far the predominant retinyl 
ester present, accounting for >80% of total vitamin A stores (Fig. 3.2C). Six additional retinyl 
esters, putatively identified by comparison of retention times with results from mass 
spectrometry experiments in the published literature 18,19, demonstrated significantly increased 
levels of accumulation, in ratios similar to retinyl palmitate. Conversely, levels of free retinol 
were not significantly modulated by Bco1 genotype (Fig. 3.2A). Overall, although Bco1 loss 
doubled total vitamin A stores, the relative abundances of free retinol and retinyl esters were not 
changed (Fig. 3.2C).  
Next, in order to rule out the possibility that variations in dietary preformed vitamin A were a 
cause of the observed increase in hepatic retinyl esters, we repeated the experiment in mice from 
Study #2, which were fed a nutritionally defined diet. Diets were devoid of provitamin A 
carotenoids, but were sufficient in preformed vitamin A. Additionally, tissues from Study #2 
allowed us to assess potential interactions between genotype and age. Bco1-/- genotype strikingly 
interacted with age to significantly modulate hepatic retinoid storage. As seen in Fig. 3.2B, Bco1 
loss at <9 or 9 weeks of age significantly reduced hepatic total vitamin A concentrations, 
whereas loss of the gene at 51 or 71 weeks of age significantly increased accumulation by more 
than 6-fold. Although not significant, Bco1 loss in 31-week old animals induced a numerical 
increase in vitamin A levels (>2-fold). As in Study #1, no changes in the relative abundances of 
retinol or retinyl esters were observed (Fig. 3.2D, Appendix Table B.1) and changes were 
driven almost entirely by levels of retinyl palmitate, which accounted for >80% vitamin A at 
every age (Appendix Table B.1). Each of the other six detected retinyl esters were modulated in 
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the same pattern as retinyl palmitate and total vitamin A stores (Appendix Table B.1). Bco1-/- 
genotype did not alter levels of retinol at any age (Appendix Table B.1).  
Bco1 loss increases hepatic total lipids in adult male mice 
Using the Folch method, we assessed total hepatic lipids in both Study #1 and Study #2. 
As seen in Figure 3.3A, Bco1 loss in adult (20-22 weeks old) male mice resulted in a modest, 
but statistically significant, increase in total lipid content of the liver. This effect appears to be 
somewhat variable in middle-aged adults, as lipid accumulation was not different between 
genotypes at 31 weeks of age in Study #2 (Fig. 3.3B). However, separation between the two 
genotypes appears to progress during aging and is statistically significant at 51 and 71 weeks of 
age (Fig. 3.3B).  
Bco1-/- genotype alters the composition of hepatic lipid pools in adult male 
 Retinoid signaling plays an important role in regulation of lipid metabolism. Therefore, 
given the observed changes in hepatic vitamin A accumulation, we assessed the percent 
abundance of 20 unique fatty acid species (derivatized to FAMEs) across four hepatic lipid pools 
(cholesteryl esters [CE], phospholipids [PL], triglycerides [TG], and free fatty acids [FFA]) in 20 
- 22-week old chow-fed WT and Bco1-/- mice (Table 3.1). Internal standards for CE, PL, and TG 
were spiked into the sample extraction mixture in known quantities (50 µg), allowing for 
estimation of the total mass of each of these three lipid pools. We observed numeric increases in 
total mass of each of the CE, PL, and TG pools in Bco1-/- mice, but none of the differences 
reached statistical significance (p = 0.26, p = 0.19, and p = 0.15, respectively; Table 3.1). Within 
the CE pool, palmitate increased from 10.6 ± 0.58% abundance in WT mice to 24.9 ± 2.32% in 
Bco1-/- mice. Three other minor species (cholesteryl gondoate, cholesteryl eicosadienoate, and 
cholesteryl erucate), ranging in abundance from 0.02 – 0.12%, were also increased in Bco1-/- 
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mice. As FAME species were calculated on the basis of percentage of the total lipid pool, the 
large increase in cholesteryl palmitate in Bco1-/- mice was accompanied by a significant 
reduction in unidentified peaks (79.4 ± 1.11% vs. 61.3 ± 5.89%). Palmitate was the predominant 
species in the CE lipid pool, but five additional species (palmitate, stearate, linoleate, 
arachidonate, and docosahexaenoate) were also in high abundance (>10%) in the PL pool. 
Changes in this pool were much more subtle than with CEs, and only one of the five high-
abundance FAMEs, stearate, was significantly modulated by Bco1-/- genotype (15.2 ± 0.31% in 
WT vs. 16.5 ± 0.29% in Bco1-/-). Four other minor species (linoleate, gondoate, eicosadienoate, 
and behenate) were significantly modulated by Bco1 loss. No lipid species were significantly 
modulated in the TG pool, which experienced relatively high variability. Finally, free fatty acids 
were also assayed. Similarly to CEs, levels of palmitate in this lipid pool were increased by Bco1 
loss (17.3 ± 0.95% vs. 20.6 ± 0.31%). Levels of free arachidonate were significantly decreased in 
Bco1-/- mice (2.34 ± 0.36 vs. 1.42 ± 0.04%).  
Genes controlling lipid and cholesterol metabolism are altered in livers of adult male Bco1-/- 
mice 
 To further elucidate the effects of Bco1 loss, we analyzed mRNA expression of genes 
controlling hepatic lipid metabolism in 20 - 22-week old chow-fed WT and Bco1-/- mice. First, 
with single-gene qPCR, we measured the expression of Scd1, which governs the ∂-9 desaturation 
of saturated fatty acids such as palmitate, and Fasn, which is the rate limiting step for fatty acid 
synthesis, and which yields palmitate. As seen in Figure 3.4A, neither Scd1 nor Fasn mRNA 
expression was altered by Bco1-/- genotype. To further characterize lipid metabolism in Bco1-/- 
mice, we assessed the mRNA expression of 163 genes involved in lipid, lipoprotein, and 
cholesterol metabolism (Appendix Table B.2). These genes were assayed with two separate 
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qPCR arrays, one focused on PPAR signaling, and the other on lipoprotein and cholesterol 
metabolism. Data output from both arrays were pooled, normalized, and analyzed together, as 
described in the Materials and Methods section. All 163 genes are shown in a volcano plot in 
Figure 3.4, with expression of the Bco1-/- group relative to WT mice as log(fold change) plotted 
against –log(p-value). Three genes which were regulated at p ≤ 0.05 but nonetheless had a basal 
(WT) expression of Ct > 30 (Mmp9, Src, Smarcd3) were not considered to be meaningfully 
expressed and were excluded from further analysis. These are noted as gray x’s on the volcano 
plot. Seven genes were significantly regulated (p ≤ 0.005; Apoa4, Sorl1, Acox3, Hsp90ab1, 
Fabp5, Gapdh, and Slc27a4), whereas an additional thirteen genes were regulated at 0.005 < p ≤ 
0.05 (Table 3.2). Most (15 / 20) of the regulated genes were present on only the PPAR signaling 
targeted qPCR array, whereas only 2 were present only on the lipoprotein and cholesterol 
metabolism array. Three regulated genes were present on both arrays, and their expression from 
each array was averaged. Regulated genes encoded lipoproteins or lipoprotein receptors (Apoa4, 
Apoa5, Sorl1), fatty acid binding or transport proteins (Fabp2, Fabp5, Slc27a1, Slc27a4), or 
were involved in β-oxidation (Cpt1b, Acox3, Mlycd) and PPAR signaling (Pparg, Ppard, Pprc1). 
The predominant liver PPAR isoform, Ppara, was not regulated by Bco1 loss. Genes involved in 
glycolysis (Gapdh) and gluconeogenesis (Pck1) were also modulated. Interestingly, Rxra and 
Rxrb were upregulated; the proteins translated from these genes are receptors for 9-cis-retinoic 
acid and are transcription factors that heterodimerize with a wide array of nuclear receptors, 
including PPARs. Notably, genes controlling cholesterol esterification (Soat1, Soat2, Lcat) and 
synthesis (Hmgcr, Hmgcs1, Hmgcs2) were not affected. Scd1 was present in the arrays and was 
not altered, confirming the previous single-gene qPCR result. Notably, seven genes were 
regulated ≥ |2|-fold by Bco1 genotype: Sorl1 (-3.92, p = 0.0001), Apoa4 (-3.54, p < 0.0001), 
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Fabp5 (-2.85, p = 0.0017), Slc27a1 (+2.67, p = 0.0095), Pprc1 (+2.33, p = 0.0105), Pparg 
(+2.32 p = 0.0126), and Cpt1b (+2.09, p = 0.0182).  
Correlations between hepatic vitamin A stores, lipid species, and gene expression in adult male 
mice 
To gain insight into the potential mechanisms by which Bco1 loss alters hepatic lipid 
metabolism, correlation analysis was performed on several endpoints measured in the 20 - 22-
week old chow-fed WT and Bco1-/- mice. Endpoints were included on the basis of significant 
regulation by Bco1, or as “negative control” variables to validate proposed relationships. All 
variables included were obtained from measurements in livers of chow-fed animals. Pearson 
correlation coefficients were calculated between endpoints of vitamin A status (total vitamin A, 
retinyl palmitate, retinyl stearate, free retinol), lipid species (cholesteryl palmitate, cholesteryl 
stearate, phospholipid palmitate, phospholipid stearate, free palmitate), gene expression (Acox3, 
Cpt1b, Fabp5, Gapdh, Hsp90ab1, Mlycd, Pck1, Ppard, Pparg, Pprc1, Rxra, Rxrb, Slc22a5, 
Slc27a1, Slc27a4, Sorl1), and organ weight (brain weight). A complete table of all factorial 
correlations is shown in Appendix Table B.1. Selected correlations are presented in Fig. 3.5. 
Total vitamin A stores, as expected, correlate almost perfectly with retinyl palmitate, the 
predominant retinyl ester (Fig. 3.5A). As seen in Fig. 3.5B, no specificity in retinyl esterification 
is seen, as retinyl stearate also correlated very strongly with total vitamin A levels. Validating 
this analysis, as expected, free retinol, does not accumulate linearly with total vitamin A stores 
(Fig. 3.5C). In contrast, total vitamin A stores correlate very strongly with cholesteryl palmitate 
(Fig. 3.5D), but not at all with cholesterol stearate (Fig. 3.5E), and inversely with phospholipid 
palmitate (Appendix Table B.1), suggesting possible specificity linking vitamin A levels to 
metabolism of particular lipid species. Furthermore, total vitamin A levels correlate strongly with 
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genes involved in retinoid signaling (Rxrb; Fig. 3.5G) and PPAR signaling (Pparg, Pprc1; Fig. 
3.5H,I). Hepatic cholesteryl palmitate levels are significantly correlated with expression of genes 
governing lipoprotein metabolism (Sorl1, Apoa4), fatty acid transport (Slc27a1, Appendix 
Table B.2; Slc27a4 Fig. 3.5M), β-oxidation (Cpt1b, Acox3, Mlycd; Appendix Table B.2), and 
retinoid and PPAR signaling (Rxrb, Rxra, Pparg, Pprc1; Appendix Table B.2). 
 
Discussion 
 The goal of this work was to identify alterations in lipid metabolism occurring as a result 
of genomic Bco1 ablation. Given that the liver is the central organ for metabolic regulation, 
including control of lipid homeostasis, we hypothesized that Bco1 loss would result in 
dysregulated hepatic lipid metabolism, as demonstrated by alterations in relative abundance of 
specific fatty acyl species, as well as by changes in expression of genes governing lipid 
synthesis, trafficking, and utilization.  
 First, we observed that chow-fed Bco1-/- mice had a roughly 2-fold increase in hepatic 
vitamin A content, entirely due to increases in concentrations of retinyl esters, and not free 
retinol. Additionally, despite the difference in absolute abundance between genotypes, no change 
in retinol esterification substrate preference was detected, as the relative abundances of hepatic 
retinyl esters in WT and Bco1-/- mice were similar, and levels of retinyl palmitate correlated 
strongly with other retinyl ester species. Importantly, we observed that age dramatically 
influenced the directionality of the impact of Bco1 loss on hepatic retinyl ester stores. Whereas 
young mice (≤9 weeks old) demonstrated a reduction in retinyl ester stores with Bco1 loss,  
Bco1-/- mice at 51 or 71 weeks of age experienced up to a 6.7-fold increase in accumulation. 
Bco1-/- mice at 31 weeks of age accumulated numerically more retinyl esters than age-matched 
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WT mice (+2-fold), but this was not statistically significant. This suggests the existence of a 
physiologically relevant interaction between Bco1 and factors changing within the liver during 
the development and aging process. Furthermore, in animals > 9 weeks of age, we observed the 
same pattern of retinyl ester accumulation in mice fed either rodent chow (Study #1) or a 
nutritionally defined, carotenoid-free, modified AIN-93G diet (Study #2). This is notable, as the 
rodent chow used in Study #1 contained roughly 10-fold more preformed vitamin A than the 
nutritionally defined diet used in Study #2 (1,500 IU/kg diet). Importantly, the levels provided in 
Study #2 are sufficient to prevent hypovitaminosis A in mice 23. Our data show that Bco1 loss 
results in a doubling of hepatic retinyl ester content in adult male mice, even when fed diets 
ranging from 1,500 IU vitamin A/kg diet to at least 16,000 IU vitamin A/kg diet. Secondly, and 
perhaps most importantly, Bco1 impacts hepatic vitamin A storage in a highly age-dependent 
manner.  
To date, twenty studies have utilized the Bco1-/- mouse model 1–5,17,24–37. Vitamin A 
source (preformed vs. provitamin A carotenoid) is a crucial detail when comparing the results 
from the current study to others in the literature that have utilized the Bco1-/- model. Ten of the 
twenty published Bco1-/- studies did not report levels of hepatic vitamin A 5,25,27,28,30–32,35–37. Of 
the ten studies that have reported levels of hepatic retinol or retinyl esters, one study 33 provided 
β-carotene to WT and Bco1-/- as the sole source of dietary vitamin A, precluding comparisons 
between Bco1-/- mice in that study and those in our current investigation. However, wild-type 
mice in that study (which were of the same strain as those used in our current study) accumulated 
hepatic retinyl esters and free retinol at approximately 1,000 and 5 nmol/g tissue, respectively. 
These values are both very similar to levels we observed in our WT mice. In another study 
allowing direct comparison, van Helden et al. provided WT and Bco1-/- mice with 1,500 IU 
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preformed vitamin A/kg diet (as in the current Study #2) and reported hepatic free retinol levels 
of approximately 6 and 8 nmol/g in WT and Bco1-/- mice, respectively 31. Again, these levels are 
very similar to those we have observed. However, it does not appear that the authors measured 
hepatic levels of retinyl esters or total vitamin A, preventing further comparison. The final 
publication amenable to direct comparison also fed a basal diet of 1,500 vitamin A IU/kg, but 
reported no change in hepatic “stored retinol” levels 2. However, this was included as “data not 
shown” and details on hepatic tissue extraction methods (i.e., saponification) are not provided, 
making interpretation difficult. Seven remaining studies exist in which hepatic vitamin A levels 
are reported, but they vary in levels of dietary vitamin A provided, β-carotene supplementation, 
and age of mice used (embryonic, juvenile, or adult). Hessel et al., when feeding 14,000 IU 
vitamin A/kg in chow, reported no difference between 25-week-old WT and Bco1-/- mice in total 
hepatic vitamin A – both genotypes accumulated 3 ± 0.2 µmol/g 1. These levels are 
approximately 100% higher than we have observed in Bco1-/- mice and 200% greater than 
recorded in WT mice. Others reported that breeding Bco1-/- dams maintained on a purified 
25,000 IU/kg diet experienced a non-significant increase in hepatic retinyl esters, compared to 
WT 29, but levels were much lower (622 nmol/g) than reported in either of our current studies. In 
another study from the same authors, adult (16 week-old) female mice fed an 18,000 IU/kg chow 
diet experienced no change in hepatic retinyl esters, but the authors did observe significant 
increases (>2-fold) in renal and splenic retinyl esters 4. Deletion of the enzyme primarily 
responsible for retinol esterification, lecithin:retinol acyltransferase (Lrat), abolished this effect 
in Bco1-/-/Lrat-/- mice, suggesting that Bco1 may influence retinyl esterification through Lrat. In 
conflict with this, however, is the fact that retinyl ester levels in the liver are highly dependent 
upon Lrat 38, and yet, Kim et al. observed no alterations in hepatic retinyl ester accumulation in 
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the Bco1-/-/Lrat+/+ strain. Tissue-specific activities of a separate acyl CoA:retinol 
acyltransferases (ARAT) may explain these discrepancies. A study in juvenile mice (6 weeks 
old) found no alterations in hepatic retinyl ester levels in male or female Bco1-/- mice maintained 
on 25,000 IU/kg vitamin A chow 24. Finally, studies in embryos have shown that loss of Bco1 
reduced retinyl esters in fetal total homogenates 3, although tissue-specific measurements 
demonstrated a non-significant reduction in embryonic liver 4. Vitamin A levels in chow diets 
fed to dams in these two studies were 29,000 IU/kg and 18,000 IU/kg, respectively. Although 
Lrat mRNA expression was reduced in whole Bco1-/- embryos and livers of Bco1-/- embryos 4,29, 
Bco1 loss did not fully abolish retinol esterification in embryos in vitro or in vivo 3,29, suggesting 
that LRAT may work in conjunction with other ARAT enzymes to link Bco1 status to retinyl 
esterification. Others have shown LRAT to play a role in the effects of Bco1 loss on retinyl 
esterification, but as we have not yet investigated Lrat expression in the livers of our mice, we 
can only speculate on this point at this time. 
Several other mechanisms to explain increased accumulation of retinyl esters in adult 
Bco1-/- may be mechanistically plausible. Elevated food intake in Bco1-/- mice, compared to WT, 
would putatively increase supply of dietary vitamin A and thus could lead to increased hepatic 
storage. We did not measure food intake in either of our present studies. However, to match 
patterns of accumulation seen, young Bco1-/- mice would have to consume much less diet than 
their WT counterparts, whereas older mice would need to consume a great deal more. Apart from 
the lack of a parsimonious mechanistic explanation for such changes in food intake, body 
weights were very similar at all ages and do not reflect the vast differences in caloric intake that 
would seem necessary for dietary vitamin A intake to be causative of the hepatic accumulations 
observed. Therefore, it is unlikely that changes in food intake are a cause of the effects seen.  
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Another possibility may involve decreased turnover of retinoids in the livers of Bco1-/- 
mice, thus requiring increased esterification for storage and prevention of retinoid-induced 
toxicity. Bco2 catalyzes the eccentric cleavage of a diverse array of carotenoids at the 9ʹ,10ʹ (or 
9,10) double bond 39. Bco2 can cleave both the 9,10 as well as the 9’,10’ double bonds from a 
single molecule of β-carotene 39, suggesting that Bco2 may degrade retinol or retinal. Bco2 
expression is increased in both hepatocytes and hepatic stellate cells isolated from 11-week-old 
Bco1-/- mice 26. If the observed ≤9 week-old retinyl ester accumulation phenotype persists until 
11 weeks of age, it is plausible that Bco2 clearance of retinol/retinal may account for the changes 
seen at these ages. However, for the mechanism to be internally consistent, Bco2 expression 
would need to be depressed by ~20 weeks of age and persist (or decrease yet further) through 71 
weeks of age. This remains to be seen. 
Differences in retinyl ester stores in the liver may be affected by distribution of retinol to 
extra-hepatic tissues. Decreased export of retinol in complex with retinol binding protein 4 
(RBP4) may lead to elevated hepatic retinyl ester levels. This hypothesis also fails scrutiny, 
however. Hessel et al., in the first paper describing the Bco1-/- model, show that RBP4 protein 
levels are equivalent or slightly increased in Bco1-/- mice, compared to WT mice, even when 
raised on a vitamin A-sufficient diet 1. Although we have not measured hepatic RBP4 expression 
or retinyl esters in extraheptic tissues in our mice, the data from Hessel et al. do not support the 
likelihood of a defect in retinol export to peripheral tissues.  
Finally, a fourth mechanism may affect retinyl ester accumulation in the liver. Retinyl 
ester hydrolases (REHs) are a functional group of enzymes (rather than family of sequence 
homologues), which are involved in multiple steps of vitamin A absorption and metabolism 40,41. 
In the liver, REHs hydrolyze retinyl esters to liberate retinol for transport to peripheral tissues. 
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Lipoprotein lipase, which serves as an REH in the liver 40, was not significantly modulated by 
Bco1-/- genotype in our mice (Appendix Table B.3). However, other enzymes with REH activity 
may have been altered. In particular, adipose triglyceride lipase (ATGL), which is expressed in 
the liver, is a highly effective triglyceride hydrolase and REH in vitro 42; in vivo, liver-specific 
knockdown of ATGL increases hepatic TG accumulation (it appears that no studies have 
examined retinyl esters in liver-specific ATGL knockdown/knockout mice) 43,44. Thus, hepatic 
depression of ATGL expression in Bco1-/- mice may unify changes observed in both lipid and 
retinyl ester accumulation. This warrants future investigation. 
Potentially relevant to the alterations in retinyl esters, we observed alterations in the 
weights of several organs in Bco1-/- mice. Brain weight was decreased by a main effect of Bco1-/- 
genotype in both Studies #1 and #2, spleen weight was decreased by genotype in Study #1 only, 
and seminal vesicle weight was modulated by a genotype*age interaction in Study #2. It is well 
established that vitamin A is necessary for proper embryological development due to the pro-
differentiative effects of retinoic acid. Kim et al. have previously shown that, when dams are 
maintained on a vitamin A deficient diet, adding Bco1-/- to an Rbp-/- background can produce 
structural abnormalities in fetuses, including exencephaly 29. Moreover, vitamin A deficiency can 
produce decreases in cerebral volume that correlate very highly with retinol status 45, and 
depletion of retinoic acid in adult mice inhibits neurogenesis 46. Vitamin A deficiency alters cell 
number and immunological capacity in the spleen 47,48, and we have already demonstrated that 
Bco1-/- loss affects seminal vesicle weight in young (9-14-week old) mice through modulation of 
serum testosterone levels (Chapter 2 of this dissertation). Androgen status is known to modulate 
the metabolism of carotenoids in the liver 49 and low retinoid status has been shown to impact 
testicular steroidogenesis 50,51. Further speculation would be unwise without more evaluations of 
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the affected peripheral organs, but it is plausible that modulation of vitamin A status in Bco1-/- 
mice may directly or indirectly alter brain, seminal vesicle, and spleen biology. 
Three points arise from evaluation of previous and current work: 1) levels of dietary 
vitamin A >1,500 IU/kg diet do not alter the effect of Bco1 genotype on hepatic retinyl 
accumulation, 2) Bco1 genotype may modulate hepatic retinol esterification through LRAT or 
REH activity, whereas in extra-hepatic tissues, other enzymes with ARAT activity may be 
important, and 3) directionality of this effect appears to be dependent on age or developmental 
stage.  
Next, focusing on the livers from 20 - 22 week-old chow-fed mice, we measured the 
relative abundance of 20 FAME species in each of four distinct hepatic lipid pools, as well as 
gene expression of 164 genes involved in lipid and cholesterol metabolism. Although not 
statistically significant, Bco1 loss numerically increased the total pools of CEs, PLs, and TGs by 
73%, 27%, and 60%, respectively (an internal standard was not used in the free fatty acid pool, 
precluding a similar estimation). In agreement with this, Hessel et al. have previously reported 
that 25-week-old Bco1-/- on vitamin A-sufficient chow (14,000 IU/kg diet) experience significant 
increases in hepatic TGs, and more generally, total lipids 1. This effect is amplified when 
exposed to vitamin A-deficient and high-fat diets 1,26. We have previously reported that 
histological assessment of livers from female Bco1-/- mice reveals increases in lipidosis 5, and 
analysis of male mice from both studies revealed significant increases in hepatic total lipids with 
Bco1 loss (Fig. 3.3).  
In contrast to our measurements in retinyl esters, we observed that Bco1-/- genotype 
significantly modulated the abundance of specific lipid species, most notably by significantly 
doubling cholesteryl palmitate abundance, increasing phospholipid stearate, increasing free 
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palmitic acid, and reducing free arachidonic acid. Within livers of chow-fed animals, cholesteryl 
palmitate levels, but not levels of cholesteryl stearate, correlated very strongly with total levels of 
vitamin A, suggesting that total stores of vitamin A may influence the formation of specific 
species of cholesteryl esters. Additionally, levels of cholesteryl palmitate did not correlate with 
levels of free retinol. Free retinol accounts for <1% of total retinoid in the liver, is tightly bound 
to cellular retinol binding proteins (CRBPs), and is little more than a transient intermediate in the 
tightly regulated conversion of stored retinyl esters to retinoic acid, which is at cellular 
concentrations 100- to 1,000-fold lower than even retinol 52. Thus, although hepatic retinyl esters 
are an inert bulk storage form of vitamin A, they represent retinoid capacity much more 
accurately than does the level of free retinol. Blaner and colleagues demonstrate this elegantly, 
showing that although hepatic retinyl esters are nearly completely eliminated in Lrat-/- mice, 
retinoic acid levels are also reduced, rather than increased 53. A correlation with hepatic total 
vitamin A suggests that retinoid signaling may be associated with levels of cholesteryl palmitate, 
and the lack of correlation with free retinol bolsters this hypothesis by serving as a “negative 
control”.  
Whereas we observed a doubling in cholesteryl palmitate levels and a non-significant 
increase in total CEs in adult Bco1-/- mice, others have reported Bco1 loss to significantly 
decrease both of these endpoints in day 14.5 post coitus embryos 3,4. The same authors also 
report that Bco1-/- embryos had 22 - 32% lower (p < 0.05) levels of phosphatidylcholines and 
phosphatidylethanolamines with 36:4 total carbons:unsaturated double bonds, which would be 
predicted to contain either 18:1 and 18:3 fatty acids or two 18:2 fatty acids 3. Our results show 
that Bco1-/- genotype resulted in a 22% decrease in phospholipid pool linoleate (18:3), in line 
with these previous results. Additionally, Dixon et al. report that 40:6 phosphatidylcholines and 
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phosphatidylethanolamines, which likely contain one each of the 22:6 and 18:0 lipid species, are 
reduced 30 – 35% by Bco1-/- genotype. We observed no changes in phospholipid 
docosahexaenoate (22:6), but find that levels of stearate (18:0) in phospholipids were 
significantly elevated by approximately 9%. A methodological difference is worth noting: as 
these authors 3 utilized LC/MS on non-methylated lipid extracts, species detected were intact 
phospholipids and not individual fatty acids; our method used derivitization to FAMEs and GC-
FID measurement of individual fatty acid species. Overall, our results in adult Bco1-/- mice – 
although at times contradictory to the directionality of effects observed in Bco1-/- embryos – 
support the hypothesis that Bco1 genotype alters lipid esterification and may do so in a 
developmentally divergent manner. This is made more plausible by the earlier observation of an 
age-dependent effect of Bco1 genotype on accumulation of hepatic retinyl esters.  
Fatty acid synthase (Fasn) catalyzes the conversion of acetyl-CoA to malonyl-CoA for 
lipid biosynthesis, whereas stearyl-CoA desaturase 1 (Scd1) is responsible for the first step in 
desaturation of saturated fatty acids, such as palmitate 54. Thus, these two genes play important 
roles in the control of de novo lipid biosynthesis. We observed an accumulation of palmitate in 
the hepatic CE and FFA pools of Bco1-/- mice, as well as accumulation of stearate in PLs. Hessel 
et al. reported a reduction in hepatic Scd1 expression in Bco1-/- mice, which might be expected to 
reduce the conversion of saturated fatty acids like palmitate and stearate to their 
monounsaturated products, resulting in accumulation of the saturated fatty acid substrate. 
Contrary to this hypothesis, we did not observe a similar reduction in gene expression as 
observed by Hessel et al., either when we measured Scd1 mRNA expression in single-gene 
qPCR experiments, or via PCR array. However, similar to the previous report 1, we observed no 
change in Fasn expression. Therefore, it seems that regulation of de novo lipogenesis and 
 131 
desaturation cannot explain the accumulation of saturated FAMEs that we observed in the CE, 
PL, and FFA pools. 
Uptake of free fatty acids into tissues from the circulation occurs via both unregulated 
and receptor-mediated mechanisms. Thus, increased tissue levels of free fatty acids may 
alternatively reflect increased uptake, rather than increased de novo synthesis. Interestingly, 
others have reported that cardiac free fatty acids, including free palmitate, were increased in 
Bco1-/- mice, as was mRNA expression of Lpl and the lipid transporter Cd36 35. Similarly, we 
observed both a significant increase in hepatic free palmitate, as well as a 1.6-fold increase in 
hepatic Cd36 expression; however, this change in Cd36 gene expression was not statistically 
significant. 
Cholesterol esterification is accomplished through the actions of cellular acyl-CoA 
cholesterol acyl transferase (ACAT, also called SOAT; not to be confused with the ACAT 
enzymes involved in β-oxidation), of which two isoforms exist (referred to hereafter by gene 
names Soat1 and Soat2). Another enzyme, LCAT, is produced in the liver, secreted into 
circulation in association with lipoproteins, and serves to convert free cholesterol to CEs in 
maturing HDL lipoproteins. Fatty acid species display varying efficiencies of incorporation into 
CEs, with Vmax for palmitate being ~53-fold higher than for stearate 55. This may be due to 
substrate-specific differences in enzyme activity 56,57, or due to changes in enzyme expression 
under various fatty acid exposures 58. While cholesteryl palmitate levels more than doubled in 
chow-fed Bco1-/- mice compared to WT, no significant changes in expression of genes 
controlling cholesterol synthesis (Hmgcr, Hmgcs1, Hmgcs2) or esterification (Soat1, Soat2, Lcat) 
were observed (Appendix Table B.2). However, other than palmitate, only linoleate (29.0%) 
was routinely detected in WT livers at ≥5% of total free fatty acids, and palmitate is esterified to 
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cholesterol more readily than is linoleate 55,57. Whether arising from passive uptake, receptor-
mediated uptake (Cd36 or hepatic lipase Lipc), or another mechanism, minor increases in hepatic 
free palmitate levels observed in Bco1-/- mice (20%) may be amplified to larger differences in 
levels of the esterified fatty acid due to substrate preferences of cholesterol esterifying enzymes.  
Apolipoprotein A-IV (Apoa4) is normally induced by SREBP-1a in response to lipid 
accumulation, increasing TG export through VLDL expansion 59. Thus, Apoa4 serves to reduce 
hepatic lipid burden. However, despite strong down regulation of Apoa4 in our chow-fed Bco1-/- 
mice compared to WT, total hepatic TGs trended higher (+60%, p = 0.15; Table 1). These data 
appear to be contradictory; however, it is possible that Apoa4 expression is reduced as a cause, 
and not consequence, of changes in hepatic TG content. Knockout of Apoa4 results in a non-
significant increase in hepatic TGs, whereas overexpression significantly decreases hepatic TG 
levels 59. Forced down regulation of Apoa4 could inhibit TG export to VLDL, potentially 
resulting in hepatic TG accumulation. Multiple transcriptional regulators of Apoa4 have been 
identified, including genes identified in this study as modulated by Bco1-/- genotype (Rxra, Rxrb, 
Ppard; 60–62). Lending further support to this hypothesis, ApoA-IV protein suppresses 
gluconeogenesis through transcriptional repression of Pck1 and G6pc in primary mouse 
hepatocytes through the nuclear receptor NR1D1 63; we find that hepatic Pck1 expression is 
significantly upregulated in Bco1-/- mice (1.72, p = 0.018). Whether – and how – repression of 
Apoa4 is a direct contributor to the hepatic lipidosis that has been repeatedly observed in the 
Bco1-/- strain requires further study, but it provides a mechanistically plausible hypothesis for 
investigation. 
Gene expression analysis also revealed that expression of sortilin-related receptor LDLR 
class A (Sorl1) was repressed nearly 4-fold in Bco1-/- livers, compared to WT. This gene was the 
 133 
most strongly regulated of all 164 genes investigated and encodes a lipoprotein receptor (which 
has at times been called SORLA, SorLA-1, LR11, and LRP9) responsible for the uptake of 
apoE-rich VLDL 64–66. Vongpromek et al. have shown that triglyceride-rich lipoproteins, but not 
LDL or HDL, induce Sorl1 mRNA and protein expression in HepG2 cells 64 and Sugiyama et al. 
showed that provision of 14C-labeled oleate in apoE-rich VLDLs resulted in accumulation of 
cholesteroyl 14C-oleate in cells overexpressing Sorl1 65. Thus, like Apoa4, the decrease that we 
observe in Sorl1 expression in Bco1-/- liver tissue is perplexing. Indeed, contrary to expectation, 
relative Sorl1 expression correlates negatively with cholesterol palmitate levels in chow-fed mice 
(Appendix Table B.1). However, the administration of PPARγ ligands (conjugated linoleic acid, 
troglitazone, and 15-deoxy-Δ-12,14-prostaglandin J2) both in vitro and in vivo reduced Sorl1 
mRNA and protein expression, and effects which were abolished in vitro by treatment with a 
PPARγ antagonist 67. Thus, PPARγ, which is significantly upregulated at the transcript level in 
livers of Bco1-/- mice (+2.32-fold, p = 0.013), negatively regulates Sorl1. It appears that the 
inverse relationship observed between Sorl1 expression and cholesteryl palmitate is likely an 
artifact of the mediating effects of PPARγ, as PPAR signaling likely accounts for other accepts 
of the phenotype observed in Bco1-/- as well. 
Fatty acid transfer protein (FATP) 4, gene name Slc27a4, was significantly (p = 0.0029) 
up regulated in the livers of chow-fed Bco1-/- mice. PPARγ ligands induce expression of Slc27a4 
and do so synergistically with 9-cis-retinoic acid, the ligand for RXRs 68,69. Additionally, 
although Slc27a4 belongs to the FATP family, it is actually a weak fatty acid transporter 70 and 
functions rather as an acyl-CoA synthetase with substrate specificity towards long- and very 
long-chain fatty acid synthesis 71. Indeed, overexpression of Slc27a4 into hepatic Huh-7 cells 
demonstrated a preference for palmitoyl-CoA synthetase activity over oleoyl-CoA synthetase 
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activity 72. Thus, PPARγ-induced Slc27a4 expression increases capacity for palmitoyl CoA 
synthesis, increasing levels of free palmitate and providing substrate for enhanced esterification 
of palmitate to cholesterol. This may explain the >2-fold accumulation of cholesteryl palmitate 
we observe in chow-fed Bco1-/- mice, although the mechanism by which circulating FFAs 
contribute to the hepatic palmitate pool, described earlier, may also play a minor role.  
A conceptual model summarizing the effects of Bco1 loss on hepatic lipid and retinoid 
metabolism is shown in Fig. 3.5. Our current data demonstrates that Bco1 loss evokes age-
dependent effects on hepatic retinyl ester accumulation; although the mechanism for this is not 
yet clear, several plausible mediators may be involved. We have also shown that expression of 
Pprc1, Pparg, Rxra, and Rxrb are induced in adult Bco1-/- mice, potentially mediating expression 
of downstream PPRE-containing target genes through 9-cis-RA-mediated signaling. Hepatic 
Rxrb, Rxra, Pparg, and Pprc1 mRNA expression all correlate strongly with total hepatic vitamin 
A levels, which other investigators have shown are positively associated with concentrations of 
the active retinoid signaling metabolites. In accordance with this model, we have observed that 
hepatic cholesteryl palmitate is elevated in Bco1-/- mice; this is a major product of the PPARγ-
induced acyl-CoA synthetase, FATP4 (gene name Slc27a4); expression of Slc27a4 correlates 
with both cholesteryl palmitate concentrations and mRNA expression of Pparg, Rxrb, and Rxra. 
We have documented elevated levels of hepatic free palmitate in Bco1-/- mice, which may 
provide substrate to FATP4 for cholesteryl palmitate synthesis. Free palmitate, in turn, may arise 
from either passive or active uptake. We observed a non-significant increase in hepatic 
expression of the fatty acid transporter CD36 with Bco1 loss, while others have observed this to 
be significantly elevated in both adipose and heart tissues of Bco1-/- mice 1,35. While we did not 
measure circulating free fatty acids, others have reported increased plasma concentrations with 
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Bco1 ablation 1. Absorbed free fatty acids may be shunted through the triglyceride synthesis 
pathway and the rate-limiting enzyme, DGAT, to induce TG storage; this would agree with the 
hepatic lipidosis we and others have observed with Bco1 loss. While hepatic Apoa4 and Sorl1 
were the most strongly regulated genes identified in our analysis (both downregulated nearly 4-
fold), due to the counteracting effects of their translated proteins on TG-rich lipoprotein 
import/export, Bco1 loss may mediate hepatic lipid accumulation through altered lipid 
metabolism in situ, rather than via lipoprotein-mediated lipid transport.  
 
Conclusions 
 Several conclusions can now be made, although other hypotheses must still be tested. 
First, adult male Bco1-/- mice accumulate 2-6-fold more hepatic retinyl esters than do WT mice, 
with no detectable fatty acyl substrate preference. Second, this accumulation is highly dependent 
on developmental age, as data from juvenile mice in our studies, and embryonic data from 
others, demonstrate significant decreases in retinyl esters as a result of Bco1 loss. Third, it is 
clear from our own work and that of others that a wide span of dietary vitamin A (ranging from 
1,500 IU/kg to nearly 30,000 IU/kg) does not modify the effect of Bco1-/- genotype on retinyl 
ester accumulation. Fourth, in adult mice, total hepatic lipid content is increased and patterns of 
lipid esterification are altered by Bco1 loss, as evidenced by alterations in unique fatty acid 
species, most notably in our study being cholesteryl palmitate. Although details of this latter 
result have not been consistent across comparisons to work in other labs, other investigators have 
indeed reported changes in unique fatty acid species due to Bco1 loss. Variability in outcomes 
may be a result of an interaction between Bco1-/- genotype and developmental stage, as in 
patterns of retinyl ester accumulation. Further work is needed to clarify this issue. Fifth, changes 
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in organ weights (brain, spleen, and seminal vesicle) may be a direct result of altered vitamin A 
status, or an indirect result (e.g., seminal vesicles per the mechanism described in Chapter 2); 
however, more work is needed before further speculation on this matter. Finally, PPAR/RXR 
signaling may explain the altered hepatic metabolism observed in Bco1-/- mice. Apoa4 mRNA 
expression is significantly down regulated in chow-fed Bco1-/- livers, nearly 4-fold, potentially 
reducing the capacity for TG export to VLDL and providing a mechanism that may explain the 
commonly reported hepatic lipidosis observed in Bco1-/- mice. A retinoid-Pparg-Slc27a4 
mechanism is proposed to account for a PPAR/RXR role in lipid metabolism: in Bco1-/- mice, 
altered retinoid signaling at RXR/PPARγ heterodimers induces the expression of Slc27a4, a 
long-chain acyl-CoA synthetase, driving palmitoyl-CoA formation, which is incorporated into 
cholesteryl palmitate esters.  
 This work has provided some clarity to the impact of Bco1 on hepatic retinoid and lipid 
metabolism, but now more questions have emerged. Future studies are needed to answer some of 
these new questions; for example, do LRAT or tissue-specific ARAT enzymes mediate the age-
dependent effect of Bco1 loss on retinyl ester accumulation? What is the mechanism of 
interaction between Bco1 and Lrat? Is altered expression of retinyl ester hydrolases or Bco2 also 
involved? Does inhibition of PPARγ signaling ablate the effects of Bco1 loss on hepatic lipid 
metabolism? Despite these critical uncertainties, at this point, we can conclude that Bco1-/- 
genotype 1) impacts hepatic retinyl ester pools in an age-dependent manner, 2) alters hepatic 
lipid metabolism, and 3) may do so through alterations in PPAR signaling. Additionally, we 
observe that PPAR signaling is associated with retinyl ester concentrations, suggesting a 
potential mechanism involving retinoid-PPAR activity. The manner through which Bco1 impacts 
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retinol and lipid metabolism independent of its carotenoid cleavage function will continue to be 
an area of intense interest. 
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Figures 
Figure 3.1. 
 
 
 
 
 
 
Figure 3.1. Impact of Bco1-/- genotype on weight body and organ weights in chow-fed mice (A-
C) and in mice fed a semi-purified, vitamin A-sufficient, carotenoid-free diet from weaning until 
<9, 9, 31, 51, or 71 weeks of age (D-I). Body weight (A), liver weight (B), and organ weights 
(C) in chow-fed mice. Body weight (D) and liver (E), brain (F), testes (G), seminal vesicles (H), 
and spleen (I) weights as percentages of total body weight. Data are presented as group mean  ± 
SEM. Group n = 8 (A-C) or n = 7 - 10/genotype/age (D-I). *p < 0.05, ***p < 0.001 between 
genotypes. G, A, and G*A indicate statistical main effects of genotype, age, or an interaction 
between genotype and age. Different lowercase letters above ages indicate significant (p < 0.05) 
results of mean separations tests for the main effect of age.   
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Figure 3.2. 
   
       
Figure 3.2. Loss of Bco1 interacts with age to modulate total hepatic vitamin A stores, but 
does not alter the relative abundance of hepatic retinol/retinyl esters. Hepatic free retinol and 
major retinyl ester species in 20 – 22-week old chow-fed mice (A, C) and 51-week old mice 
fed a semi-purified, vitamin A-sufficient, carotenoid-free diet (D). Total vitamin A (free retinol 
plus all measured retinyl esters) in WT and Bco1-/- mice <9, 9, 31, 51, or 71 weeks of age (B). 
Composition of hepatic vitamin A pools are shown in (C) for chow-fed mice and (D) for 51 
week-old mice fed a semi-purified, vitamin A-sufficient, carotenoid-free diet. Data in (A,B) are 
displayed as mean nmol/g tissue ± SEM. Some error bars are too small to be visible. Group n = 
4 - 6. Data in (C, D) display vitamers as a percent of the total hepatic vitamin A pool within 
each genotype. Ret. Lau., retinyl laurate; Ret. Lin/Po.,  retinyl linoleate/retinyl palmitoleate co-
eluted peaks;, Ret. Myr., retinyl myristate;, Ret. Pent., retinyl pentadecanoate;, Ret. O., retinyl 
oleate;, Ret. Hept., retinyl heptadecanoate;, Ret. S., retinyl stearate;, Ret. Pal., retinyl palmitate. 
*p < 0.05 vs. WT, **p < 0.01 vs. WT, ***p < 0.005 vs. WT. G*A denotes significant 
interaction between genotype and age; A denotes significant main effect of age. Means with 
different letters are statistically significant from one another. nd, not detected. 
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Figure 3.3. 
  
Figure 3.3. Bco1 loss increases total hepatic lipids in adult male mice. Total hepatic lipids in 
chow-fed adult 20- 22-week-old male mice (A). Data are presented as group mean  ± SEM. n = 
6/group. **p = 0.011. Total hepatic lipid content in mice fed a vitamin A-sufficient, carotenoid-
free, semi-purified diet (B). Data are presented as group mean  ± SEM. n = 7 - 10/genotype/age. 
*p < 0.05 between genotypes. G, A, and G*A indicate statistical main effects of genotype, age, 
or an interaction between genotype and age. Different lowercase letters above ages indicate 
significant results of mean separations tests for the main effect of age (p < 0.05).  
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Figure 3.4. 
 
Figure 3.4.  Bco1-/- genotype alters hepatic expression of genes involved in lipid and cholesterol 
metabolism in chow-fed mice. Fasn (A) and Scd1 (B) expression, normalized to Rpl19, are 
unchanged by Bco1 loss; n=6-8/genotype. Gene expression was assayed using qPCR arrays 
focused on PPAR signaling and lipoprotein and cholesterol metabolism (C). Log(fold change) 
and –log(p-value) [derived from pairwise t-tests] for 163 lipid- and cholesterol metabolism-
related gene is plotted in a volcano plot. Absolute log(fold change) values of 0.30, 0.60, and 0.90 
approximately equal absolute fold-change values of 2.0, 4.0, and 6.0. Selected genes are noted. 
Genes which had p-values below or approaching p = 0.005 but which had extremely low basal 
expression (Ct > 30.0; Mmp9, Smarcd3, and Src) are marked with x’s.  
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Figure 3.5. 
 
 
 
 
 
Figure 3.5. Correlation between measured outcomes in livers of chow-fed mice. Retinyl palmitate (A) 
and retinyl stearate (B) both correlate with total vitamin A stores, while free retinol does not (C). 
Cholesteryl palmitate (D), but not cholesteryl stearate (E), correlates with total hepatic vitamin A stores. 
Free retinol does not correlate with cholesteryl palmitate levels (F). Total hepatic vitamin A stores are 
positively associated with mRNA expression of Rxrb (G), Pparg (H), and Pprc1 (I). mRNA expression 
of Apoa4 is inversely associated with total vitamin A levels (J), mRNA expression of Sor1l (K) and 
Slc27a4 (L) are inversely and positively correlated with Pparg expression, respectively, while Slc27a4 
expression is positively associated with cholesteryl palmitate (M). 
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Figure 3.6. 
 
 
Figure 3.6. Conceptual model of Bco1 loss-induced changes in hepatic lipid and retinoid 
metabolism in adult mice (Bco1 loss reduces retinyl esters in embryonic and juvenile samples). 
Arrows indicate induction, blunted lines indicate inhibition. Green plus signs indicate induction 
in Bco1-/- mice, red minus signs indicate repression in Bco1-/- mice, and black “NC” signs 
indicate no change observed in Bco1-/- mice. Model incorporates findings from the current study, 
as well as previous work from the literature. ARAT, acyl CoA:retinol-acyltransferase; LRAT, 
lecithin:retinol acyltransferase; REHs, retinyl ester hydrolases; RDH, retinol dehydrogenase; 
RALDH, retinaldehyde dehydrogenase; MG, monoacylglyceride; DG, diacylglyceride; TG, 
triacylglyceride.  
 
 155 
CHAPTER 4 
Dietary tomato reduces castration-resistant prostate cancer  
progression in the TRAMP model 
Abstract 
 Observational data in humans continue to support the hypothesis that tomato intake is 
associated with a reduced risk of primary prostate cancer (PCa). However, few studies have 
examined the effects of dietary tomato on castration-resistant prostate cancer (CRPC), which 
constitutes the late and lethal stage of PCa. CRPC is defined as PCa progression after surgical 
castration or pharmacological reduction of circulating androgens through androgen deprivation 
therapy (ADT). One mechanism that has previously been implicated in the transition from PCa 
to CRPC is the acquired ability for local androgen synthesis. We have previously shown in 
animal models that dietary tomato powder can reduce incidence of primary PCa, and that tomato 
feeding modulated genes controlling tumoral androgen in the direction of reduced steroidogenic 
capacity. Therefore, we hypothesized that lifelong dietary intake of tomato, as well as a dietary 
intervention following castration, would reduce cancer progression in a mouse model of CRPC. 
Transgenic adenocarcinoma of the mouse prostate (TRAMP) mice were acclimated to a 
powdered, AIN-93G diet (CON) for one week and then randomized to consume CON (n = 28) or 
10% w/w lyophilized tomato paste (TP; n = 30) from 4 weeks of age until euthanization. A third 
group, modeling adjuvant dietary intervention, consumed CON diet from 4 weeks of age until 12 
weeks of age, and then 10% w/w lyophilized tomato paste from week 12 until euthanization (TP-
I; n = 27). All animals were castrated at 12 weeks of age. Beginning at 10 weeks of age, mice 
were monitored longitudinally with biweekly ultrasound scans for tumor detection. For each 
ultrasound scan, serial 2D image slices were used to generate a 3D volume measurement. Upon 
tumor detection, mice were switched from biweekly to weekly scans and imaged 4 additional 
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times for volumetric tumor measurement and determination of tumor growth rate. 
Two criteria were implemented for euthanasia: after 5 tumor scans (tumor detection + 4 
weekly), or if no tumor had been detected by 30 weeks of age. No differences between TP or  
TP-I treatments in hepatic, prostatic, or tumoral carotenoid accumulation were observed. TP-I, 
but not TP, significantly reduced in vivo tumor growth rate (p < 0.0001) and tumor volume        
(p < 0.05) by approximately 50%, compared to CON. At necropsy, compared to CON, tumor 
weight trended (p = 0.07) towards a reduction with TP-I treatment, but not TP. TP-I reduced 
gross metastasis to lungs (p < 0.05) and preserved body weight (p < 0.01) and gonadal adipose 
depot weight (p < 0.05), compared to CON. However, no significant effect by dietary treatment 
was observed in tumoral mRNA expression of androgen receptor or androgen biosynthetic 
genes. In conclusion, we have shown, for the first time, that dietary tomato can reduce CRPC 
progression in an animal model. Epidemiological work suggests that the human equivalent 
lycopene dose provided by tomato diets in the present study is both easily achievable and 
potentially protective against both incident and lethal PCa in humans. Future work should 
address the efficacy of adjuvant combinations of dietary tomato with the front-line therapies 
currently in clinical use against CRPC, in order to assess the potential for this approach to 
translate into clinical benefits for men with this lethal disease. 
 
Introduction 
Tomato intake has been linked to a reduced risk of PCa since the first observational 
studies noting an inverse association were published in the late 1990s 1–4. Notably, these studies 
often reported that the strongest inverse associations were between tomato or lycopene intake 
and lethal or aggressive cancers 1–6. This is important, because PCa is often diagnosed at a 
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Gleason grade of  7 4,6,7, and tumors with a grade ≥ 7 are associated with higher rates of mortality 
8. Moreover, cancers that are at an advanced stage at diagnosis (classified by the TNM staging 
system 9) suffer worse prognosis than those with localized disease 10. Men with low-grade cancer 
are likely to survive in spite of their diagnosis 8, and so identification of dietary agents that are 
especially effective against aggressive and lethal cancers is especially desirable.  
 Several animal studies have provided data to support the observational association 
between tomato intake and a reduced risk of PCa. Pannellini et al. showed that a 10% w/w 
tomato paste diet reduced incidence in TRAMP mice 11, and we have shown that tomato feeding 
reduces PCa tumorigenesis 12,13 and carcinogenesis 14. However, although these studies support 
the hypothesis of the incorporation of dietary tomato to reduce a lifetime risk of primary disease, 
they do not directly address the efficacy of tomato on the lethal phase of clinical PCa, castration 
resistant prostate cancer (CRPC). Men with primary PCa are treated with radiation or 
prostatectomy, but some cancers will recur, either locally or with distant metastasis 15. First-line 
therapy for these cancers has been androgen-deprivation therapy (ADT), which involves the 
pharmacological ablation of circulating androgens (formerly surgical castration), or the 
pharmacological blockade of androgen receptor (AR) signaling. ADT is initially successful, but 
which eventually gives rise to CRPC in 2 to 3 years; CRPC is fatal 16. Some pharmacological 
agents have shown promise in prolonging survival 17,18, but other effective approaches, including 
adjuvant therapies, are needed.  
 Due to the positive data linking tomato intake to reduced rates of primary PCa, some 
researchers have turned to dietary tomato for the prevention or treatment of CRPC. Indeed, men 
may change dietary habits following a PCa diagnosis 19, and increased consumption of tomato 
products after PCa diagnosis has been shown to reduce the risk of progression 6.  However, very 
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few human studies have examined tomato or lycopene interventions in men with CRPC. One 
study provided 15 mg lycopene twice daily in the form of a tomato supplement, but it did not 
include a control group and the majority of patients experienced cancer progression 20. Another 
compared surgical castration alone to surgical castration + lycopene (2 mg twice daily), and 
reported that men in the castration + lycopene group experienced greater survival 21. However, 
this study was small (27 men) and suffered from errors in data reporting, which severely 
detracted from its reliability 22,23. Although a few animal studies have examined the effects of 
lycopene or tomato on growth of androgen-insensitive human cell xenografts 24,25, these models 
of tumorigenesis do not recapitulate the carcinogenic process, nor do they avoid the limitations 
of anatomical fidelity that are inherent with xenograft studies. To our knowledge, no previous 
experimental study has examined the effects of dietary tomato on CRPC carcinogenesis in vivo. 
Moreover, we wondered whether lifelong vs. adjuvant intervention may be equally effective.  
 
Materials and Methods 
Diets 
Tomato paste (Contadina®, San Francisco, CA) was purchased from a local Schnuck’s® 
supermarket between September 2014 and July 2015. Tomato paste from freshly opened cans 
was spread into aluminum pans, covered loosely with aluminum foil, and lyophilized in a VirTis 
Freezemobile 12SL/Unitop 600 SL freeze dryer (SP Scientific, Warminster, PA). Dried yield 
was approximately 25% of wet weight. Dried tomato paste was broken into pieces and ground 
for 1 minute to fine powder in a tabletop food processor. Lyophilized tomato paste powder (LTP) 
was transferred to resealable gallon storage bags, air removed, and kept in the dark at 4 ˚C until 
diet mixing. New diet was made approximately every 1.5 months. 7 batches of 10% LTP diet 
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were made throughout the course of the study and each was analyzed for carotenoid content by 
HPLC. 
Proximate analysis was performed on the 100% LTP (data not shown) and diet formulas 
were balanced for total energy, carbohydrates, protein, fat, and fiber. Two experimental diets 
were used in this study: a powdered, AIN-93G-based diet and a powdered, AIN-93G-based diet 
supplemented with 10% (w/w) LTP (Table 4.1). Proximate analysis of the two diets revealed 
that total carbohydrates were within 5% (w/w), whereas crude protein, crude fat, crude fiber, 
organic matter, ash, dry matter, and moisture contents were all within 3% (w/w; data not shown). 
Animals and experimental design 
The University of Illinois Laboratory Institutional Animal Care and Use Committee 
reviewed and approved all animal procedures. Male C57BL/6-Tg(TRAMP)8247Ng/J, female 
C57BL/6J, and female FVB/NJ mice were purchased from The Jackson Laboratory (Bar Harbor, 
ME). The C57BL/6-Tg(TRAMP)8247Ng/J strain is heterozygotic for the SV40Tag transgene, 
which is responsible for prostatic transformation and carcinogenesis in this model 26. A breeding 
colony was maintained with crosses of C57BL/6J females and C57BL/6-Tg(TRAMP)8247Ng/J 
males, and F1 offspring of C57BL/6-Tg(TRAMP)8247Ng/J and FVB/NJ mice were enrolled on 
study via rolling admission (hereafter referred to as TRAMP mice). Tail DNA of pups was 
isolated with an Extract-N-Amp™ Tissue PCR kits (Sigma-Aldrich, St. Louis, MO) and mice 
were genotyped with the following PCR primers: Pbsn Fwd, 5ʹ- CCG GTC GAC CGG AAG 
CTT CCA CAA GTG CAT TTA -3ʹ; SV40Tag Fwd, 5ʹ- CTC CTT TCA AGA CCT AGA AGG 
TCC A -3ʹ; Csn2 (β-casein) Fwd, 5ʹ- GAT GTG CTC CAG GCT AAA GTT -3ʹ; Csn2 Rev, 5ʹ- 
AGA AAC GGA ATG TTG TGG AGT -3ʹ. TRAMP pups were weaned to a powdered, modified 
AIN-93G diet at 3 weeks of age. At 4 weeks of age, mice were randomized to consume a 
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modified AIN-93G diet CON (n = 34) or 10% w/w lyophilized tomato paste (TP; n = 34) from 4 
weeks of age until euthanization. A third group, modeling adjuvant dietary intervention, 
consumed CON diet from 4 weeks of age until 12 weeks of age, and then 10% w/w lyophilized 
tomato paste from week 12 until euthanization (TP-I; n = 31). Non-transgenic littermates (WT; n 
= 5) were maintained on CON diet for the duration of study. Mice were housed in shoebox cages 
under controlled conditions (12 hour light/dark cycle, 22˚C, 55% humidity). Mice were weighed 
weekly (Mondays) and diet was refreshed 3x/week (M, W, F). Diet removal from bowls was 
recorded on each day that fresh diet was provided. Mice were provided with separate nesting 
bowls for enrichment and in an effort to reduce burrowing and nesting activities in powdered 
diet. 
TRAMP mice were castrated by surgical orchiectomy at 12 - 13 weeks of age through an 
abdominal incision while under 2% inhalation isofluorane. At this age, TRAMP mice are 
expected to have high-grade prostatic intraepithelial neoplasia (PIN) or well- to moderately-
differentiated adenocarcinoma 27,28. Animals were provided pre- and post-op analgesic 
(buprenorphine, 0.05 mg/kg IP) and all peri-surgical procedures complied with recommendations 
of the NIH Guide for the Care and Use of Laboratory Animals 29. TRAMP mice in the TP-I 
group were not switched to the 10% w/w tomato paste diet until after castration.  
Beginning at 10 weeks of age, mice were monitored longitudinally via ultrasound 
imaging for tumor development. Animals were scanned biweekly until tumor detection, at which 
time scans were switched to a weekly schedule for 5 consecutive weeks (detection + 4 
subsequent). Mice were anesthetized in a chamber with 4 - 5% isofluorane for induction of 
anesthesia and then with 2% isofluorane (or to effect) for maintenance via facemask. The depth 
of anesthesia was monitored by pedal reflex and respiratory rate. Prior to ultrasonic scanning, 
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hair over the lower abdomen was shaved, followed by application of a depilatory agent and 
ultrasound coupling gel (Aquasonic, Parker Laboratories, Inc., Fairfield NJ) to maximize sound 
transmission. Anesthetized mice were scanned while in dorsal recumbency on a heated table. 
Scans were obtained through the ventral body wall using the Vevo 2100 pre-clinical imaging 
platform (VisualSonics, Inc., Toronto, Canada) and various transducers; the MS550D (22 – 55 
MHz) was used for most scans, whereas the MS250 or MS200 (13 – 24 MHz or 9 – 18 MHz, 
respectively) were used for larger tumors. Scans were conducted in 3D B-mode, which enables 
the automated stepwise collection of serial 2-dimensional frames. For each animal, between 30 
and 100 frames were collected in a caudal to cranial direction at intervals of approximately 0.3 
mm. Serial 2-dimensional image slices were used to generate prostatic or tumor volume 
estimates as previously described 30. Previous work in our lab has shown that in vivo volume 
estimates using this method correlate very strongly with tumor volume estimates obtained using 
three-axis calipers measurement at necropsy 31.  
Mice were euthanized if they reached 30 weeks of age with no detectable tumor, or after 
5 consecutive tumor ultrasound scans (tumor detection + 4 weekly). Euthanization was 
performed by rendering the animal unconscious by 5% inhalation isofluorane, followed by CO2 
asphyxiation while unconscious. Blood was collected by cardiac puncture (processed to obtain 
serum portion) and tissues were removed and weighed. Animals and tissues were dissected on an 
ice-chilled petri dish to reduce sample degradation. Gross metastases were identified by visual 
inspection. Entire cross-sections of tumors, half of each prostatic lobe, lungs, liver, regional 
lymph node metastases (medial iliac, lumbar aortic; when metastases present), and various 
distant organ metastases (when present) were fixed in 10% neutral-buffered formalin for 12 - 24 
h and held in 70% aqueous ethanol until paraffin embedding. Necrotic tumor tissue was 
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identified by visual inspection, dissected away from vascularized tissue, and discarded. 
Remaining tissues (tumor, half of each prostate lobe, lymph node metastases, seminal vesicles, 
liver, gonadal adipose, and serum) were frozen in liquid N2 and stored at -80 ˚C until analysis.  
Thirteen mice were found dead while on study protocol and were not available for tissue 
analysis, but did contribute data points to weight gain and food intake (3 CON, 5 TP, 5 TP-I). 
None of these animals developed a tumor as detected by ultrasound before their death. 14 mice 
were removed from the study early for various reasons: loss of ≥15% body weight in 1 week (1 
CON), hydrocephaly (1 TP-I), kidney tumor detected before prostatic tumor (1 CON), neck 
tumor detected before prostatic tumor (1 CON, 1 TP), or prostate tumor detected via ultrasound 
before castration (3 CON, 3 TP, 3 TP-I). These 14 mice were enrolled on study, but were not 
included in any subsequent analysis. Therefore, final group sizes were n = 28, n = 30, and n = 27 
for CON, TP, and TP-I, respectively. 
 
Carotenoid measurement 
 Carotenoids were extracted from diet, anterior prostate, tumor, and liver tissue and 
analyzed via HPLC as previously described 32,33. Approximately 300 mg tumor tissue, 100 mg 
liver tissue, and 25 mg diet were used for analysis. Due to castration, anterior prostates were too 
small to be assayed individually and thus were pooled to achieve quantifiable signal. Anterior 
prostates from 8 - 12 mice (one lobe per mouse) were pooled into individual replicates and two 
such replicates per diet group were measured via HPLC. Total mass of each replicate ranged 
from 44 – 91 mg. On-column lower limits of quantification (LLOQ) were 2.0 ng phytoene, 2.0 
ng phytofluene, 500 pg ζ-carotene, 500 pg lycopene (250 pg on-column lower limit of detection, 
LLOD), 2.0 ng α-carotene, 3.4 ng β-carotene, and 3.4 ng lutein.  
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Histopathology 
 Tissues were embedded in paraffin and 4 µm sections were stained with hematoxylin and 
eosin for pathological grading. A blinded examiner (S.K. Clinton; Division of Medical 
Oncology, Department of Medicine, College of Medicine, The Ohio State University) evaluated 
the extent and severity of neoplasia in prostate and tumor sections. Regional lymph node gross 
metastases were confirmed or rejected by histopathology.  
Immunohistochemistry 
 Immunohistochemistry to detect endogenous expression of Ki67 was performed on 4 µm 
paraffin sections of dorsolateral prostate lobes. Ki67 staining was performed using a monoclonal 
antibody (D3B5, catalog #12202, Cell Signaling Technology, Danvers, MA). Slides were 
deparaffinized and rehydrated, followed by antigen retrieval in citrate buffer (pH 6.0) under 
steam heat for 60 min. Endogenous peroxidase was inhibited with H2O2 for 10 min, washed with 
TBS-Tween 20, and blocked with Background Punisher blocking agent (Biocare Medical, 
Concord, CA) for 15 min. Slides were incubated with the primary antibody for 60 min at 1:600 
dilution, rinsed 3 times for 5 min each in TBS-Tween 20, and incubated with the secondary 
antibody (Rabbit on Rodent HRP-Polymer, Biocare Medical) for 30 min. Slides were again 
rinsed 3 times for 5 min each in TBS-Tween 20, followed by staining with DAB (5 min) and 
counterstain with hematoxylin. Small intestine was used as a positive control. Negative controls 
were prepared by omitting the primary antibody. Slides were digitized with a NanoZoomer 2.0-
HT slide scanner (Hamamatsu, Bridgewater, NJ) equipped with an Olympus Uplansapo 20X 
objective (Tokyo, Japan). Images were captured with NDP View software (Hamamatsu) and 
dietary assignment was blinded. Images were processed in Fiji 34. Stromal cells were manually 
removed from the RGB TIFF images and Ki67-positive DAB signal was extracted using a 
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previously described color deconvolution plugin 35. Total epithelial images and extracted 
epithelial Ki67 signal images were thresholded to binary, and positive pixels were counted. 
Proliferative index (PI) was calculated as PI = epithelial Ki67-positive pixels/total epithelial 
pixels. All images were captured at 20x magnification. 
Gene expression analysis 
Total RNA was extracted from ~30 mg tumor tissue using RNEasy Mini spin columns 
(Qiagen, Valencia, CA) according to manufacturer’s instructions. RNA was quantified 
spectrophotometrically and integrity verified using agarose gel electrophoresis. cDNA was 
synthesized using a High-Capacity Reverse Transcription Kit (Life Technologies, Grand Island, 
NY). qPCR was carried out with SYBR Green chemistry (Life Technologies) on an ABI 7900 
HT qPCR platform (Life Technologies), using pre-designed primer assays (Ar, Srd5a1, Srd5a2, 
Hsd17b2, Hsd17b3, Akr1c6, Vegfa, Bco2, and Rpl19; SA Biosciences, Valencia, CA). Rpl19 was 
used as the reference gene for 2-ΔΔCt relative expression analysis.  
Statistical analysis 
Tumor growth rate was compared by exponential non-linear regression in GraphPad 
Prism 6 (GraphPad Software, Inc., La Jolla, CA). All other analysis was conducted in SAS 
version 9.3 (SAS Institute, Cary, NC). Repeated-measures ANOVA with Toeplitz covariance 
structure was used for analysis of body weight over time. Individual post hoc contrast statements 
were used to compare body weight at each time point under CON and TP-I treatments. 
Bonferroni’s adjusted α was calculated and used for this test (α = 0.05 / 27 tests = 0.0018). CON-
fed animals were not included in statistical comparisons of tissue carotenoid accumulation. 
Tissue carotenoids, tissue weights, PI index, and gene expression were compared using mixed 
model two-way analysis of variance with multiple-comparison adjustment by Tukey’s method. 
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Tumor weight and tumor volume were compared similarly, but with date of birth and castration-
tumor interval (time in weeks between castration and tumor detection via ultrasound) as 
covariates. Sacrifice age was used as a covariate on measures of tissue weight. Data were log 
transformed when not meeting assumptions of normality and individual group variances were 
used in place of the pooled variance when the Brown-Forsyth test indicated heterogeneity of 
variances. Tumor incidence, metastasis incidence, and histopathological cancer incidence were 
compared using a two-tailed Fisher’s Exact Test. 
 
Results 
Carotenoid profile of diet and accumulation in tissue in vivo 
Carotenoid composition of the 10% LTP diet is shown in Figure 4.1. Lycopene was the 
predominant carotenoid, accounting for 45% of the total carotenoids. Likely due to the presence 
of some under-ripe tomatoes in the commercial tomato paste used, a large proportion of dietary 
carotenoids were the lycopene precursors phytoene (29%) and phytofluene (18%). Lycopene, 
phytoene, and phytofluene were present at 37.5, 25.1, and 16.0 nmol/g diet, respectively.           
ζ-carotene, another lycopene precursor, constituted only 3% of total carotenoids; three other 
minor carotenoids (α-carotene, β-carotene, and lutein) also contributed <5% of total dietary 
carotenoid content. With the HPLC method used, it was not possible to separate all-trans from 5-
cis lycopene. However, aside from the 5-cis species, dietary lycopene was not commonly 
isomerized, as only 20% of total lycopene were present in other cis conformations.  
Tissue carotenoid profiles contrasted starkly with dietary carotenoids. In the livers of 
animals in the TP group, whereas lycopene, phytoene, and phytofluene were still the 
predominant carotenoids, the proportions of phytoene and phytofluene were approximately 
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switched, making phytofluene the second-most abundant hepatic carotenoid behind lycopene 
(Fig. 4.2A). β-carotene and lutein were not detected at all in the liver (Table 4.2), and α-carotene 
was present at <1% of total hepatic carotenoids (Fig. 4.2A). These patterns were similar between 
TP and TP-I treatments (Table 4.2). We did detect small amounts of all-trans/5-cis lycopene in 
the livers of CON-fed mice, but these levels were more than 700-fold lower than levels of total 
lycopene in the TP- and TP-I-fed mice (Table 4.2). We suspect that these signals were the result 
of trace cross-sample contamination during the sample extraction and preparation procedures; 
this is feasible since our HPLC assay is very sensitive for lycopene (≤500 pg on-column LLOD). 
No significant differences in hepatic carotenoid accumulation were observed between the TP and 
TP-I groups (Table 4.2). 
Tumors and anterior prostate (AP) samples demonstrated an even more selective 
carotenoid distribution pattern than the liver. Although lycopene was still the most abundant 
carotenoid in both tissues (48% and 44%, respectively), ζ-carotene accumulation increased to 
21% and 39% of total carotenoids, respectively (Fig. 4.2B, C). Notably, although present at 29% 
in the diet and 16% in the liver, phytoene was not detected in any tumor or AP samples (Table 
4.2). Like the liver, no significant differences between TP and TP-I treatments were observed in 
tumoral carotenoid accumulation (Table 4.2). Due to tissue limitations, only two pooled 
replicates per group (8 - 12 mice/replicate) were possible for AP analysis; therefore, we did not 
analyze these data statistically. However, for all detected carotenoids, the replicates in the TP or 
TP-I groups overlap with replicates in the other group (Table 4.2), suggesting that no significant 
differences would be observed had greater replication been possible. 
Finally, levels of accumulation suggest that tumors and AP tissues experienced 
carotenoid saturation, whereas the liver did not. Average lycopene accumulation in the liver was 
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in the range of 14.5 – 17.5 nmol/g, whereas accumulation was ≥31-fold lower in AP samples 
(0.291 – 0.474 nmol/g) and ≥121-fold lower in tumors (0.010 – 0.012 nmol/g; Table 4.2). 
Moreover, across both TP and TP-I groups, hepatic total lycopene accumulation exhibited linear 
correlation with age at sacrifice (Fig. 4.2D). This relationship was also present with phytofluene 
(Fig. 4.2E), phytoene (data not shown), and ζ-carotene (Fig. 4.2F). In contrast, tumoral 
carotenoid accumulation did not demonstrate correlation with age at sacrifice (Fig. 4.2G, H, I). 
It is important to note that since no significant difference in sacrifice age was present between 
the treatment groups (CON: 28.1 ± 0.8 weeks, TP: 26.5 ± 0.8 weeks, TP-I: 27.4 ± 1.0 weeks), the 
only difference between the TP and TP-I treatments in length of dietary exposure to tomato 
carotenoids was due to the earlier exposure of animals in the TP group (at 4 weeks of age) 
compared to the TP-I group (12 weeks of age). Despite this, liver accumulation was not different 
between the two treatment groups (Table 4.2) and no differences in correlation between sacrifice 
age and liver carotenoid accumulation were observed (data not shown).  
TP-I treatment preserves body weight compared to CON and TP treatments 
Average group body weights were calculated from animals alive at each study week. As 
seen in Figure 4.3, a main effect of diet indicated that TP-I treatment preserved body weight     
(p < 0.01) compared to both the CON and TP treatment groups. Intact WT littermates are shown 
as a reference. Although there was no significant treatment*time interaction effect, a priori-
defined contrast statements were used to compare the TP-I treatment to CON at each week of 
age. Six time points (weeks 19, 26, 27, 28, 29, and 30) reached p ≤ 0.01 and one passed the 
Bonferroni’s adjusted α (week 29, p < 0.0018; Fig. 4.3). Comparisons for every time point after 
11 weeks of age were lower than p < 0.05 (data not shown).  
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TP-I treatment reduces CRPC tumor growth in vivo 
 Longitudinal 3D ultrasound measurements began at 10 weeks of age and continued 
biweekly until tumor detection. At the week of tumor detection (“Week 0”), tumor-bearing 
animals were switched to weekly scans for four subsequent weeks (Weeks +1, +2, +3, and +4) 
for construction of tumor growth curves in vivo. Age at tumor detection raged from 14 to 30 
weeks of age (data not shown). Animals were sacrificed within one week of the final (Week +4) 
scan. Compared to both CON and TP, TP-I treatment significantly reduced the growth rate of 
CRPC tumors in vivo (p ≤ 0.0001; Fig. 4.4A). Volumes at the last tumor scan, Week +4, were 
significantly reduced by TP-I compared to CON, but not compared to TP (p = 0.05; Fig. 4.4B).  
TP-I treatment modulates tissue weights of mice at necropsy 
At necropsy, TP-I trended towards a reduction in tumor weight, compared to CON         
(p = 0.07, Fig. 4.5A). Compared to CON, TP-I also decreased non-tumor-involved dorsolateral 
prostate weight (p = 0.05; Fig. 4.5B) and increased non-tumor-involved ventral prostate weight 
(p = 0.03, Fig. 4.5C). TP reduced DLP weight, relative to CON (p = 0.04; Fig. 4.5B). The 
difference between TP-I and TP in non-tumor-involved ventral prostate weight was also 
significant (p = 0.01; Fig. 4.5C). No significant differences were seen in seminal vesicle or non-
tumor-involved anterior prostate weights (Fig. 4.5D, E). Although not significant, TP-I induced 
a numerical decrease in total weight of regional lymph node metastases (Fig. 4.5F); variability in 
this measure was driven by large metastases in the CON group. Finally, TP-I induced alterations 
in gonadal adipose depot weight in a tumor-dependent manner. No differences between 
treatments were observed in animals not bearing a tumor, but gonadal adipose depot weight in 
tumor-bearing mice was higher with TP-I treatment, compared to CON (p ≤ 0.01, Fig. 4.5G). 
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This difference was also observed when analyzing all mice together (tumor-bearing and non-
tumor-bearing mice; Fig. 4.5G). 
TP-I does not significantly alter tumor or PCa incidence, but does inhibit metastasis to distant 
organs 
 No diet effects were observed in tumor incidence or histopathologically confirmed PCa 
incidence (Fig. 4.6). Sizable numerical decreases by TP-I treatment were observed in the 
incidences of neuroendocrine phenotypes in tumors and prostatic lobe-confined PCa, but these 
did not reach statistical significance (Fig. 4.6). However, whereas CON animals experienced a 
20% incidence of gross lung metastasis, no mice in the TP-I group experienced gross metastasis 
to this organ (Fig. 4.7); this effect was statistically significant. TP-I non-significantly prevented 
gross metastasis to the liver; this lack of statistical effect likely owed to the low hepatic 
metastasis incidence observed in the CON group. TP treatment numerically reduced metastasis 
to the lungs and liver, but these changes were not significant. Incidence of regional lymph node 
metastasis was high (68% positive in CON) and although TP-I and TP both reduced this figure  
(-18 and -8 percentage points, respectively), these changes were not statistically significant (Fig. 
4.7). 
TP-I does not appear to inhibit CRPC progression through modulation of genes controlling 
androgen synthesis 
 We measured the tumoral expression of five genes that play a critical role in 
paracrine/autocrine androgen synthesis (Hsd17b2, Hsd17b3, Akr1c6, Srd5a1, Srd5a2), as well as 
the androgen receptor (Ar). No changes by dietary treatment were observed (Fig. 4.8A). In 
addition, we measured the expression of a mediator of angiogenesis (Vegfa) and carotenoid 
metabolism (Bco2) – neither gene was significantly modulated (Fig. 4.8A). 
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 In addition, we assessed immunohistochemical Ki67 staining in non-tumor-involved 
dorsolateral prostatic tissue to determine whether dietary treatments may alter rates of cell 
division in the prostate. As seen in Figure 4.8B, although both TP and TP-I numerically reduced 
rates of proliferation, no significant differences were seen. The lack of effect may be due to high 
degree of variability seen in CON mice. 
 
Discussion 
 In response to observational research suggesting that tomato intake may reduce the risk 
of PCa 1–6,36–38, several experimental animal studies have found that tomato feeding reduces 
carcinogenesis and tumorigenesis in models of primary PCa 11–13. Although providing results to 
support the hypothesis that dietary sources of lycopene, like tomato, may reduce the risk of 
primary PCa, they do not address the role of dietary tomato in the etiology of CRPC, which is the 
late and lethal stage of the disease. To our knowledge, no studies have investigated the use of 
dietary tomato or lycopene in a model of CRPC carcinogenesis in vivo. Therefore, the objective 
of this work was to evaluate the effect of dietary tomato, imitating either lifelong consumption 
(TP) or adjuvant intervention (TP-I), on the incidence and progression of CRPC in the TRAMP 
model. Although the TP and TP-I treatment schemes produced no measureable differences in 
tissue carotenoid accumulation, we observed that TP-I and not TP treatment effectively reduced 
CRPC progression. TP-I reduced tumor growth in vivo, inhibited distant organ metastasis, and 
preserved body weight and gonadal adipose stores.  
 Levels of tomato feeding used in this study were intended to model achievable quantities 
of dietary lycopene intake and accumulation, as well as provide a translatable source and 
composition of tomato carotenoids. Epidemiological studies suggest that median/mean intakes of 
 171 
13 – 19 mg lycopene/day 1,3,4 have been associated with a reduced risk of primary PCa.  As one 
serving of tomato sauce (1 cup) or tomato paste (0.25 cup) contains 34 mg or 19 mg lycopene, 
respectively (per the U.S.D.A. Nutrient Composition Database), achievable levels of tomato 
intake may have protective effects. Indeed, consumption of as little as 1 serving of tomato 
sauce/week has been inversely associated with PCa risk 1,3. At 10% w/w of the diet, the tomato 
paste used in this study provided, on average, 0.1 mg lycopene/day to a mouse; converted to a 
human equivalent dose 39, this would be comparable to approximately 19 mg/day in a 90-kg 
adult human. This would be equivalent to consumption of about ½ serving of tomato sauce, or 
about 1 serving of tomato paste. Thus, the level of dietary tomato inclusion in the current study 
reflects levels of human lycopene intake that are both physiologically relevant and likely 
protective. Tomatoes contain many bioactives aside from lycopene 40 and evidence suggests that 
tomatoes may be more effective in reducing PCa carcinogenesis and tumorigenesis than 
lycopene alone 12,13,41. Our choice to use a whole tomato product, and moreover one which is 
commercially available to consumers, reflects our desire to investigate dietary treatments with 
the greatest translatability possible in an animal study.  
Rates of tumor incidence were slightly lower than previously reported 28, even after the 
original protocol was extended from 24 weeks to 30 weeks due to low tumor incidence at 24 
weeks (data not shown). Neuroendocrine tumor pathology incidence was also lower than 
previously reported 42.  
Compared to CON, TP-I reduced tumor growth and volume in vivo, while simultaneously 
resulting in greater body weight and gonadal adipose. Notably, this effect on gonadal adipose 
weight was not present in non-tumor-bearing animals. The main-effect difference in body weight 
between CON and TP-I treatments was approximately 1.9 grams; nearly one third of that gap 
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was accounted for by the difference in gonadal adipose depot weight (0.6 grams). Cancer 
cachexia is characterized by wasting of adipose and skeletal muscle, reduced quality of life, and 
decreased survival 43. Cancer cachexia is driven primarily by metabolic derangements and a mix 
of tumor and host-derived inflammatory cytokines 44. Within CRPC patients, elevated BMI 
(>25) is inversely associated with PCa-specific mortality 45, suggesting that preservation of body 
mass is indicative of either lower cancer burden or alteration of cancer biology. TP-I treatment 
may have lessened a pro-cachectic tumor burden, thus helping to preserve adipose stores and 
body weight. It is interesting to note that, temporally, the first indication of an effect (p < 0.05) 
of TP-I on longitudinal body weight (relative to CON) was observed at the 12-week time point, 
when animals were castrated and the transition from control diet to 10% LTP occurred in the TP-
I group. Although provision of diet was measured and recorded three times a week, due to 
burrowing activity and waste on the floor of the cage, accurate food intake data were not 
available from which to draw conclusions. Regardless, these differences in body weight and 
adipose depot weight suggest a unique role of the TP-I treatment in reducing the impact of CRPC 
in this model. 
 Surprisingly, TP did not reduce mean CRPC tumor growth rate and volume in vivo, as 
seen with TP-I treatment. We hypothesized that the longer dietary exposure provided by the TP 
treatment would result in a stronger effect than the TP-I treatment, which was designed to model 
adjuvant intervention. The present results were unexpected, given that a tomato powder 
intervention (initiated at 8 weeks of age) had previously failed to prevent primary PCa in the 
TRAMP model 27. One possibility to explain our findings is that heterogeneity in tumor 
responses may have masked positive effects of the TP treatment. Although comparison of group 
mean tumor growth curves (Fig. 4.4A) show the CON and TP groups to have nearly identical 
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growth rates, examination of individual curves demonstrates the potential existence of 
phenotypic non-responders (Appendix Fig. C.1). Both fast- and slow-growing tumors can be 
seen in the CON group and rates of growth are evenly distributed; in contrast, TP and TP-I 
treatments both demonstrate a predominance of slow-growing tumors, with the exception of 
three tumors in the TP group and one in the TP-I treatment group. These divergent tumors can 
also be seen on graphs of the Week +4 tumor volume (Fig. 4.4B) and tumor weight at necropsy 
(Fig. 4.5A; two of these mice in the TP group died between their last ultrasound scan and 
necropsy, making tumor weight data unavailable). If these animals were to be excluded from 
group mean tumor growth rates, the TP growth rate curve approximated the TP-I curve more so 
than the CON growth curve (Appendix Fig. C.2). It can also be seen in Figs. 4.4B and 4.5A that 
these data points drive their respective group means upward. Data which follow binomial 
distributions, such as incidence data, are inherently unbiased by individual values and thus may 
reflect average group behavior in the presence of outliers more faithfully than continuous data. In 
binomial measures of metastasis incidence, TP performs similarly to TP-I in lung metastasis, 
liver metastasis, and all distant organ metastasis, albeit non-significantly relative to CON (Fig. 
4.7).  
It is known that genomic and transcriptomic signatures of CRPC tumors demonstrate 
large patient-to-patient variability 46 and that molecular subtype can be prognostic for clinical 
outcomes 47–51. Among these signatures are markers of hormonal responsiveness; most CRPC 
tumors are androgen-sensitive 52,53 and often rely on local production of androgens despite 
ablation of circulating androgens by androgen deprivation therapy 54–56. It has been shown that 
tomato carotenoids may modulate androgen-metabolic genes 57–59 and unpublished data from our 
own lab suggest that dietary tomato inhibits primary PCa in the TRAMP model while altering 
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expression of androgen biosynthetic genes Hsd17b2 and Hsd17b3 (Zuniga, unpublished data). 
However, gene expression analysis on CRPC tumors in the present study revealed no significant 
differences between treatment groups in the mRNA expression of Hsd17b2, Hsd17b3, Srd5a1, 
Srd5a2, or Ar (Fig. 4.8A). Moreover, expression of these genes did not correlate with tumor 
weight at necropsy (data not shown). Angiogenesis markers have been associated with increased 
risk of PCa metastasis and mortality 7, and dietary lycopene is associated with lower levels of 
angiogenesis and mortality 4. However, tumoral mRNA expression of Vegfa was not modulated 
by treatment group (Fig. 4.8A), nor did it correlate with tumor growth (data not shown). Protein 
expression analysis of several of these genes is underway. The current study captures too few 
non-responder tumors to definitely conclude that divergent tumor phenotypes contributed to 
heterogeneity in the TP treatment group. Furthermore, the gene expression endpoints 
investigated thus far do not support the existence of heterogeneity in transcriptional subtypes 
within the TP treatment group. Additional analysis is needed to clarify the mechanism of reduced 
tumor growth by TP-I and whether a heterogeneity of tumor phenotypes exists within the TP 
treatment group.  
Tissue carotenoid accumulation in the present study supports previous reports in various 
rodent models. Liver represents a major site of carotenoid metabolism, as well as a major depot 
of storage 60–63. The two previous TRAMP studies from our lab provided 533 and 23.8 nmol 
nmol lycopene/g diet from tomato powder, resulting in hepatic lycopene concentrations of 4.6 
and 1.9 nmol/g after 14 and 12 weeks of feeding, respectively 14,27. In contrast, whereas the 
current study provided only 37.5 nmol/g dietary lycopene, hepatic accumulation of this 
carotenoid was 14.5 or 17.5 nmol/g with TP or TP-I treatment, respectively. These hepatic 
concentrations were up to 3.8-fold higher than reported by Zuniga et al, despite feeding 14-fold 
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lower levels of dietary lycopene. This difference is very likely due to the difference in castration 
status between the to studies – prior work has shown that castrated rats accumulated roughly 
double that of intact rats, even when fed 10-fold lower levels of dietary lycopene 64,65. Hepatic 
concentrations of the four major carotenoids significantly correlated with length of exposure in 
the current study. These data additionally suggest that carotenoids accumulated in the liver as a 
function of time on diet and that the accumulation was still in a linear phase (i.e., no saturation 
occurring) up to 30 weeks of exposure within this study. Moreover, hepatic accumulation of 
phytoene and ζ-carotene was significantly (p < 0.05) increased ~ 1.7-fold in non-tumor-bearing 
animals compared to tumor-bearing animals; lycopene and phytofluene exhibited similar, but 
non-significant trends (data not shown). This, too, was almost certainly an effect of dietary 
exposure length, as non-tumor-bearing mice were sacrificed at 30 wk of age (per protocol) and 
tumor-bearing animals were, by design, not on study as long (average age 23.3 ± 0.8 wk). An 
alternative explanation could be that the presence of a tumor increased systemic inflammation, 
oxidative stress, or metabolic rate, thus resulting in greater catabolism of hepatic carotenoids. 
Although dietary exposure length and tumor presence are confounded in this endpoint, 
precluding a definitive conclusion, exposure length is a more parsimonious explanation for the 
patterns of hepatic accumulation observed. Despite the strong effect of dietary exposure length 
on hepatic carotenoid accumulation, hepatic carotenoid accumulation did not differ between the 
TP and TP-I treatments, which differed in average dietary exposure by approximately 8 weeks of 
age. However, Conlon et al. also reported no significant difference between mice fed tomato 
diets for 8 or 12 weeks 27.  
Interestingly, carotenoid accumulation in serum and extra-hepatic tissues, in contrast to 
the liver, is not affected by androgen status 64,65. This suggests that either carotenoid metabolism 
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in the liver is uniquely responsive to circulating androgens, that extra-hepatic tissues experience 
saturation at levels of exposure much lower than the liver, or both. Comparing data from the 
report by Conlon et al. (feeding 23.8 nmol lycopene/g tomato diet to TRAMP mice for 4, 8, or 12 
wk) to the current study (feeding 37.5 nmol lycopene/g tomato diet to castrated TRAMP mice for 
2 – 30 wk) sheds light on this issue. Lycopene accumulation in anterior prostate tissue from 
castrated TRAMP mice (0.3 – 0.5 nmol/g, Table 4.2) is equivalent to that in intact TRAMP mice 
(0.4 nmol/g, 27). This suggests that despite atrophy of the anterior prostate after androgen 
deprivation by castration, relative accumulation of carotenoids proceeds unimpaired. Moreover, 
carotenoid accumulation in the anterior prostate 27 and prostatic tumor tissue (Fig. 4.2G-I) does 
not increase with longer dietary exposure, in contrast to the liver. This demonstrates that these 
tissues indeed do saturate at carotenoid exposures lower than those necessary to saturate the 
liver.  
In agreement with previous reports in gerbils, mice, and rats, phytoene was not detected 
in prostates or tumors 14,27,33,66. As previously reported in gerbils 66, ζ-carotene was a highly 
abundant carotenoid in prostatic tissues, despite its presence at <5% of the diet. Mechanisms 
responsible for these differences in carotenoid distribution remain unresolved. This area 
continues to be one of active research, and genetic factors, tissue-specific receptors, or 
differences in lipoprotein handling may play a role 61.  
 
Conclusions  
In conclusion, we have shown, for the first time, that dietary tomato can reduce CRPC 
progression in an animal model. CRPC tumor volume and rate of CRPC tumor growth were 
reduced nearly 50% by adjuvant dietary tomato intervention following surgical castration. In 
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addition, compared to control feeding, adjuvant tomato treatment reduced distant gross 
metastasis to the lungs, and preserved gonadal adipose and body weights. Importantly, CRPC 
progression was reduced with clearly achievable levels of dietary tomato intake, and through use 
of a common tomato food source that is already commercially available to consumers. These 
effects should be replicated and extended in future animal studies to examine the effects of 
adjuvant dietary tomato in conjunction with pharmacological androgen deprivation therapy, 
which is the current first-line therapy in men with metastatic recurrent PCa. Additionally, it 
would be important to ascertain whether a dose escalation intervention - e.g., lifelong basal 
tomato exposure + elevated exposure at intervention – would yield similar results, as few men 
abstain from all tomato intake prior to PCa diagnosis and treatment. Hopefully, these data can 
eventually be translated into improved clinical outcomes for men with CRPC. 
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Table 4.1. 
	
g/100	g	diet	
		 CON	 10%	LTP	d	
Cornstarch	 39.0	 36.3	
Maltodextrin	 13.0	 10.5	
Sucrose	 9.8	 9.7	
Casein	 19.6	 17.7	
Cellulose	 4.9	 4.1	
Mineral	Mix	a	 3.4	 3.4	
Vitamin	Mix	b	 1.0	 1.0	
L-Cystine	 0.3	 0.3	
Choline	bitartrate	 0.2	 0.2	
Soybean	oil	 7.0	 6.8	
LTP	 0.0	 10.0	e	
Water	 1.8	 0.0	
Total	 100.0	 100.0	
Energy	density	(kcal/g	diet)	c	 3.88	 3.84	
 
Table 4.1. Composition of experimental diets.  
a AIN-93-MX formulation  
b AIN-93-VX formulation  
c Calculated. 
d Lyophilized tomato paste (Contadina® Foods, San Francisco, CA) 
e As determined by proximate analysis, 10.0 g LTP provided 4.5 g total carbohydrates, 1.7 g 
crude protein, 0.1 g crude fat, 0.8 g crude fiber, 1.8 g water, and 1.1 g ash.  
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Figure 4.1. 
 
Figure 4.1. 10% LTP diet carotenoid composition. Data are group means ± SEM across all 7 diet 
batches. n = 2 replicates/batch. Inset displays average diet profile. Four minor carotenoids (<5%) 
are listed in the legend to the side of the pie chart. at, all trans; LYC, lycopene; PE, phytoene; 
PF, phytofluene; ζ C, ζ-Carotene; βC, β-Carotene; α C, α-Carotene; Lut, lutein. 
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Table 4.2. 
  
nmol/g 
    CON TP TP-I 
Liver         
Total carotenoids 
 
0.02 ± 0.01 30.6 ± 1.77 36.4 ± 2.17 
Total Lycopene 
 
0.02 ± 0.01 14.5 ± 1.96 17.51 ± 2.09 
at- + 5-cis Lycopene   
 
0.02 ± 0.01 10.9 ± 1.49 13.3 ± 1.60 
Other cis Lycopene 
 
n.d. 3.60 ± 0.47 4.19 ± 0.49 
Phytoene 
 
n.d. 5.01 ± 0.83 5.80 ± 0.70 
Phytofluene 
 
n.d. 9.54 ± 1.48 11.43 ± 1.42 
ζ-Carotene 
 
n.d. 1.50 ± 0.19 1.59 ± 0.18 
β-Carotene 
 
n.d. n.d. n.d. 
α-Carotene 
 
n.d. 0.03 ± 0.00 0.02 ± 0.00 
Lutein 
 
n.d. n.d. n.d. 
Anterior Prostate         
Total carotenoids 
 
n.d., 0.010 0.695, 1.055 0.785, 0.838 
Total Lycopene 
 
n.d., 0.010 0.291, 0.474 0.324, 0.407 
at- + 5-cis Lycopene   
 
n.d., 0.010 0.165, 0.283 0.194, 0.251 
Other cis Lycopene 
 
n.d., n.d. 0.126, 0.191 0.130, 0.156 
Phytoene 
 
n.d., n.d. n.d., n.d. n.d., n.d. 
Phytofluene 
 
n.d., n.d. 0.131, 0.169 0.111, 0.134 
ζ-Carotene 
 
n.d., n.d. 0.274, 0.412 0.296, 0.350 
β-Carotene 
 
n.d., n.d. n.d., n.d. n.d., n.d. 
α-Carotene 
 
n.d., n.d. n.d., n.d. n.d., n.d. 
Lutein 
 
n.d., n.d. n.d., n.d. n.d., n.d. 
Tumor         
Total carotenoids 
 
n.d. 0.19 ± 0.05 0.31 ± 0.06 
Total Lycopene 
 
n.d. 0.10 ± 0.02 0.12 ± 0.02 
at- + 5-cis Lycopene   
 
n.d. 0.06 ± 0.01 0.08 ± 0.01 
Other cis Lycopene 
 
n.d. 0.03 ± 0.01 0.04 ± 0.01 
Phytoene 
 
n.d. n.d. n.d. 
Phytofluene 
 
n.d. 0.05 ± 0.02 0.13 ± 0.03 
ζ-Carotene 
 
n.d. 0.04 ± 0.01 0.06 ± 0.01 
β-Carotene 
 
n.d. n.d. n.d. 
α-Carotene 
 
n.d. n.d. n.d. 
Lutein 
 
n.d. n.d. n.d. 
 
Table 4.2. Tissue carotenoid accumulation. Values for liver and tumor are mean ± SEM, 
whereas both duplicates analyzed are reported for anterior prostate. Liver n = 14 for TP and TP-I, 
n = 3 for CON; tumors n = 5 for TP and TP-I, n = 3 for CON; anterior prostate n = 2 pools of      
8 - 12 mice/group. n.d., not detectable. There were no significant differences in accumulation 
between the TP and TP-I diets. 
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Figure 4.2.  
 
 
 
Figure 4.2. Carotenoids accumulate in a tissue-specific manner in the CRPC TRAMP model. 
Liver (A), anterior prostate (B), and tumor (C) accumulation profiles in TP mice. Mice in the 
TP-I dietary group had similar patterns of accumulation (data not shown). Liver accumulation of 
lycopene (D), phytofluene (E), and  ζ-carotene (ζC, F) correlates with length of dietary exposure 
(“Weeks old” indicates weeks old at sacrifice), whereas tumor accumulation of lycopene (G), 
phytofluene (H), and  ζC (I) does not.   
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Figure 4.3 
 
Figure 4.3. TP-I treatment preserves body weight compared to CON and TP in the CRPC 
TRAMP model. Data represent weekly weight ± SEM. Intact (non-castrated) WT littermates are 
shown for reference. Longitudinal comparison of CON and TP-I treatment was tested with 27 
individual contrasts (Bonferroni’s adjusted α = 0.0018); ^ TP-I vs. CON p < 0.0018; ** TP-I vs. 
CON p ≤ 0.01.  # Indicates significant main effect of diet (p < 0.01 for both CON vs. TP-I and 
TP vs. TP-I).  
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Figure 4.4. 
 
Figure 4.4. TP-I reduces CRPC tumor growth in vivo. A, TP-I reduces rate of tumor growth as 
measured by longitudinal 3D ultrasound. Week of tumor detection is set at “0”. Data shown are 
means ± SEM. Group n = 15 - 17. Non-linear exponential regression was used to determine best-
fit curves from all data points within a group. ***p ≤ 0.0001 for the test of the null hypothesis 
that one best-fit curve describes both groups. B, Tumor volume at the Week +4 scan (calculated 
by 3D ultrasound) is reduced in TP-I animals, compared to CON-fed animals. Data represent 
individual mice. Group n = 15 – 17. The black line marks the group mean. *p ≤ 0.05 vs. CON. 
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Figure 4.5. 
 
 
 
Figure 4.5. Selected tissue weights in TRAMP CRPC mice. Tumor weight (A) trends lower in  
TP-I mice, relative to CON. Data points represent individual mice and the black line marks the 
group mean. TP and TP-I reduce dorsolateral prostate weight (B), whereas TP-I increases ventral 
prostate weight (C). No significant differences were observed in the weights of anterior prostate 
(D), seminal vesicles (E), or gross regional lymph node metastases (F), although within gross 
lymph node metastases, there was a trend for main effect of diet (p = 0.07). TP-I increases 
gonadal adipose depot weights in a tumor-dependent manner (G). *p ≤ 0.05 vs. CON; **p ≤ 0.01 
vs. CON, ^^p ≤ 0.01 vs. TP. n.s.d., no significant differences. 
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Figure 4.6.  
 
Figure 4.6. Tomato diets do not significantly reduce CRPC incidence. Tumor incidence was 
identified by visual inspection during necropsy. All tumors were confirmed by histopathology 
(data not shown). Neuroendocrine (NE) incidence and PCa incidence in non-tumor-involved 
prostatic lobes were determined by histopathology by a blinded examiner. Prostatic lobe PCa 
was considered positive if observed in any of the dorsolateral, ventral, or anterior lobes.   
Statistical analysis was done by two-tailed Fisher’s Exact Test. n.s.d., no significant differences. 
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Figure 4.7. 
  
Figure 4.7. TP-I reduces CRPC gross lung cancer metastasis. Gross metastases were identified 
on visual inspection during necropsy. * p < 0.05. by two-tailed Fisher’s Exact Test. 
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Figure 4.8.  
     
 
Figure 4.8. Dorsolateral prostate Ki67 staining and selected tumoral mRNA expression are not 
modified by tomato diets. Genes involved in androgen synthesis and signaling (Ar, Hsd17b2, 
Hsd17b3, Akr1c6, Srd5a1, Srd5a2), carotenoid metabolism (Bco2) and angiogenesis (Vegfa) 
were measured via qPCR in tumoral tissue (A). Data are 2-ΔΔCt means ± SEM of n = 11 - 16/diet. 
Genes were measured relative to Rpl19, which was stable across all diet treatments and qPCR 
runs (data not shown). Immunohistochemical epithelial Ki67 labeling in dorsolateral prostate 
was not altered by diet (B). Data are group means ± SEM. n = 3 - 4 replicates/group. Each 
replicate is the average of 2 - 3 images. n.s.d., no significant differences. 
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CHAPTER 5 
Summary and future directions 
 There is substantial evidence in the literature that inversely links PCa incidence to intake 
of dietary tomato carotenoids; additionally, much work has been done since the early 20th 
century to elucidate the mechanisms of carotenoid metabolism and distribution in vivo. It has 
become clear that each of these areas of research contributes to the other: without a thorough 
understanding of the molecular mechanisms of carotenoid metabolism, research on the dietary 
prevention of PCa would be ill-equipped; likewise, without firm mechanistic knowledge of the 
role of carotenoids in PCa etiology, the significance and impact of research on metabolism of 
dietary tomato carotenoids is lessened. The aim of this dissertation, broadly, was to contribute to 
both of these fields and perhaps shed light onto their intersection. More specifically, the aims of 
this dissertation were to: 
 
1. Elucidate the impact of Bco1 loss on prostatic physiology, with a focus on androgen 
status and signaling, 
2. Determine the impact of Bco1 loss on lipid, cholesterol, and retinoid metabolism in the 
liver, a key organ in the metabolism and biodistribution of dietary carotenoids, and 
3. Evaluate the effects of dietary tomato feeding in an animal model of CRPC and 
determine its efficacy in preventing disease progression. 
 
In Chapters 2 and 3, we aimed to review the background literature and clarify the in vivo 
role of a major mediator of carotenoid metabolism, BCO1. Conserved through much of the 
animal kingdom, BCO1 is the primary mediator of central provitamin A carotenoid cleavage for 
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the production of retinal, and subsequently, the active form of vitamin A, all-trans retinoic acid 1. 
However, subsequent work has shown that this enzyme is not limited to production of retinal 
from non-substituted cyclized carotenes, but rather can cleave non-provitamin A carotenoids, 
such as lycopene 2. Given the abundance of work linking dietary tomato carotenoid intake to a 
reduced risk of PCa, we questioned whether interactions between Bco1 genotype and dietary 
tomato carotenoids might modulate aspects of prostatic biology. Originally, the plan of work was 
to analyze interactions at both short- and long-term tomato exposures; whereas long-term 
exposures more realistically approximate a human diet, evaluation of short-term exposures 
would allow for the potential identification of “primary” molecular targets of lycopene, or its 
BCO1-mediated metabolites. However, a quote from Richard Feynman, the Nobel Prize-winning 
physicist, presaged the sharp change in trajectory that this dissertation would soon take: “We are 
not to tell nature what she’s gotta be. She’s always got better imagination than we have.” 
Although short-term (4 day) tomato carotenoid feeding did interact with Bco1 genotype to 
modulate some endpoints (HMG-CoA reductase protein expression and StAR mRNA expression 
were altered by tomato or lycopene in a Bco1-dependent manner), the major finding was that 
Bco1 loss, independent of dietary carotenoid feeding, significantly and dramatically reduced 
circulating testosterone concentrations, accompanied by significant decreases in prostatic organ 
weight, proliferation, cell cycle progression, and androgen signaling. In concert with these 
changes, testicular mRNA expression of Hsd17b3, a major regulator of testosterone synthesis, 
was significantly reduced, as were populations of Leydig cells, the primary cells in the body 
responsible for maintenance of serum testosterone levels in males. These changes were 
unexpected, as few researchers had envisioned a role for BCO1 apart from its function in 
carotenoid cleavage. Multiple implications were raised with these findings. First, relevance to 
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human populations lies within the fact that single nucleotide polymorphisms in the human BCO1 
gene are common (with major allele frequencies of 0.25 – 0.50) and occur within protein coding 
regions of the gene 3. Moreover, loss-of-function alleles that result in decreased provitamin A 
conversion have been identified, showing that these polymorphisms are not silent 4,5. Secondly, 
although no studies have investigated the effects of BCO1 polymorphisms on androgen status in 
human populations, the level of serum testosterone decrease observed could be clinically 
significant. Ever since the seminal studies by Huggins in the 1940s 6, many scientists have 
assumed that modulation of endogenous circulating testosterone levels in eugonadal men 
subsequently modulated PCa risk; in fact, several epidemiological studies supported this 
hypothesis 7–9. However, these associations were apparently spurious. Subsequent analysis and 
refined understanding has led the scientific community to appreciate that, due to the saturation of 
AR binding sites under endogenous levels of circulating testosterone 10,11, modifications of 
serum testosterone within the reference range does not result in changes in PCa risk. We 
observed a large and significant reduction in serum testosterone levels in Bco1-/- mice compared 
to WT, accompanied by a significant decrease in an immunohistochemical marker of prostatic 
proliferation. Despite these changes in androgen status and prostatic proliferative index, due to 
the AR saturation effect, WT mice were almost certainly at no higher risk of PCa than Bco1-/- 
mice; in fact, we have never observed a spontaneous case of PCa in WT or Bco1-/- mice up to 71 
weeks of age. Consequently, reductions in serum testosterone in humans due to the putative 
effects of BCO1 variation would likely not directly reduce prostate cancer risk.  However, given 
the broad impacts of circulating androgens, such an effect of BCO1 may impact a myriad of 
other endpoints. Hypogonadism may be a causal factor for dyslipidemia and metabolic syndrome 
in males 12,13 and androgen status has been shown to modulate carotenoid accumulation             
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in vivo 14,15. Similarly, a common BCO1 variant (0.49 minor allele frequency) significantly 
predicts circulating HDL concentrations in humans 16, and loss of Bco1 in mice alters lycopene 
accumulation – strikingly, increasing prostatic accumulation 4-fold 17! Other studies have 
demonstrated effects of Bco1 loss on various endpoints of lipid metabolism in vivo 18–22. Given 
the fact that carotenoid metabolism and distribution is in turn highly dependent on the 
mechanisms of lipid metabolism 23, it would be unwise to reject a potential network linking 
BCO1 status, androgens, and lipids. Our study in Chapter 2 contributed to the elucidation of this 
relationship. Future work is required to assess whether polymorphisms in the human BCO1 gene 
have similar effects on androgen status in humans, as well as to identify a direct mechanism 
through which ablation of Bco1 alters testicular testosterone production. 
 More work in humans is needed to expand on the hypothesis that BCO1 status may alter 
lipid metabolism, but we pursued this question in Chapter 3, again using the Bco1-/- mouse 
model. Other labs had identified changes in lipid esterification, cholesterol metabolism, retinol 
esterification, and hepatic steatosis as a result of Bco1 loss 18–21, but results were sometimes 
contradictory. Furthermore, although each study had used descendants of the same Bco1-/- 
founder pair, ages, sex of animals studied, and the carotenoid/retinoid content of study diets 
varied widely. Given the impact of Bco1 loss on hormonal status uncovered in Chapter 2, and 
concerned about changes in phenotype that might occur over the wide range of ages used in 
previous studies, we decided to assess how Bco1 loss altered hepatic lipid and retinoid 
metabolism in male mice, as well as include analysis of a wide range of developmental stages. 
Two primary findings arose from our work in Chapter 3. First, we found that adult male Bco1-/- 
mice accumulate roughly 2 - 6 greater levels of hepatic retinyl esters than did age-matched WT 
mice, but that this effect was reversed in juveniles. Notably, whereas others had previously 
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reported a similar effect of Bco1 loss on retinol esterification in younger mice, our finding 
demonstrates that Bco1 interacts with hepatic retinol metabolism in an age-dependent manner, a 
novel finding with potentially more broad implications. Secondly, we found that hepatic retinoid 
metabolism was altered in concert with changes in cholesterol and phospholipid esterification, 
and we propose that altered retinoid levels may act through PPAR/RXR signaling pathways to 
mediate the changes that we and others have observed in hepatic lipid metabolism. Third, our 
finding that Bco1-dependent changes in retinol metabolism are not only present from youth 
through old age, but also are developmentally regulated, may help to explain other findings from 
Chapter 2 as well. In Chapter 2, we reported that, in young mice (9 – 14 weeks old), weight of 
the androgen-dependent seminal vesicles were reduced by Bco1 loss, in concert with testicular 
production of testosterone. In Chapter 3, we also found that seminal vesicles were reduced in 
weight in young mice (≤9 weeks of age), but conversely, that Bco1-/- seminal vesicle weight was 
greater than WT in older mice (≥51 weeks of age). Moreover, it was striking that this change 
occurred in almost lockstep with hepatic retinyl ester accumulation. As vitamin A has long been 
known to impact testicular steroidogenesis and function 24, modulation of systemic and testicular 
retinoid status may mediate the effects previously seen on testosterone status with Bco1 loss.  
This, of course, is currently only speculative, and it remains to be seen whether hepatic changes 
in retinoid status would have any impact on testicular and subsequently androgen-sensitive 
tissues, but this possibility should be investigated.  
It is important to note that the genetic techniques used to create genetically modified 
models, such as the Bco1-/- mouse, may directly introduce off-target effects that are unrelated to 
the gene under study. Indeed, in a very similar mouse model, the β-carotene-9’,10’-dioxygenase 
(Bco2) knockout, prostatic mRNA expression of interleukin 18 (Il18) was reduced 25-fold, 
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compared to WT mice (unpublished data). The murine Bco2 exon 1, which was replaced with a 
lacZ cassette during generation of the Bco2-/- strain 25, overlaps with the complementary 
sequence on chromosome 9 that encodes the murine Il18 gene (NCBI); this may account for our 
observations in Il18 expression. In fact, a similar juxtaposition of IL18 and BCO2 is present on 
the human chromosome 11 and a large genome-wide association study found that four of the top 
seven SNPs associated with circulating IL18 levels were located within the IL18 gene, whereas 
the other three, including the most strongly associated SNP, were present in the BCO2 gene 26. 
The regions of the Bco1 gene that were modified to create the Bco1-/- strain 18 do not have similar 
juxtapositions (they are roughly 15 Kb upstream from the closest gene; NCBI), but even the 
basic gene targeting techniques used in genetic modification can alter expression of genes 
located up to 3.1 Mb from the site of insertion 27. This is not to suggest that the presence of off-
target effects inherently negates the value of a genetically engineered model; the Bco2-/- strain, 
despite the likely off-target effect on IL18 levels, has proven to be hugely informative for our 
understanding of lycopene metabolism 28. Rather, it is clear that the more thoroughly a mouse 
model can be described, “warts and all”, the better the data arising from its use can be 
interpreted. Additionally, the accretion of evidence consistent with a singular mechanism (for 
example, of altered retinoid metabolism) would help to assuage fears of off-target effects. 
Nonetheless, these concerns must always be kept in mind when using genetically engineered 
models generated with techniques similar to those used to create the Bco1-/- and Bco2-/- models. 
Finally, in Chapter 4, we aimed to assess the impact of dietary tomato treatments, 
administered to model either lifelong consumption or adjuvant intervention, on the progression 
of castration-resistant prostate cancer. We administered a physiologically relevant dose of a 
commercially available tomato food (Contadina® brand tomato paste), in order to maximize 
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translatability of this animal study. Specifically, the 19 mg/day human equivalent dose provided 
to mice in this study (calculated for a 90-kg man using previously described body surface area 
conversions 29) would be achievable through the consumption of 0.6 servings of tomato sauce 
per day (1.0 C/serving; U.S.D.A. Nutrient Database), or 1 serving of tomato paste per day (0.25 
C/serving). To our knowledge, this is the first report of the effects of dietary tomato in an animal 
model of CRPC carcinogenesis. We found that tomato intervention, and not lifelong 
consumption, was effective in reducing CRPC tumor growth and metastasis. No differences in 
tissue carotenoid accumulation were observed between the treatment groups, nor were any 
differences observed in mRNA markers of tumoral steroidogenesis and androgen signaling. 
Despite these null effects in mRNA expression of genes related to androgen metabolism, due to 
the abundance of literature in the area, we are continuing with our a priori plans to investigate 
protein expression of several of these enzymes, as well as measure intratumoral androgen 
profiles with mass spectrometry techniques. Both of those projects are currently underway. 
However, the difference in TP and TP-I results were contradictory to our hypothesis, as 
epidemiological studies and conventional thought would suggest that lifelong consumption, and 
not a shorter intervention, would be most effective. Additionally, the TP-I intervention was 
initiated at 12 weeks, when the majority of animals would already have had high-grade pre-
neoplastic intraepithelial neoplasia, or low-grade adenocarcinoma 30,31. Although the intervention 
was purposely administered at such a stage of early carcinogenesis, again, conventional wisdom 
would suggest that such timing would miss the “critical window” to prevent progression. Indeed, 
in a previous study from our group, it appears that a tomato powder intervention in primary PCa 
in the TRAMP model was ineffective due to administration of tomato diets outside of such a 
window 31. Apart from the hypothesis proposed in Chapter 4 – that the TP diet was actually not 
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wholly ineffective, but rather suffered from bias by “non-responder” outliers – we can think of 
another plausible mechanism which may explain the results. Castration in the TRAMP model has 
been shown to induce treatment effects in the cancer genome, inducing androgen receptor 
mutations and other molecular alterations, which otherwise may not have been acquired 32,33. 
Similar effects may be seen with ADT in humans with CRPC 34. It may be possible that tomato 
consumption prior to castration “primes” the nascent cancer to evade its effects, and this only 
becomes evident once the evolutionarily selective pressure of castration is applied and forces the 
selection of the “fittest” cellular populations. We have engaged in discussions with multiple unit 
leaders at the Roy J. Carver Center for Biotechnology to lay groundwork for a project to 
sequence the AR from each tumor. If differential types or numbers of AR mutations were to be 
revealed between the TP and TP-I treatment groups, it would lend credence to this hypothesis.  
Despite the uncertainty about both the mechanism of action of the TP-I group, as well as 
uncertainty surrounding the reason for a lack of effect in the TP group, important conclusions 
can be drawn from the data presented in Chapter 4. For the first time, we have shown that dietary 
tomato can reduce CRPC progression in an animal model, particularly when provided as an 
adjuvant dietary intervention. This is encouraging, and provides preliminary data for larger 
follow-on studies. We see two key studies as being necessary: first, it will be important to assess 
whether a dose-escalation tomato intervention – for example, increasing consumption from 2% 
at weaning to 10% at castration – would be effective. Although our current TP-I group was 
meant to model men who increase tomato consumption following a cancer diagnosis, most men 
in such a situation would likely have consumed some sub-protective level of tomato prior to 
diagnosis, rather than completely abstaining form tomato intake. Thus, it would be important to 
further refine the model to more closely match human dietary patterns. Second, studies 
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combining dietary tomato with pharmacological ADT, rather than surgical castration, would 
more fully recapitulate clinical treatment combinations available as first-line therapy to men with 
CRPC. These would need to be successfully completed and replicated before any attempt to 
translate our results to clinical trials.  
In conclusion, this work has revealed that BCO1, a key enzyme involved in carotenoid 
metabolism, impacts steroid, lipid, and retinoid metabolism independent of its role in carotenoid 
cleavage. Further work in animal models and humans is needed, but we have shed additional 
light on a somewhat unexamined corner of the carotenoid field. Future work should incorporate 
our findings in mice and assess their relevance in humans. Secondly, we have demonstrated that 
a relevant level and source of dietary tomato can reduce CRPC progression in mice. This work 
requires confirmation and further expansion in order to be considered for translation to humans. 
In total, this dissertation has contributed novel findings to our understanding of carotenoid 
metabolism and bioactivity in vivo.  
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Appendix A 
Supplemental tables and figures for Ch. 2 
 
Figure A.1. Designs of Studies 1, 2, and 3. 
 
A. Study 1. 
 
 
B. Study 2. 
 
 
C. Study 3. 
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Figure A.2. 
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Figure A.2. Body weights and testes, prostate, and seminal vesicle weight as percent of total 
body weight (%BW). Study 2 prostate (A) and seminal vesicle %BW (B). Study 2 testes %BW 
(C) and total BW (D). Data are presented as mean group %BW relative to the mean %BW of the 
control group, ± SEM. n = 14 - 18; ***p < 0.001. Prostate (E) and seminal vesicle (F) data from 
Study #3 were similar, as were testes and total body weight (data not shown) 
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Figure A.3. 
 
A           B  
       
 
 
C           D 
      
 
 
Figure A.3. Serum testosterone, but not serum estradiol, is reduced by Bco1 loss. Data are 
presented as means ± SEM; n = 10 - 15. ***p < 0.001. Data are from Study 1 (C, D), Study 2 
(A), and Study 3 (B). 
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Figure A.4. 
A           B 
           
 
C           D 
               
 
E           F 
               
 
Figure A.4. Bco1 loss alters expression of testicular steroidogenic genes. A significant genotype-
diet interaction decreased HMG-CoA reductase protein expression in lycopene-fed WT mice, but 
elevated expression in lycopene-fed Bco1-/- mice (B). A similar, but non-significant, trend is 
observed with tomato feeding (A). Gene expression of Star is up-regulated by Bco1 loss, but 
down-regulated by TP diet (C, D). Bco1, loss, but not tomato or lycopene feeding, reduced 
Hsd17b3 mRNA expression (E, F). Data are presented as means ± SEM, *p < 0.05, **p < 0.01, 
***p < 0.001. All data are from Study 1.  
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Figure A.5. 
A           B 
           
C           D 
           
E           F 
             
 
Figure A.5. Bco1 loss does not alter testicular total cholesterol (A, B) or free cholesterol (C, D), 
but has inconsistent effects on levels of esterified cholesterol (E, F). 
  
0.00#
1.00#
2.00#
3.00#
4.00#
WT# BCMO1.KO#
m
g/
g#
CON#
TP#
0.00#
1.00#
2.00#
3.00#
4.00#
WT# BCMO1.KO#
m
g/
g#
CON+P#
LYC#
0.00#
1.00#
2.00#
3.00#
4.00#
WT# BCMO1.KO#
m
g/
g#
CON#
TP#
0.00#
1.00#
2.00#
3.00#
4.00#
WT# BCMO1.KO#
m
g/
g#
CON+P#
LYC#
0.00#
0.10#
0.20#
0.30#
0.40#
WT# BCMO1.KO#
m
g/
g#
CON#
TP#
0.00#
0.10#
0.20#
0.30#
0.40#
WT# BCMO1.KO#
m
g/
g#
CON+P#
LYC######*#
 214 
Figure A.6. 
A           B 
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Figure A.6. Bco1 loss does not alter testicular mRNA expression of  the cholesterol esterases 
Soat1 (A, B) or Soat2 (C, D), but has inconsistent effects on expression of Lcat (E, F). 
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Figure A.7. 
A            B 
           
 
Figure A.7. AR mRNA expression is unchanged in Bco1-/- mice (A, B). Data are presented as 
means ± SEM; n = 11 - 14 (A,B). Data in (A, B) are from Study 1. 
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Figure A.8. 
 
 
 
Figure A.8. Gene expression of Msmb, Igfbp3, and Vim in the prostates of mice from Study 1, n 
= 7 - 14 (A). ***p < 0.001. 
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Figure A.9. 
 
 
 
Figure A.9. PCR genotyping confirms Bco1 ablation in several tissues of male Bco1-/- mice. 
Lane 1: DNA ladder; lane 2: tail snip from Bco1-/- breeding dam; lane 3: tail snip from WT 
breeding dam (Jackson Laboratories); lane 4: liver sample from male Bco1-/- study animal; lane 
5: testicle sample from Bco1-/- study animal; lane 6: anterior prostate sample from Bco1-/- study 
animal. WT and Bco1-/- band weights correspond to those reported by Hessel et al (Hessel S et 
al., J Biol Chem. 2007; 282(46):33553-61).  
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Table A.1. Formulation of experimental diets. 
 
 
Study 1 Study 2 Study 3 
Component (g/kg) CON TP 1 CON+P LYC 2 CON+P TP+P 3 LYC 4 CON+P 
Cornstarch 397.5 331.5 397.5 397.5 397.5 331.1 397.5 397.5 
Casein 200.0 187.5 200.0 200.0 200.0 187.5 200.0 200.0 
Maltodextrin 102.0 132.0 102.0 102.0 102.0 102.0 102.0 102.0 
Sucrose 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
Cellulose 50.0 34.0 50.0 50.0 50.0 33.8 50.0 50.0 
Mineral Mix 5 35.0 35.0 35.0 35.0 35.0 35.0 35.0 35.0 
Vitamin Mix 6 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0 
L-Cystine 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 
Choline bitartrate 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Soybean oil 100.0 65.0 100.0 100.0 100.0 95.1 100.0 100.0 
Tomato powder 0.0 100.0 0.0 0.0 0.0 100.0 0.0 0.0 
10% lycopene beadlets 0.0 0.0 0.0 1.0 0.0 0.0 1.2 0.0 
Placebo beadlets 0.0 0.0 1.0 0.0 1.2 1.2 0.0 1.2 
Energy density (kcal/g) 7 4.11 3.98 4.11 4.11 4.11 4.13 4.11 4.11 
 
1 As measured by HPLC-PDA, Study 1 TP diet contained 204 nmol lycopene/g diet, 10.1 nmol phytoene/g diet, 2.6 nmol 
phytofluene/g diet, and 0.8 nmol β-carotene/g diet. 
2 As measured by HPLC-PDA, Study 1 LYC diet contained 248 nmol lycopene/g diet. 
3 As measured by HPLC-PDA, Study 2 TP+P diet contained 214 nmol lycopene/g diet, 24.6 nmol phytoene/g diet, 14.6 nmol 
phytofluene/g diet, and 1.9 nmol beta-carotene/g diet. 
4 As measured by HPLC-PDA, Study 2 LYC diet contained 185 nmol lycopene/g diet. 
5 AIN-93-MX formulation (Reeves PG et al., J Nutr. 1993; 123:1939-51). 
6 AIN-93-VX formulation (Reeves PG et al., J Nutr. 1993; 123:1939-51), modified to contain reduced levels of vitamin A (1,500 IU 
retinyl palmitate/g diet). 
7 Calculated from composition as formulated. 
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Table A.2. Primer sequences (purchased from Integrated DNA Technologies) used for single-gene qPCR. 
 
Star Forward 5’-TTGGGCATACTCAACAACCA-3’ 
Reverse 5’-CCTTGACATTTGGGTTCCAC-3’ 
Ar Forward 5’-TCTTTCAAGGGAGGTTACGC-3’ 
Reverse 5’-AGGACGGGATCTCAAGTGTC-3’ 
Msmb Forward 5’-GTCAATCACCTGCTGTACCAAC-3’ 
Reverse 5’-CTGGGTTCTTCCGATCCAC-3’ 
Igfbp3 Forward 5’-TCCACTCCATGCCAAGATG-3' 
Reverse 5’-CTGTCTCCCGCTTAGACTCG-3’ 
Rpl19 Forward 5’-AAATCGCCAATGCCAACTC-3’ 
Reverse 5’-ACCCTTCCTCTTCCCTATGC-3’ 
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Table A.3. Complete results from NanoString array codeset. 
 
Test	 Gene	symbol	 Accession	#	
Mean	WT	
count	 SD	WT	
Mean	Bco1-/-	
count	 SD	Bco1
-/-	 BCO1
-/-	
vs.	WT	 Raw	p	 Adj	p	 FDR	
1	 Gpx3	 NM_008161	 3,286.62	 944.17	 10,053.72	 3,472.64	 3.06	 <0.0001	 0.0020	 0.0004	
2	 Kras	 NM_021284	 198.07	 22.25	 104.69	 22.23	 -1.89	 <0.0001	 0.0020	 0.0004	
3	 Met	 NM_008591	 361.32	 52.85	 598.01	 83.79	 1.66	 <0.0001	 0.0020	 0.0004	
4	 Tgfb2	 NM_009367	 521.18	 71.24	 328.74	 37.83	 -1.59	 <0.0001	 0.0020	 0.0004	
5	 Vegfa	 NM_001025250	 350.03	 20.25	 526.87	 70.63	 1.51	 <0.0001	 0.0020	 0.0004	
6	 Bco1	 NM_001163028	 9.58	 6.91	 78.70	 16.59	 8.21	 0.0001	 0.0200	 0.0033	
7	 Aurkb	 NM_011496	 37.89	 12.18	 17.27	 7.11	 -2.19	 0.0005	 0.1200	 0.0171	
8	 Prom1	 NM_008935	 2,763.65	 308.31	 1,997.24	 337.06	 -1.38	 0.0006	 0.2000	 0.0250	
9	 Esr2	 NM_010157	 105.51	 34.93	 168.79	 28.32	 1.60	 0.0016	 0.3200	 0.0356	
10	 Ccnb2	 NM_007630	 59.36	 10.83	 29.31	 15.03	 -2.03	 0.0021	 0.4200	 0.0420	
11	 Mki67	 NM_001081117	 125.32	 24.18	 70.72	 30.89	 -1.77	 0.0025	 0.5000	 0.0450	
12	 Pcna	 NM_011045	 1,062.05	 77.57	 938.59	 66.39	 -1.13	 0.0027	 0.5400	 0.0450	
13	 Bax	 NM_007527	 296.56	 27.41	 244.34	 28.51	 -1.21	 0.0030	 0.6000	 0.0462	
14	 Hif1a	 NM_010431	 1,027.56	 62.70	 1,232.14	 193.33	 1.20	 0.0078	 1.0000	 0.1013	
15	 Trp63	 NM_011641	 143.06	 21.81	 187.08	 38.91	 1.31	 0.0079	 1.0000	 0.1013	
 
Table A3. Gene symbols, accession numbers (NCBI), and expression values are provided for the entire NanoString codeset. Data are presented as mean and standard deviation 
(SD) of transcript count. Fold regulation by Bco1-/- genotype  (relative to WT) and raw p-values (via T-test) were calculated with NanoString nSolver Analysis Software. 
Bonferroni’s-corrected p-values (Adj p) and false discovery rates (FDR) were calculated in SAS 9.3 using PROC MULTTEST. Green highlight indicates raw p ≤ 0.005, 
Bonferroni’s-corrected p ≤ 0.05, or FDR ≤ 0.05. Red highlight indicates transcript count values were lower than average negative control values for WT, Bco1-/-, or both 
genotypes. WT n = 9,  Bco1-/- n = 8. 
 
* In this analysis, Bco1 expression was increased 8.21-fold (p=0.0001) in Bco1-/- mice compared to WT mice. When this genetically engineered mouse model was created, 
disruption of Bco1 gene function was achieved through homozygous replacement of exons 2 and 3 of the Bco1 gene (approximately 8.8 kb) with IRES-lacZ and a neomycinR 
cassette (Hessel S et al., J Biol Chem. 2007; 282(46):33553-61). This was confirmed by PCR genotyping (see also Figure A.9). Mice of this strain do not express BCO1 protein 
(Hessel S et al., 2007 J Biol Chem) and they accumulate β-carotene when fed tomato powder (Lindshield BL et al., J Nutr. 2008;138:2367-71), consistent with a lack of BCO1 
cleavage function. However, the Bco1 probe used in this NanoString array targets 100 nt within exons 9 and 10 (see footnote †) – a portion of the gene that was not modified 
during generation of this model. The increased expression detected with this specific Bco1 probe is likely a feedback response to the absence of functional BCO1 protein. Bco1-/- 
genotype of mice in this study was confirmed by PCR (Figure A.9). 
† Sequence of Bco1 probe: 5’ – 
CTTACAACGGGAAGCCATATCGCTACATCTTTGCAGCTGAAGTACAGTGGAGTCCAGTCCCAACCAAGATACTGAAATATGACATTCTCACAAAGTCCTC – 3’ 
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Table A.3, (continued). Complete results from NanoString array codeset. 
 
Test	 Gene	symbol	 Accession	#	
Mean	WT	
count	 SD	WT	
Mean	Bco1-/-	
count	 SD	Bco1
-/-	 BCO1
-/-	
vs.	WT	 Raw	p	 Adj	p	 FDR	
16	 Sod1	 NM_011434	 10,849.24	 1,165.58	 9,312.06	 875.78	 -1.17	 0.0081	 1.0000	 0.1013	
17	 Mcl1	 NM_008562	 1,702.52	 105.75	 1,531.22	 132.00	 -1.11	 0.0146	 1.0000	 0.1568	
18	 Birc5	 NM_009689	 27.62	 7.01	 16.70	 8.49	 -1.65	 0.0154	 1.0000	 0.1568	
19	 Foxm1	 NM_008021	 24.01	 6.72	 13.74	 6.77	 -1.75	 0.0157	 1.0000	 0.1568	
20	 Nkx3-1	 NM_010921	 6,740.67	 1,298.23	 5,031.51	 1,260.41	 -1.34	 0.0165	 1.0000	 0.1568	
21	 Vegfb	 NM_011697	 712.93	 67.58	 623.56	 71.70	 -1.14	 0.0179	 1.0000	 0.1568	
22	 Acpp	 NM_207668	 26.47	 15.73	 93.58	 170.85	 3.54	 0.0181	 1.0000	 0.1568	
23	 Prlr	 NM_011169	 4,372.66	 1,028.15	 5,620.04	 937.36	 1.29	 0.0182	 1.0000	 0.1568	
24	 B2m	 NM_009735	 76,292.03	 11,538.21	 109,993.51	 50,653.70	 1.44	 0.0190	 1.0000	 0.1568	
25	 Igf1r	 NM_010513	 966.03	 171.07	 1,208.09	 233.20	 1.25	 0.0196	 1.0000	 0.1568	
26	 Parp1	 NM_007415	 416.73	 49.95	 371.02	 22.75	 -1.12	 0.0204	 1.0000	 0.1569	
27	 Vdr	 NM_009504	 46.27	 10.22	 55.90	 6.26	 1.21	 0.0232	 1.0000	 0.1719	
28	 Tert	 NM_009354	 22.82	 6.33	 30.45	 6.49	 1.33	 0.0263	 1.0000	 0.1879	
29	 Akt2	 NM_001110208	 146.86	 24.35	 181.12	 38.08	 1.23	 0.0276	 1.0000	 0.1903	
30	 Ccne2	 NM_001037134	 44.91	 7.68	 35.32	 8.86	 -1.27	 0.0291	 1.0000	 0.1940	
31	 Becn1	 NM_019584	 2,208.44	 266.79	 1,965.73	 164.08	 -1.12	 0.0307	 1.0000	 0.1981	
32	 Casp3	 NM_009810	 232.96	 14.35	 216.56	 13.66	 -1.08	 0.0320	 1.0000	 0.1994	
33	 Igfbp5	 NM_010518	 7,878.26	 1,614.37	 9,979.93	 2,028.14	 1.27	 0.0336	 1.0000	 0.1994	
34	 Itgav	 NM_008402	 735.64	 64.19	 672.58	 44.19	 -1.09	 0.0339	 1.0000	 0.1994	
35	 Egfr	 NM_007912	 583.51	 52.85	 503.75	 71.71	 -1.16	 0.0376	 1.0000	 0.2149	
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Table A.3, (continued). Complete results from NanoString array codeset. 
 
Test	 Gene	symbol	 Accession	#	
Mean	WT	
count	 SD	WT	
Mean	Bco1-/-	
count	 SD	Bco1
-/-	 BCO1
-/-	
vs.	WT	 Raw	p	 Adj	p	 FDR	
36	 Selp	 NM_011347	 12.41	 4.54	 7.16	 4.18	 -1.73	 0.0401	 1.0000	 0.2189	
37	 Foxo1	 NM_019739	 174.26	 17.65	 194.42	 17.65	 1.12	 0.0405	 1.0000	 0.2189	
38	 Aurka	 NM_011497	 33.85	 8.19	 22.90	 8.85	 -1.48	 0.0449	 1.0000	 0.2363	
39	 Jun	 NM_010591	 497.89	 90.40	 406.28	 89.29	 -1.23	 0.0484	 1.0000	 0.2430	
40	 Akt1	 NM_009652	 1,741.89	 168.09	 1,581.92	 143.38	 -1.10	 0.0486	 1.0000	 0.2430	
41	 Casp1	 NM_009807	 20.29	 7.16	 13.33	 6.46	 -1.52	 0.0568	 1.0000	 0.2771	
42	 E2f1	 NM_007891	 22.36	 8.36	 13.85	 8.17	 -1.61	 0.0708	 1.0000	 0.3371	
43	 Casp2	 NM_007610	 89.09	 13.53	 101.37	 12.82	 1.14	 0.0758	 1.0000	 0.3433	
44	 Ar	 NM_013476	 545.12	 61.78	 620.38	 104.29	 1.14	 0.0778	 1.0000	 0.3433	
45	 Gpx1	 NM_008160	 2,752.99	 324.80	 2,516.30	 207.88	 -1.09	 0.0791	 1.0000	 0.3433	
46	 Il18	 NM_008360	 128.04	 28.86	 95.87	 38.38	 -1.34	 0.0807	 1.0000	 0.3433	
47	 Cdkn1a	 NM_007669	 89.54	 19.02	 113.24	 35.70	 1.26	 0.0810	 1.0000	 0.3433	
48	 Erg	 NM_133659	 26.83	 8.24	 20.81	 6.00	 -1.29	 0.0824	 1.0000	 0.3433	
49	 Cdc25b	 NM_001111075	 18.53	 8.97	 26.40	 9.75	 1.42	 0.0849	 1.0000	 0.3465	
50	 Mapk1	 NM_011949	 2,509.49	 277.48	 2,286.04	 216.99	 -1.10	 0.0887	 1.0000	 0.3504	
51	 Gstp1	 NM_013541	 2,533.88	 85.04	 2,414.00	 152.79	 -1.05	 0.0915	 1.0000	 0.3504	
52	 Pten	 NM_008960	 1,570.42	 132.12	 1,452.83	 131.07	 -1.08	 0.0923	 1.0000	 0.3504	
53	 Krt5	 NM_027011	 120.56	 48.88	 155.31	 41.82	 1.29	 0.0943	 1.0000	 0.3504	
54	 Slc2a1	 NM_011400	 230.77	 17.26	 275.35	 76.47	 1.19	 0.0946	 1.0000	 0.3504	
55	 Mmp9	 NM_013599	 81.79	 18.70	 61.49	 22.55	 -1.33	 0.0977	 1.0000	 0.3518	
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Table A.3, (continued). Complete results from NanoString array codeset. 
 
 
Test	 Gene	symbol	 Accession	#	
Mean	WT	
count	 SD	WT	
Mean	Bco1-/-	
count	 SD	Bco1
-/-	 BCO1
-/-	
vs.	WT	 Raw	p	 Adj	p	 FDR	
56	 Rb1	 NM_009029	 236.03	 26.69	 257.65	 22.36	 1.09	 0.0985	 1.0000	 0.3518	
57	 Hdac6	 NM_010413	 57.78	 13.14	 70.86	 16.38	 1.23	 0.1026	 1.0000	 0.3600	
58	 Igfbp3	 NM_008343	 202.20	 55.96	 240.78	 43.25	 1.19	 0.1092	 1.0000	 0.3756	
59	 Cdc25c	 NM_009860	 14.18	 3.66	 8.98	 6.16	 -1.58	 0.1108	 1.0000	 0.3756	
60	 Bcl2	 NM_009741	 56.10	 13.77	 69.34	 21.27	 1.24	 0.1201	 1.0000	 0.4003	
61	 Cdh1	 NM_009864	 2,596.86	 327.79	 2,348.31	 327.98	 -1.11	 0.1282	 1.0000	 0.4203	
62	 Csf1	 NM_001113530	 236.72	 33.79	 210.45	 31.51	 -1.12	 0.1351	 1.0000	 0.4358	
63	 Tgfbr2	 NM_009371	 392.58	 59.46	 346.30	 60.73	 -1.13	 0.1409	 1.0000	 0.4469	
64	 Arntl	 NM_007489	 112.23	 23.21	 92.39	 27.96	 -1.21	 0.1430	 1.0000	 0.4469	
65	 Erbb2	 NM_001003817	 296.84	 50.23	 333.43	 51.82	 1.12	 0.1489	 1.0000	 0.4576	
66	 Cyp7b1	 NM_007825	 90.57	 11.36	 100.16	 14.88	 1.11	 0.1510	 1.0000	 0.4576	
67	 Cyp27a1	 NM_024264	 166.85	 30.70	 147.88	 21.55	 -1.13	 0.1574	 1.0000	 0.4699	
68	 Etv1	 NM_007960	 38.62	 10.11	 46.13	 11.13	 1.19	 0.1633	 1.0000	 0.4803	
69	 Srd5a1	 NM_175283	 73.42	 14.96	 63.88	 12.22	 -1.15	 0.1702	 1.0000	 0.4933	
70	 Mtor	 NM_020009	 94.66	 18.83	 84.49	 11.53	 -1.12	 0.1838	 1.0000	 0.5251	
71	 Ptgs2	 NM_011198	 61.41	 338.88	 190.61	 853.04	 3.10	 0.1893	 1.0000	 0.5278	
72	 Hdac2	 NM_008229	 445.67	 23.11	 429.91	 24.32	 -1.04	 0.1900	 1.0000	 0.5278	
73	 Il1a	 NM_010554	 29.97	 9.95	 24.59	 6.51	 -1.22	 0.1935	 1.0000	 0.5301	
74	 Hsp90ab1	 NM_008302	 11,523.73	 1,699.68	 10,512.53	 1,622.53	 -1.10	 0.2106	 1.0000	 0.5692	
75	 Srebf1	 NM_011480	 1,345.05	 217.85	 1,481.86	 238.83	 1.10	 0.2196	 1.0000	 0.5856	
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Table A.3, (continued). Complete results from NanoString array codeset. 
 
Test	 Gene	symbol	 Accession	#	
Mean	WT	
count	 SD	WT	
Mean	Bco1-/-	
count	 SD	Bco1
-/-	 BCO1
-/-	
vs.	WT	 Raw	p	 Adj	p	 FDR	
76	 Pthlh	 NM_008970	 33.44	 8.04	 39.36	 16.24	 1.18	 0.2337	 1.0000	 0.6150	
77	 Dnmt1	 NM_010066	 145.03	 16.56	 155.53	 19.37	 1.07	 0.2421	 1.0000	 0.6249	
78	 Esr1	 NM_007956	 528.14	 92.13	 480.11	 77.04	 -1.10	 0.2437	 1.0000	 0.6249	
79	 Pxn	 NM_133915	 419.93	 35.80	 449.71	 68.42	 1.07	 0.2533	 1.0000	 0.6339	
80	 Syp	 NM_009305	 184.87	 102.79	 130.92	 89.47	 -1.41	 0.2561	 1.0000	 0.6339	
81	 Flt1	 NM_010228	 68.46	 22.45	 77.96	 7.67	 1.14	 0.2572	 1.0000	 0.6339	
82	 Stat5a	 NM_011488	 2,993.95	 566.70	 3,295.51	 573.01	 1.10	 0.2599	 1.0000	 0.6339	
83	 Aldh1a1	 NM_013467	 1,651.30	 483.28	 1,419.00	 436.02	 -1.16	 0.2651	 1.0000	 0.6367	
84	 Bid	 NM_007544	 53.19	 9.98	 63.14	 26.73	 1.19	 0.2685	 1.0000	 0.6367	
85	 Odc1	 NM_013614	 49.02	 11.01	 42.65	 14.03	 -1.15	 0.2718	 1.0000	 0.6367	
86	 Atg5	 NM_053069	 711.92	 74.75	 669.97	 73.28	 -1.06	 0.2738	 1.0000	 0.6367	
87	 Ccna1	 NM_007628	 2.00	 1.54	 3.12	 3.17	 1.56	 0.2867	 1.0000	 0.6503	
88	 Hmgcr	 NM_008255	 261.59	 28.58	 284.67	 50.81	 1.09	 0.2880	 1.0000	 0.6503	
89	 Casp8	 NM_009812	 396.09	 49.89	 372.01	 44.05	 -1.06	 0.2894	 1.0000	 0.6503	
90	 Rxra	 NM_011305	 148.69	 20.98	 161.99	 32.92	 1.09	 0.3047	 1.0000	 0.6771	
91	 Gata2	 NM_008090	 4,385.97	 823.83	 4,851.34	 1,076.70	 1.11	 0.3181	 1.0000	 0.6991	
92	 Ezh2	 NM_007971	 170.12	 19.95	 155.07	 35.42	 -1.10	 0.3253	 1.0000	 0.7052	
93	 Cd44	 NM_009851	 561.05	 93.50	 616.17	 139.91	 1.10	 0.3334	 1.0000	 0.7052	
94	 Igfbp2	 NM_008342	 282.35	 64.79	 250.29	 61.37	 -1.13	 0.3337	 1.0000	 0.7052	
95	 Mapk3	 NM_011952	 2,431.24	 388.68	 2,652.08	 562.51	 1.09	 0.3352	 1.0000	 0.7052	
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Table A.3, (continued). Complete results from NanoString array codeset. 
 
Test	 Gene	symbol	 Accession	#	
Mean	WT	
count	 SD	WT	
Mean	Bco1-/-	
count	 SD	Bco1
-/-	 BCO1
-/-	
vs.	WT	 Raw	p	 Adj	p	 FDR	
96	 Cdk2	 NM_016756	 107.29	 20.99	 98.63	 17.23	 -1.09	 0.3385	 1.0000	 0.7052	
97	 Ep300	 NM_177821	 824.97	 64.43	 798.54	 48.19	 -1.03	 0.3505	 1.0000	 0.7134	
98	 Cdkn1b	 NM_009875	 1,799.30	 119.59	 1,725.71	 184.90	 -1.04	 0.3551	 1.0000	 0.7134	
99	 Atg7	 NM_028835	 203.96	 20.23	 196.18	 12.77	 -1.04	 0.3568	 1.0000	 0.7134	
100	 Igf1	 NM_001111274	 161.85	 56.01	 133.91	 58.64	 -1.21	 0.3591	 1.0000	 0.7134	
101	 H6pd	 NM_173371	 403.10	 62.47	 436.96	 95.68	 1.08	 0.3665	 1.0000	 0.7134	
102	 Ccng1	 NM_009831	 1,892.81	 189.56	 1,808.73	 195.34	 -1.05	 0.3702	 1.0000	 0.7134	
103	 Ngfr	 NM_033217	 344.94	 140.06	 244.96	 211.50	 -1.41	 0.3703	 1.0000	 0.7134	
104	 Sirt1	 NM_019812	 336.65	 13.92	 325.91	 27.90	 -1.03	 0.3738	 1.0000	 0.7134	
105	 Ran	 NM_009391	 130.64	 18.20	 139.22	 18.17	 1.07	 0.3773	 1.0000	 0.7134	
106	 Ccnb1	 NM_172301	 2.17	 1.60	 3.20	 4.79	 1.48	 0.3781	 1.0000	 0.7134	
107	 Hsd3b2	 NM_153193	 1.37	 2.48	 1.11	 0.17	 -1.24	 0.3869	 1.0000	 0.7232	
108	 Il6	 NM_031168	 1.09	 0.14	 1.25	 0.83	 1.15	 0.4000	 1.0000	 0.7407	
109	 Cyp24a1	 NM_009996	 11.74	 5.18	 9.51	 4.25	 -1.23	 0.4048	 1.0000	 0.7428	
110	 Cdk4	 NM_009870	 1,016.14	 124.44	 973.93	 89.72	 -1.04	 0.4228	 1.0000	 0.7586	
111	 Gstm1	 NM_010358	 44.16	 9.15	 40.31	 10.03	 -1.10	 0.4233	 1.0000	 0.7586	
112	 Irs1	 NM_010570	 189.41	 54.42	 208.38	 58.76	 1.10	 0.4248	 1.0000	 0.7586	
113	 Ugt1a1	 NM_201645	 9.40	 38.18	 6.43	 3.73	 -1.46	 0.4468	 1.0000	 0.7898	
114	 Cdkn2a	 NM_001040654	 1.74	 1.24	 1.41	 1.14	 -1.23	 0.4502	 1.0000	 0.7898	
115	 Notch1	 NM_008714	 589.51	 77.13	 614.97	 69.22	 1.04	 0.4566	 1.0000	 0.7941	
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Table A.3, (continued). Complete results from NanoString array codeset. 
 
Test	 Gene	symbol	 Accession	#	
Mean	WT	
count	 SD	WT	
Mean	Bco1-/-	
count	 SD	Bco1
-/-	 BCO1
-/-	
vs.	WT	 Raw	p	 Adj	p	 FDR	
116	 Vim	 NM_011701	 1,000.75	 264.77	 914.77	 156.16	 -1.09	 0.4633	 1.0000	 0.7988	
117	 Smad3	 NM_016769	 171.38	 25.32	 179.21	 16.86	 1.05	 0.4787	 1.0000	 0.8127	
118	 Ncoa1	 NM_010881	 392.92	 31.22	 406.63	 46.61	 1.03	 0.4795	 1.0000	 0.8127	
119	 Cav1	 NM_007616	 1,632.79	 209.29	 1,562.95	 205.84	 -1.04	 0.4983	 1.0000	 0.8367	
120	 Gapdh	 NM_008084	 5,763.76	 592.61	 6,073.88	 1,247.30	 1.05	 0.5027	 1.0000	 0.8367	
121	 Wnt1	 NM_021279	 6.64	 4.89	 5.16	 2.72	 -1.29	 0.5062	 1.0000	 0.8367	
122	 Etv4	 NM_008815	 19.90	 6.00	 21.89	 6.08	 1.10	 0.5157	 1.0000	 0.8454	
123	 Tgfb1i1	 NM_009365	 93.51	 12.93	 99.62	 25.08	 1.07	 0.5297	 1.0000	 0.8561	
124	 Mdk	 NM_001012335	 42.01	 21.69	 46.95	 13.66	 1.12	 0.5308	 1.0000	 0.8561	
125	 Myc	 NM_001177352	 174.22	 24.35	 184.61	 42.96	 1.06	 0.5456	 1.0000	 0.8730	
126	 Cdh2	 NM_007664	 68.32	 43.83	 49.10	 45.24	 -1.39	 0.5598	 1.0000	 0.8886	
127	 Kit	 NM_001122733	 19.13	 11.30	 22.35	 15.15	 1.17	 0.5661	 1.0000	 0.8904	
128	 Ccnd1	 NM_007631	 766.60	 434.61	 916.16	 1,022.09	 1.20	 0.5703	 1.0000	 0.8904	
129	 Bmp6	 NM_007556	 30.75	 9.19	 27.78	 10.75	 -1.11	 0.5779	 1.0000	 0.8904	
130	 Hgf	 NM_010427	 53.36	 5.56	 55.53	 9.67	 1.04	 0.5822	 1.0000	 0.8904	
131	 Plaur	 NM_011113	 26.98	 9.92	 30.97	 25.14	 1.15	 0.5912	 1.0000	 0.8904	
132	 Shh	 NM_009170	 86.94	 43.69	 77.84	 50.91	 -1.12	 0.5920	 1.0000	 0.8904	
133	 Mmp2	 NM_008610	 199.68	 57.20	 184.23	 55.51	 -1.08	 0.5921	 1.0000	 0.8904	
134	 Egf	 NM_010113	 8,259.22	 1,545.95	 7,872.64	 1,388.03	 -1.05	 0.6016	 1.0000	 0.8930	
135	 Sele	 NM_011345	 14.29	 5.47	 12.70	 7.19	 -1.12	 0.6028	 1.0000	 0.8930	
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Table A.3, (continued). Complete results from NanoString array codeset. 
 
Test	 Gene	symbol	 Accession	#	
Mean	WT	
count	 SD	WT	
Mean	Bco1-/-	
count	 SD	Bco1
-/-	 BCO1
-/-	
vs.	WT	 Raw	p	 Adj	p	 FDR	
136	 Stat3	 NM_011486	 191.38	 24.57	 197.66	 27.05	 1.03	 0.6113	 1.0000	 0.8985	
137	 Hdac4	 NM_207225	 100.02	 12.71	 96.94	 11.75	 -1.03	 0.6155	 1.0000	 0.8985	
138	 Hoxb13	 NM_008267	 1,618.69	 407.62	 1,522.96	 471.01	 -1.06	 0.6330	 1.0000	 0.9145	
139	 Atm	 NM_007499	 129.25	 11.31	 133.70	 24.28	 1.03	 0.6356	 1.0000	 0.9145	
140	 Cyp19a1	 NM_007810	 1.61	 2.03	 1.88	 1.84	 1.17	 0.6551	 1.0000	 0.9321	
141	 Pbsn	 NM_017471	 166,923.14	 32,045.77	 159,204.27	 37,507.88	 -1.05	 0.6571	 1.0000	 0.9321	
142	 Bad	 NM_007522	 120.13	 12.96	 117.10	 14.87	 -1.03	 0.6658	 1.0000	 0.9377	
143	 Ncor1	 NM_011308	 608.83	 44.85	 620.39	 65.94	 1.02	 0.6740	 1.0000	 0.9406	
144	 Cyp2r1	 NM_177382	 28.56	 7.81	 27.19	 6.04	 -1.05	 0.6783	 1.0000	 0.9406	
145	 Pou5f1	 NM_013633	 1.13	 0.15	 1.22	 1.17	 1.08	 0.6819	 1.0000	 0.9406	
146	 Tgfb1	 NM_011577	 118.27	 20.19	 114.23	 23.37	 -1.04	 0.7120	 1.0000	 0.9420	
147	 Rbp1	 NM_011254	 25.51	 5.48	 26.52	 5.61	 1.04	 0.7132	 1.0000	 0.9420	
148	 Tmprss2	 NM_015775	 2,674.15	 452.17	 2,769.21	 607.11	 1.04	 0.7146	 1.0000	 0.9420	
149	 Krt18	 NM_010664	 4,828.25	 845.28	 4,707.34	 504.30	 -1.03	 0.7158	 1.0000	 0.9420	
150	 Pdha1	 NM_008810	 1,347.06	 88.97	 1,366.52	 125.50	 1.01	 0.7195	 1.0000	 0.9420	
151	 Fgfr1	 NM_001079908	 101.23	 15.83	 104.25	 18.84	 1.03	 0.7276	 1.0000	 0.9420	
152	 Spp1	 NM_009263	 18.20	 19.67	 15.13	 47.80	 -1.20	 0.7362	 1.0000	 0.9420	
153	 Fasn	 NM_007988	 1,046.94	 414.58	 1,109.78	 720.32	 1.06	 0.7453	 1.0000	 0.9420	
154	 Ncoa4	 NM_001033988	 5,277.69	 1,419.30	 5,027.93	 1,873.21	 -1.05	 0.7502	 1.0000	 0.9420	
155	 Casp9	 NM_015733	 121.04	 22.57	 124.35	 21.46	 1.03	 0.7516	 1.0000	 0.9420	
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Table A.3, (continued). Complete results from NanoString array codeset. 
 
Test	 Gene	symbol	 Accession	#	
Mean	WT	
count	 SD	WT	
Mean	Bco1-/-	
count	 SD	Bco1
-/-	 BCO1
-/-	
vs.	WT	 Raw	p	 Adj	p	 FDR	
156	 Bcl2l1	 NM_009743	 567.27	 71.09	 579.28	 82.80	 1.02	 0.7536	 1.0000	 0.9420	
157	 Pdgfra	 NM_001083316	 242.70	 66.32	 253.08	 52.77	 1.04	 0.7569	 1.0000	 0.9420	
158	 Braf	 NM_139294	 396.41	 54.83	 389.83	 26.38	 -1.02	 0.7579	 1.0000	 0.9420	
159	 Foxa1	 NM_008259	 371.64	 100.43	 385.41	 110.22	 1.04	 0.7670	 1.0000	 0.9420	
160	 Ctnnb1	 NM_007614	 2,924.97	 262.29	 2,889.87	 235.62	 -1.01	 0.7737	 1.0000	 0.9420	
161	 Ccl2	 NM_011333	 21.68	 13.83	 20.01	 8.28	 -1.08	 0.7741	 1.0000	 0.9420	
162	 Cflar	 NM_009805	 883.71	 92.13	 870.15	 107.48	 -1.02	 0.7832	 1.0000	 0.9420	
163	 Srd5a2	 NM_053188	 105.63	 21.80	 101.46	 36.12	 -1.04	 0.7832	 1.0000	 0.9420	
164	 Ptgs1	 NM_008969	 1,305.90	 161.02	 1,329.90	 198.13	 1.02	 0.7835	 1.0000	 0.9420	
165	 Rarb	 NM_011243	 41.68	 10.57	 42.83	 7.05	 1.03	 0.7840	 1.0000	 0.9420	
166	 Il6ra	 NM_010559	 148.87	 20.57	 153.00	 39.00	 1.03	 0.7844	 1.0000	 0.9420	
167	 Pparg	 NM_011146	 7.87	 7.24	 8.75	 10.42	 1.11	 0.7866	 1.0000	 0.9420	
168	 Hk1	 NM_001146100	 39.54	 10.80	 40.76	 8.90	 1.03	 0.8019	 1.0000	 0.9546	
169	 Gsk3b	 NM_019827	 1,095.73	 94.55	 1,106.68	 99.65	 1.01	 0.8114	 1.0000	 0.9553	
170	 Trp53	 NM_011640	 93.37	 16.97	 95.26	 17.56	 1.02	 0.8180	 1.0000	 0.9553	
171	 Pdgfrb	 NM_008809	 34.87	 9.50	 35.80	 7.94	 1.03	 0.8249	 1.0000	 0.9553	
172	 Pecam1	 NM_008816	 384.56	 117.54	 372.85	 80.45	 -1.03	 0.8270	 1.0000	 0.9553	
173	 Cdk6	 NM_009873	 50.74	 11.47	 49.20	 17.40	 -1.03	 0.8272	 1.0000	 0.9553	
174	 Fasl	 NM_010177	 1.30	 1.36	 1.25	 0.40	 -1.04	 0.8311	 1.0000	 0.9553	
175	 Bco2	 NM_133217	 22.44	 6.18	 23.02	 6.76	 1.03	 0.8399	 1.0000	 0.9564	
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Table A.3, (continued). Complete results from NanoString array codeset. 
 
Test	 Gene	symbol	 Accession	#	
Mean	WT	
count	 SD	WT	
Mean	Bco1-/-	
count	 SD	Bco1
-/-	 BCO1
-/-	
vs.	WT	 Raw	p	 Adj	p	 FDR	
176	 Alox5	 NM_009662	 19.68	 8.85	 20.44	 5.72	 1.04	 0.8416	 1.0000	 0.9564	
177	 Brca1	 NM_009764	 39.11	 11.11	 40.15	 10.52	 1.03	 0.8509	 1.0000	 0.9566	
178	 Brca2	 NM_009765	 24.88	 6.89	 25.49	 6.38	 1.02	 0.8514	 1.0000	 0.9566	
179	 Ccnd2	 NM_009829	 383.79	 63.24	 388.23	 46.14	 1.01	 0.8712	 1.0000	 0.9658	
180	 Spdef	 NM_013891	 558.00	 97.71	 551.53	 88.92	 -1.01	 0.8827	 1.0000	 0.9658	
181	 Cd34	 NM_001111059	 646.89	 271.67	 668.16	 199.63	 1.03	 0.8833	 1.0000	 0.9658	
182	 Insr	 NM_010568	 327.95	 38.02	 325.57	 32.23	 -1.01	 0.8913	 1.0000	 0.9658	
183	 Smad4	 NM_008540	 1,157.48	 145.75	 1,166.31	 121.27	 1.01	 0.8977	 1.0000	 0.9658	
184	 Ncoa2	 NM_008678	 307.03	 26.62	 305.61	 19.84	 -1.00	 0.9014	 1.0000	 0.9658	
185	 Gadd45a	 NM_007836	 300.72	 38.78	 303.48	 52.80	 1.01	 0.9059	 1.0000	 0.9658	
186	 Egr1	 NM_007913	 211.05	 72.66	 204.09	 325.85	 -1.03	 0.9085	 1.0000	 0.9658	
187	 Sod2	 NM_013671	 640.52	 36.72	 642.62	 40.36	 1.00	 0.9088	 1.0000	 0.9658	
188	 Hsd3b1	 NM_008293	 3.40	 2.84	 3.29	 1.14	 -1.03	 0.9168	 1.0000	 0.9658	
189	 Tnf	 NM_013693	 2.32	 3.03	 2.23	 2.46	 -1.04	 0.9231	 1.0000	 0.9658	
190	 Fgf2	 NM_008006	 126.27	 29.44	 125.09	 17.22	 -1.01	 0.9249	 1.0000	 0.9658	
191	 Hdac1	 NM_008228	 694.56	 71.43	 697.77	 63.52	 1.00	 0.9253	 1.0000	 0.9658	
192	 Ncoa3	 NM_008679	 600.69	 32.69	 602.93	 64.10	 1.00	 0.9307	 1.0000	 0.9658	
193	 Prkab1	 NM_031869	 897.84	 128.70	 892.63	 120.85	 -1.01	 0.9320	 1.0000	 0.9658	
194	 Hdac3	 NM_010411	 745.48	 89.32	 741.95	 97.54	 -1.00	 0.9390	 1.0000	 0.9680	
195	 Gja1	 NM_010288	 158.86	 31.06	 158.05	 43.50	 -1.01	 0.9646	 1.0000	 0.9893	
196	 Actb	 NM_007393	 21,207.69	 1,435.81	 21,177.38	 1,984.89	 -1.00	 0.9728	 1.0000	 0.9902	
197	 Acaca	 NM_133360	 512.75	 110.44	 514.72	 201.48	 1.00	 0.9753	 1.0000	 0.9902	
198	 Ly6a	 NM_010738	 718.57	 313.22	 716.24	 276.32	 -1.00	 0.9884	 1.0000	 0.9916	
199	 Nfkb1	 NM_008689	 501.33	 63.93	 500.95	 57.02	 -1.00	 0.9897	 1.0000	 0.9916	
200	 Cdk1	 NM_007659	 14.57	 6.97	 14.53	 6.07	 -1.00	 0.9916	 1.0000	 0.9916	
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Supplemental tables and figures for Ch. 3 
 
Figure B.1. 
 
 
Figure B.1. Heart weight as a percent of body weight in mice fed a semi-purified, vitamin A-
sufficient, carotenoid-free diet (Study #2). WT heart tissues were not collected at ages <9 or 9 
weeks of age. No statistical differences were observed.  
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Figure B.2. 
 
 
 
Figure B.2. Serum cholesterol in mice fed vitamin A-sufficient, carotenoid-free semi-
purified diets. G*A and A indicate statistical main effect of age or an interaction between 
genotype and age. Different lowercase letters above groups indicate significant (p < 0.05) 
results of mean separations tests for interaction effect.  
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Table B.1. 
 
 
 
Table B.1. Loss of Bco1 interacts with age to modulate total hepatic vitamin A stores, but does not alter the relative abundance of 
hepatic retinol/retinyl esters. Data are mean nmol/g ± SEM. The percent of the total vitamin A pool (retinol plus all quantified retinyl 
esters) within each genotype-age combination is denoted by % total. Group n = 4 - 6, except for ret. pent., which was detected in only 
one 9-week old Bco1-/- mouse. All data were log transformed and analyzed with individual group variances, due to heterogeneity of 
variance. Repeated-measure ANOVA p-values for main effects of genotype and age, and the interaction between genotype and age 
(G*A), are shown at the bottom of the table. Means in each column with different letters are significantly different using post hoc 
Tukey-Kramer adjustment for multiple comparisons. Ret. Pal., retinyl palmitate; Ret. Lau., retinyl laurate; Ret. Lin/Po., retinyl 
linoleate/retinyl palmitoleate co-eluted peaks; Ret. Myr., retinyl myristate; Ret. Pent., retinyl pentadecanoate; Ret. O., retinyl oleate; 
Ret. Hept., retinyl heptadecanoate; Ret. S., retinyl stearate; Total VitA, sum of retinol + all quantified retinyl esters. nd, not detected. 
Retinol Ret. Pal Ret. Lau. Ret. Lin/Po. Ret. Myr. Ret. Pent. Ret. O. Ret. Hept. Ret. S. Total VitA
nmol/g 4.62%±%0.82%b 326.5%±%30.90%c nd 11.50%±%1.36%c 1.72%±%0.22%c 1.35%±%0.12%bc 10.29%±%1.33%b 3.68%±%0.33%c 22.70%±%2.35%c 382.4%±%36.96%c
% total 1.2% 85.4% 0.0% 3.0% 0.5% 0.4% 2.7% 1.0% 5.9% 100.0%
nmol/g 2.36%±%0.77%ab 146.3%±%18.72%b nd 4.44%±%0.57%b 0.78%±%0.13%ab 0.32%±%0.04%a 3.42%±%0.50%a 0.93%±%0.12%a 9.97%±%1.68%b 168.5%±%21.55%b
% total 1.4% 86.8% 0.0% 2.6% 0.5% 0.2% 2.0% 0.6% 5.9% 100.0%
nmol/g 2.28%±%0.22%ab 662.8%±%46.66%d nd 20.06%±%1.55%d 3.52%±%0.29%d 3.65%±%0.28%d 18.33%±%1.23%c 8.67%±%0.59%be 40.04%±%2.15%d 759.4%±%52.79%d
% total 0.3% 87.3% 0.0% 2.6% 0.5% 0.5% 2.4% 1.1% 5.3% 100.0%
nmol/g nd 25.50%±%15.26%a nd 0.94%±%0.53%a 0.19%±%0.10%a 0.19 0.84%±%0.39%a 1.68%±%1.10%abcd 1.87%±%0.87%a 29.82%±%17.17%a
% total 0.0% 85.5% 0.0% 3.1% 0.6% 0.6% 2.8% 5.6% 6.3% 100.0%
nmol/g 24.84%±%4.37%c 696.0%±%137.68%cde nd 24.04%±%6.74%cde 3.89%±%1.06%cd 2.39%±%0.56%bcd 22.28%±%7.13%bc 5.24%±%1.12%bc 39.57%±%8.39%cd 818.3%±%162.7%cde
% total 3.0% 85.1% 0.0% 2.9% 0.5% 0.3% 2.7% 0.6% 4.8% 100.0%
nmol/g 42.83%±%13.44%c 1,495.3%±%264.9%ef nd 47.47%±%8.17%ef 7.76%±%2.02%def 3.21%±%0.85%cde 34.94%±%5.36%cd 7.95%±%1.82%ce 76.90%±%12.89%de 1,724.7%±%297.4%ef
% total 2.5% 86.7% 0.0% 2.8% 0.4% 0.2% 2.0% 0.5% 4.5% 100.0%
nmol/g 2.19%±%0.15%ab 375.8%±%37.20%c nd 12.15%±%1.21%c 1.62%±%0.03%c 1.35%±%0.01%c 11.39%±%1.01%b 5.11%±%1.27%ce 22.05%±%2.63%c 430.48%±%43.48%c
% total 0.5% 87.3% 0.0% 2.8% 0.4% 0.3% 2.6% 1.2% 5.1% 100.0%
nmol/g 2.60%±%0.38%ab 2,486.1%±%281.0%f nd 93.52%±%9.03%g 17.23%±%1.98%f 7.34%±%1.12%e 75.44%±%8.87%e 23.35%±%5.00%d 173.0%±%22.59%f 2,878.5%±%323.2%f
% total 0.1% 86.4% 0.0% 3.2% 0.6% 0.3% 2.6% 0.8% 6.0% 100.0%
nmol/g 1.63%±%0.23%a 347.0%±%32.17%c nd 11.09%±%0.74%c 1.14%±%0.13%bc 0.90%±%0.08%b 11.15%±%0.78%b 3.27%±%0.62%c 19.78%±%2.12%c 395.13%±%34.25%c
% total 0.4% 87.8% 0.0% 2.8% 0.3% 0.2% 2.8% 0.8% 5.0% 100.0%
nmol/g 16.90%±%12.52%abc 1,953.1%±%88.00%f nd 61.64%±%6.10%fg 9.89%±%0.49%e 4.27%±%0.38%de 59.11%±%6.25%de 13.45%±%1.41%de 106.7%±%9.38%ef 2,225.1%±%111.1%f
% total 0.8% 87.8% 0.0% 2.8% 0.4% 0.2% 2.7% 0.6% 4.8% 100.0%
Genotype 0.0786 0.6565 = 0.9732 0.0905 0.1841 0.4329 0.6226 0.9831 0.6606
Age <0.0001 <0.0001 = <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
G*A 0.0062 <0.0001 = <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
<9 weeks
9 weeks
31 weeks
Bco1-/-
WT
Bco1-/-
WT
Bco1-/-
51 weeks
71 weeks
WT
Bco1-/-
WT
Bco1-/-
ANOVA+p-values
WT
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Table B.2. 
 
 
Table B.2. Pearson correlation coefficients (R2) and p-values for endpoints measured in livers of chow-fed WT and Bco1-/- mice. 
Correlations were calculated using values from both genotypes; n = 8 - 16. R2 values > 0.8 are highlighted in red, while R2 values       
<-0.8 are highlighted in blue. P-values < 0.05 are highlighted in green. BrainWt, brain weight; TotVA, total retinyl esters + retinol; 
RetPal, retinyl palmitate; RetS, retinyl stearate; FrRol, free retinol; CEPal, cholesteryl palmitate; PLPal, phospholipid palmitate; PLS, 
phospholipid stearate; FFAPal, free palmitate; Acox3, Apoa4, Cpt1b, Fabp5, Gapdh, Hsp90ab1, Mlycd, Pck1, Ppard, Pparg, Pprc1, 
Rxra, Rxrb, Slc22a5, Slc27a1, Slc27a4, Sorl1: gene names.  
Pearson Correlation Coefficients
BrainWt TotVA RetPal RetS FrRol CEPal PLPal PLS FFAPal Acox3 Apoa4 Cpt1b Fabp5 Gapdh Hsp90ab1 Mlycd Pck1 Ppard Pparg Pprc1 Rxra Rxrb Slc22a5 Slc27a1 Slc27a4 Sorl1
-0.75
0.012
-0.68 0.96
0.031 <.0001
-0.56 0.91 0.97
0.090 0.000 <.0001
-0.36 0.23 -0.05 -0.16
0.313 0.528 0.886 0.657
-0.76 0.86 0.86 0.82 -0.35
0.003 0.006 0.006 0.012 0.396
0.30 -0.84 -0.84 -0.81 0.64 -0.23
0.339 0.019 0.017 0.028 0.125 0.479
-0.36 0.55 0.56 0.52 -0.43 0.56 -0.70
0.256 0.201 0.191 0.232 0.330 0.059 0.011
-0.53 0.71 0.73 0.69 -0.75 0.72 -0.59 0.76
0.078 0.048 0.040 0.060 0.031 0.009 0.056 0.007
-0.70 0.82 0.83 0.79 -0.11 0.88 -0.24 0.70 0.51
0.017 0.023 0.022 0.035 0.815 0.002 0.575 0.054 0.161
0.71 -0.85 -0.84 -0.85 0.11 -0.91 0.02 -0.61 -0.55 -0.91
0.014 0.016 0.018 0.017 0.810 0.001 0.965 0.109 0.124 <.0001
-0.73 0.71 0.73 0.64 -0.26 0.70 -0.12 0.25 0.37 0.59 -0.59
0.010 0.073 0.065 0.124 0.568 0.035 0.786 0.553 0.322 0.058 0.058
0.85 -0.76 -0.74 -0.73 -0.24 -0.77 -0.19 -0.33 -0.32 -0.63 0.76 -0.74
0.001 0.049 0.055 0.061 0.608 0.014 0.652 0.420 0.406 0.038 0.007 0.009
-0.74 0.66 0.67 0.60 -0.07 0.88 -0.11 0.56 0.63 0.75 -0.82 0.75 -0.73
0.010 0.110 0.102 0.152 0.877 0.002 0.804 0.147 0.068 0.007 0.002 0.008 0.011
-0.54 0.78 0.79 0.77 -0.71 0.81 -0.20 0.59 0.62 0.76 -0.83 0.64 -0.56 0.66
0.088 0.039 0.035 0.042 0.072 0.008 0.639 0.126 0.075 0.006 0.001 0.032 0.073 0.029
-0.68 0.61 0.63 0.51 -0.34 0.81 -0.07 0.39 0.47 0.74 -0.68 0.89 -0.58 0.82 0.68
0.022 0.149 0.129 0.238 0.459 0.008 0.870 0.335 0.200 0.010 0.022 0.000 0.064 0.002 0.020
-0.72 0.71 0.72 0.65 -0.25 0.76 -0.12 0.33 0.52 0.64 -0.65 0.91 -0.67 0.88 0.61 0.93
0.012 0.075 0.067 0.113 0.593 0.018 0.778 0.428 0.153 0.034 0.030 <.0001 0.024 0.000 0.045 <.0001
-0.26 0.48 0.48 0.46 -0.18 0.41 -0.08 0.29 0.08 0.52 -0.55 0.50 -0.54 0.43 0.59 0.34 0.31
0.432 0.277 0.276 0.295 0.706 0.270 0.853 0.480 0.841 0.099 0.083 0.116 0.084 0.188 0.055 0.306 0.346
-0.72 0.76 0.76 0.71 0.00 0.69 -0.16 0.27 0.35 0.66 -0.63 0.87 -0.77 0.76 0.46 0.79 0.88 0.44
0.012 0.049 0.048 0.072 0.997 0.040 0.703 0.511 0.353 0.026 0.037 0.001 0.006 0.006 0.151 0.004 0.000 0.180
-0.85 0.86 0.86 0.85 -0.21 0.77 -0.03 0.31 0.55 0.64 -0.72 0.78 -0.71 0.78 0.68 0.81 0.87 0.12 0.72
0.001 0.013 0.013 0.016 0.654 0.015 0.952 0.448 0.129 0.034 0.012 0.005 0.013 0.005 0.022 0.002 0.000 0.735 0.013
-0.65 0.72 0.73 0.70 -0.36 0.75 -0.08 0.37 0.48 0.76 -0.72 0.77 -0.52 0.81 0.68 0.93 0.92 0.25 0.76 0.86
0.030 0.067 0.062 0.080 0.431 0.019 0.848 0.371 0.187 0.007 0.013 0.006 0.099 0.002 0.020 <.0001 <.0001 0.451 0.006 0.001
-0.55 0.91 0.91 0.87 -0.41 0.74 -0.08 0.38 0.36 0.84 -0.76 0.76 -0.61 0.65 0.72 0.84 0.75 0.53 0.81 0.65 0.81
0.078 0.005 0.004 0.012 0.363 0.023 0.852 0.349 0.346 0.001 0.006 0.006 0.048 0.031 0.013 0.001 0.008 0.096 0.003 0.031 0.002
-0.74 0.63 0.65 0.55 -0.16 0.73 -0.22 0.34 0.44 0.63 -0.56 0.95 -0.64 0.81 0.53 0.93 0.96 0.35 0.90 0.79 0.85 0.75
0.010 0.130 0.116 0.203 0.731 0.026 0.600 0.414 0.236 0.038 0.075 <.0001 0.033 0.003 0.091 <.0001 <.0001 0.298 0.000 0.004 0.001 0.008
-0.79 0.69 0.70 0.64 0.02 0.81 -0.17 0.43 0.52 0.74 -0.71 0.81 -0.65 0.90 0.55 0.89 0.95 0.26 0.87 0.85 0.91 0.72 0.92
0.004 0.086 0.082 0.124 0.965 0.008 0.695 0.293 0.155 0.009 0.014 0.003 0.029 0.000 0.080 0.000 <.0001 0.444 0.000 0.001 <.0001 0.013 <.0001
-0.66 0.95 0.96 0.92 -0.55 0.82 -0.15 0.50 0.48 0.90 -0.83 0.77 -0.63 0.74 0.83 0.89 0.80 0.51 0.75 0.76 0.90 0.94 0.77 0.78
0.028 0.001 0.001 0.004 0.198 0.006 0.730 0.203 0.195 0.000 0.002 0.005 0.039 0.009 0.002 0.000 0.003 0.109 0.008 0.006 0.000 <.0001 0.005 0.005
0.71 -0.86 -0.86 -0.84 0.25 -0.88 0.34 -0.74 -0.55 -0.97 0.89 -0.60 0.66 -0.71 -0.82 -0.69 -0.62 -0.59 -0.64 -0.64 -0.72 -0.80 -0.61 -0.69 -0.90
0.015 0.014 0.014 0.017 0.589 0.002 0.408 0.038 0.125 <.0001 0.000 0.050 0.027 0.014 0.002 0.019 0.043 0.057 0.034 0.033 0.013 0.003 0.047 0.020 0.000Sorl1
Pprc1
Rxra
Rxrb
Slc22a5
Slc27a1
Slc27a4
Gapdh
Hsp90ab1
Mlycd
Pck1
Ppard
Pparg
FFAPal
Acox3
Apoa4
Cpt1b
Fabp5
RetS
FrRol
CEPal
PLPal
PLS
BrainWt
TotVA
RetPal
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Table B.3. Hepatic expression of lipid metabolism- and cholesterol metabolism-related genes. 
 
Test	 Array	 Refseq	 Gene	 Fold	Regulation	 Raw	p	 Adj	p	 FDR	
1	 LipoproChol	 NM_007468	 Apoa4	 -3.54	 0.0000	 0.0067	 0.0047	
2	 LipoproChol	 NM_011436	 Sorl1	 -3.92	 0.0001	 0.0095	 0.0047	
3	 PPAR	 NM_030721	 Acox3	 1.83	 0.0003	 0.0502	 0.0167	
4	 PPAR	 NM_013599	 Mmp9	 2.53	 0.0005	 0.0778	 0.0195	
5	 Both	 NM_008302	 Hsp90ab1	 1.28	 0.0017	 0.2721	 0.0459	
6	 PPAR	 NM_010634	 Fabp5	 -2.85	 0.0017	 0.2754	 0.0459	
7	 Both	 NM_008084	 Gapdh	 1.30	 0.0020	 0.3267	 0.0467	
8	 PPAR	 NM_011989	 Slc27a4	 1.61	 0.0029	 0.4648	 0.0581	
9	 PPAR	 NM_009271	 Src	 1.84	 0.0047	 0.7741	 0.0860	
10	 PPAR	 NM_025891	 Smarcd3	 1.89	 0.0071	 1.0000	 0.1152	
11	 PPAR	 NM_011977	 Slc27a1	 2.67	 0.0095	 1.0000	 0.1413	
12	 PPAR	 NM_001081214	 Pprc1	 2.33	 0.0105	 1.0000	 0.1429	
13	 PPAR	 NM_011306	 Rxrb	 1.91	 0.0120	 1.0000	 0.1472	
14	 PPAR	 NM_011146	 Pparg	 2.32	 0.0126	 1.0000	 0.1472	
15	 PPAR	 NM_011044	 Pck1	 1.72	 0.0177	 1.0000	 0.1853	
16	 PPAR	 NM_009948	 Cpt1b	 2.09	 0.0182	 1.0000	 0.1853	
17	 PPAR	 NM_024264	 Cyp27a1	 1.40	 0.0209	 1.0000	 0.1907	
18	 PPAR	 NM_080434	 Apoa5	 1.77	 0.0211	 1.0000	 0.1907	
19	 PPAR	 NM_011305	 Rxra	 1.48	 0.0233	 1.0000	 0.1995	
20	 PPAR	 NM_019966	 Mlycd	 1.56	 0.0270	 1.0000	 0.2200	
21	 PPAR	 NM_011396	 Slc22a5	 1.98	 0.0287	 1.0000	 0.2225	
22	 PPAR	 NM_007980	 Fabp2	 1.47	 0.0352	 1.0000	 0.2609	
23	 Both	 NM_011145	 Ppard	 1.45	 0.0443	 1.0000	 0.3141	
24	 PPAR	 NM_010174	 Fabp3	 1.59	 0.0641	 1.0000	 0.4351	
25	 LipoproChol	 NM_013703	 Vldlr	 2.08	 0.0819	 1.0000	 0.5343	
 
Table B.3. Bco1-/- genotype alters hepatic expression of genes involved in lipid and cholesterol 
metabolism. Gene expression was assayed using qPCR arrays focused on PPAR signaling 
(PPAR) and lipoprotein and cholesterol metabolism (LipoproChol); several genes were present 
on both arrays (Both). Results for all genes measured are displayed. Fold regulation values are 
displayed, with fold regulation ≥ 2 in red and ≤ -2 in blue. NCBI RefSeq identifiers are provided 
for each gene. Raw p values, Bonferroni’s adjusted p-values (Adj p), and FDR q-values (FDR) 
are displayed for each gene; Bonferroni’s adjusted p-values and FDR q-values were calculated 
after ranking genes by raw p-value, smallest first. For raw p-values, yellow highlighting indicates 
0.005 < p ≤ 0.05, while green highlighting indicates p ≤ 0.005. For Bonferroni’s adjusted           
p-values and FDR q-values, green highlighting indicates values < 0.05. Several genes did not 
have Ct values above 35 for more than two replicates per group, and so fold regulation 
calculations were either inaccurate (Cela3b, Apod, Adipoq) or not quantifiable (n.q., several). 
Statistical tests were not done for those genes. 
 235 
Table B.3, (continued). Hepatic expression of lipid metabolism- and cholesterol metabolism-
related genes.  
 
Test	 Array	 Refseq	 Gene	 Fold	Regulation	 Raw	p	 Adj	p	 FDR	
26	 LipoproChol	 NM_011850	 Nr0b2	 1.74	 0.0931	 1.0000	 0.5837	
27	 Both	 NM_177470	 Acaa2	 1.23	 0.1055	 1.0000	 0.6358	
28	 PPAR	 NM_019699	 Fads2	 1.38	 0.1113	 1.0000	 0.6358	
29	 PPAR	 NM_024406	 Fabp4	 -1.27	 0.1131	 1.0000	 0.6358	
30	 PPAR	 NM_010011	 Cyp4a10	 3.75	 0.1193	 1.0000	 0.6481	
31	 PPAR	 NM_007925	 Eln	 1.33	 0.1334	 1.0000	 0.6817	
32	 PPAR	 NM_010046	 Dgat1	 1.30	 0.1353	 1.0000	 0.6817	
33	 PPAR	 NM_013839	 Nr1h3	 1.20	 0.1380	 1.0000	 0.6817	
34	 LipoproChol	 NM_011480	 Srebf1	 -1.43	 0.1449	 1.0000	 0.6826	
35	 PPAR	 NM_020581	 Angptl4	 1.46	 0.1466	 1.0000	 0.6826	
36	 LipoproChol	 NM_178082	 Insig2	 1.76	 0.1594	 1.0000	 0.6935	
37	 Both	 NM_023114	 Apoc3	 -1.22	 0.1601	 1.0000	 0.6935	
38	 PPAR	 NM_008679	 Ncoa3	 1.25	 0.1642	 1.0000	 0.6935	
39	 LipoproChol	 NM_020010	 Cyp51	 1.18	 0.1689	 1.0000	 0.6935	
40	 PPAR	 NM_183162	 Helz2	 1.26	 0.1776	 1.0000	 0.6935	
41	 PPAR	 NM_016772	 Ech1	 1.28	 0.1780	 1.0000	 0.6935	
42	 LipoproChol	 NM_007379	 Abca2	 1.15	 0.1805	 1.0000	 0.6935	
43	 PPAR	 NM_013495	 Cpt1a	 1.37	 0.1829	 1.0000	 0.6935	
44	 LipoproChol	 NM_145942	 Hmgcs1	 1.54	 0.2046	 1.0000	 0.7447	
45	 PPAR	 NM_015729	 Acox1	 1.39	 0.2056	 1.0000	 0.7447	
46	 PPAR	 NM_009949	 Cpt2	 1.18	 0.2216	 1.0000	 0.7851	
47	 Both	 NM_009696	 Apoe	 1.11	 0.2272	 1.0000	 0.7877	
48	 LipoproChol	 NM_145364	 Akr1d1	 1.17	 0.2320	 1.0000	 0.7877	
49	 PPAR	 NM_019825	 Ncoa6	 1.29	 0.2597	 1.0000	 0.8472	
50	 PPAR	 NM_011125	 Pltp	 1.52	 0.2599	 1.0000	 0.8472	
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Table B.3, (continued). Hepatic expression of lipid metabolism- and cholesterol metabolism-
related genes.  
 
Test	 Array	 Refseq	 Gene	 Fold	Regulation	 Raw	p	 Adj	p	 FDR	
51	 PPAR	 NM_001025432	 Crebbp	 1.19	 0.2689	 1.0000	 0.8595	
52	 PPAR	 NM_011062	 Pdpk1	 1.25	 0.2830	 1.0000	 0.8736	
53	 PPAR	 NM_133828	 Creb1	 1.18	 0.2896	 1.0000	 0.8736	
54	 LipoproChol	 NM_138656	 Mvd	 1.31	 0.2904	 1.0000	 0.8736	
55	 PPAR	 NM_007381	 Acadl	 1.23	 0.3005	 1.0000	 0.8736	
56	 PPAR	 NM_023737	 Ehhadh	 1.27	 0.3135	 1.0000	 0.8736	
57	 PPAR	 NM_011978	 Slc27a2	 1.27	 0.3151	 1.0000	 0.8736	
58	 LipoproChol	 NM_009885	 Cel	 -34.82	 0.3218	 1.0000	 0.8736	
59	 LipoproChol	 NM_001004157	 Scarf1	 1.21	 0.3222	 1.0000	 0.8736	
60	 Both	 NM_009692	 Apoa1	 -1.18	 0.3260	 1.0000	 0.8736	
61	 LipoproChol	 NM_019707	 Cdh13	 1.28	 0.3269	 1.0000	 0.8736	
62	 PPAR	 NM_177821	 Ep300	 1.21	 0.3479	 1.0000	 0.8926	
63	 PPAR	 NM_007643	 Cd36	 1.61	 0.3486	 1.0000	 0.8926	
64	 PPAR	 NM_008194	 Gk	 1.16	 0.3608	 1.0000	 0.8926	
65	 LipoproChol	 NM_172814	 Lrp12	 -1.14	 0.3630	 1.0000	 0.8926	
66	 Both	 NM_138648	 Olr1	 -1.40	 0.3685	 1.0000	 0.8926	
67	 PPAR	 NM_008904	 Ppargc1a	 -1.29	 0.3730	 1.0000	 0.8926	
68	 LipoproChol	 NM_172622	 Trerf1	 -1.32	 0.3750	 1.0000	 0.8926	
69	 LipoproChol	 NM_009230	 Soat1	 1.26	 0.3875	 1.0000	 0.8926	
70	 LipoproChol	 NM_153565	 Pcsk9	 1.14	 0.4005	 1.0000	 0.8926	
71	 PPAR	 NM_001033606	 Acsl3	 1.20	 0.4035	 1.0000	 0.8926	
72	 LipoproChol	 NM_010719	 Lipe	 -1.13	 0.4038	 1.0000	 0.8926	
73	 PPAR	 NM_008509	 Lpl	 -1.26	 0.4049	 1.0000	 0.8926	
74	 LipoproChol	 NM_130449	 Colec12	 1.14	 0.4118	 1.0000	 0.8926	
75	 PPAR	 NM_017399	 Fabp1	 -1.24	 0.4152	 1.0000	 0.8926	
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Table B.3, (continued). Hepatic expression of lipid metabolism- and cholesterol metabolism-
related genes.  
 
Test	 Array	 Refseq	 Gene	 Fold	Regulation	 Raw	p	 Adj	p	 FDR	
76	 LipoproChol	 NM_007825	 Cyp7b1	 1.24	 0.4162	 1.0000	 0.8926	
77	 PPAR	 NM_054089	 Tgs1	 1.17	 0.4410	 1.0000	 0.9335	
78	 PPAR	 NM_007981	 Acsl1	 -1.14	 0.4519	 1.0000	 0.9443	
79	 LipoproChol	 NM_178143	 Prkaa2	 1.10	 0.4878	 1.0000	 0.9599	
80	 LipoproChol	 NM_033218	 Srebf2	 1.10	 0.4901	 1.0000	 0.9599	
81	 LipoproChol	 NM_001081970	 Apol8	 -1.45	 0.4935	 1.0000	 0.9599	
82	 PPAR	 NM_019477	 Acsl4	 1.13	 0.4949	 1.0000	 0.9599	
83	 LipoproChol	 NM_029787	 Cyb5r3	 -1.09	 0.4966	 1.0000	 0.9599	
84	 LipoproChol	 NM_022993	 Lrp10	 1.08	 0.5065	 1.0000	 0.9599	
85	 LipoproChol	 NM_013913	 Angptl3	 1.11	 0.5090	 1.0000	 0.9599	
86	 LipoproChol	 NM_001001144	 Scap	 -1.15	 0.5093	 1.0000	 0.9599	
87	 PPAR	 NM_028994	 Pck2	 -1.14	 0.5133	 1.0000	 0.9599	
88	 LipoproChol	 NM_013454	 Abca1	 -1.07	 0.5203	 1.0000	 0.9599	
89	 LipoproChol	 NM_009693	 Apob	 1.09	 0.5294	 1.0000	 0.9599	
90	 PPAR	 NM_001081072	 Slc27a6	 1.27	 0.5330	 1.0000	 0.9599	
91	 PPAR	 NM_013634	 Med1	 1.07	 0.5411	 1.0000	 0.9599	
92	 PPAR	 NM_013692	 Klf10	 -1.25	 0.5418	 1.0000	 0.9599	
93	 LipoproChol	 NM_007856	 Dhcr7	 -1.12	 0.5634	 1.0000	 0.9875	
94	 LipoproChol	 NM_018887	 Cyp39a1	 -1.18	 0.5883	 1.0000	 0.9931	
95	 LipoproChol	 NM_021283	 Il4	 1.31	 0.5908	 1.0000	 0.9931	
96	 LipoproChol	 NM_010191	 Fdft1	 1.08	 0.5973	 1.0000	 0.9931	
97	 LipoproChol	 NM_019709	 Mbtps1	 1.08	 0.5999	 1.0000	 0.9931	
98	 Both	 NM_008256	 Hmgcs2	 1.08	 0.6029	 1.0000	 0.9931	
99	 LipoproChol	 NM_001013367	 Prkaa1	 1.06	 0.6077	 1.0000	 0.9931	
100	 PPAR	 NM_177224	 Chd9	 1.08	 0.6093	 1.0000	 0.9931	
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Table B.3, (continued). Hepatic expression of lipid metabolism- and cholesterol metabolism-
related genes.  
 
Test	 Array	 Refseq	 Gene	 Fold	Regulation	 Raw	p	 Adj	p	 FDR	
101	 LipoproChol	 NM_134469	 Fdps	 -1.07	 0.6271	 1.0000	 1.0000	
102	 LipoproChol	 NM_013493	 Cnbp	 1.07	 0.6431	 1.0000	 1.0000	
103	 LipoproChol	 NM_207530	 Osbpl1a	 -1.09	 0.6453	 1.0000	 1.0000	
104	 LipoproChol	 NM_026784	 Pmvk	 -1.07	 0.6507	 1.0000	 1.0000	
105	 Both	 NM_010368	 Gusb	 1.04	 0.6590	 1.0000	 1.0000	
106	 LipoproChol	 NM_007768	 Crp	 -1.06	 0.6640	 1.0000	 1.0000	
107	 LipoproChol	 NM_008255	 Hmgcr	 1.11	 0.6687	 1.0000	 1.0000	
108	 LipoproChol	 NM_021547	 Stard3	 1.06	 0.6712	 1.0000	 1.0000	
109	 LipoproChol	 NM_007898	 Ebp	 1.04	 0.6772	 1.0000	 1.0000	
110	 PPAR	 NM_010208	 Fgr	 -1.34	 0.6985	 1.0000	 1.0000	
111	 LipoproChol	 NM_153526	 Insig1	 1.07	 0.6999	 1.0000	 1.0000	
112	 LipoproChol	 NM_146064	 Soat2	 -1.06	 0.7004	 1.0000	 1.0000	
113	 LipoproChol	 NM_153680	 Snx17	 1.06	 0.7037	 1.0000	 1.0000	
114	 LipoproChol	 NM_133997	 Apof	 -1.04	 0.7113	 1.0000	 1.0000	
115	 PPAR	 NM_009512	 Slc27a5	 -1.07	 0.7214	 1.0000	 1.0000	
116	 PPAR	 NM_013492	 Clu	 1.07	 0.7217	 1.0000	 1.0000	
117	 LipoproChol	 NM_023158	 Cxcl16	 -1.06	 0.7259	 1.0000	 1.0000	
118	 PPAR	 NM_010562	 Ilk	 1.05	 0.7417	 1.0000	 1.0000	
119	 LipoproChol	 NM_009108	 Nr1h4	 -1.06	 0.7603	 1.0000	 1.0000	
120	 PPAR	 NM_133249	 Ppargc1b	 -1.10	 0.7637	 1.0000	 1.0000	
121	 PPAR	 NM_019812	 Sirt1	 1.06	 0.7694	 1.0000	 1.0000	
122	 LipoproChol	 NM_010700	 Ldlr	 1.04	 0.7730	 1.0000	 1.0000	
123	 PPAR	 NM_008960	 Pten	 -1.05	 0.7731	 1.0000	 1.0000	
124	 PPAR	 NM_011144	 Ppara	 1.07	 0.7827	 1.0000	 1.0000	
125	 LipoproChol	 NM_145554	 Ldlrap1	 1.03	 0.7896	 1.0000	 1.0000	
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Table B.3, (continued). Hepatic expression of lipid metabolism- and cholesterol metabolism-
related genes.  
 
Test	 Array	 Refseq	 Gene	 Fold	Regulation	 Raw	p	 Adj	p	 FDR	
126	 LipoproChol	 NM_010941	 Nsdhl	 -1.03	 0.7898	 1.0000	 1.0000	
127	 PPAR	 NM_009166	 Sorbs1	 -1.06	 0.8209	 1.0000	 1.0000	
128	 LipoproChol	 NM_024289	 Osbpl5	 1.08	 0.8240	 1.0000	 1.0000	
129	 LipoproChol	 NM_145360	 Idi1	 -1.04	 0.8300	 1.0000	 1.0000	
130	 LipoproChol	 NM_013587	 Lrpap1	 1.02	 0.8485	 1.0000	 1.0000	
131	 LipoproChol	 NM_028454	 Tm7sf2	 1.02	 0.8677	 1.0000	 1.0000	
132	 LipoproChol	 NM_023472	 Ankra2	 -1.03	 0.8697	 1.0000	 1.0000	
133	 PPAR	 NM_009107	 Rxrg	 -1.05	 0.8720	 1.0000	 1.0000	
134	 PPAR	 NM_010477	 Hspd1	 1.02	 0.8769	 1.0000	 1.0000	
135	 LipoproChol	 NM_009593	 Abcg1	 -1.03	 0.8795	 1.0000	 1.0000	
136	 LipoproChol	 NM_013474	 Apoa2	 -1.03	 0.8823	 1.0000	 1.0000	
137	 LipoproChol	 NM_177197	 Idi2	 1.03	 0.8854	 1.0000	 1.0000	
138	 PPAR	 NM_023719	 Txnip	 -1.06	 0.8886	 1.0000	 1.0000	
139	 LipoproChol	 NM_138673	 Stab2	 -1.02	 0.8964	 1.0000	 1.0000	
140	 Both	 NM_007824	 Cyp7a1	 -1.05	 0.9013	 1.0000	 1.0000	
141	 LipoproChol	 NM_133808	 Hdlbp	 -1.01	 0.9072	 1.0000	 1.0000	
142	 LipoproChol	 NM_145401	 Prkag2	 1.03	 0.9182	 1.0000	 1.0000	
143	 LipoproChol	 NM_207242	 Npc1l1	 1.04	 0.9242	 1.0000	 1.0000	
144	 LipoproChol	 NM_008514	 Lrp6	 1.01	 0.9286	 1.0000	 1.0000	
145	 LipoproChol	 NM_008490	 Lcat	 -1.01	 0.9320	 1.0000	 1.0000	
146	 PPAR	 NM_010431	 Hif1a	 1.01	 0.9364	 1.0000	 1.0000	
147	 LipoproChol	 NM_010010	 Cyp46a1	 -1.03	 0.9528	 1.0000	 1.0000	
148	 PPAR	 NM_025794	 Etfdh	 1.01	 0.9579	 1.0000	 1.0000	
149	 LipoproChol	 NM_023556	 Mvk	 1.01	 0.9664	 1.0000	 1.0000	
150	 PPAR	 NM_027976	 Acsl5	 -1.01	 0.9710	 1.0000	 1.0000	
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Table B.3, (continued). Hepatic expression of lipid metabolism- and cholesterol metabolism-
related genes.  
 
Test	 Array	 Refseq	 Gene	 Fold	Regulation	 Raw	p	 Adj	p	 FDR	
151	 PPAR	 NM_009127	 Scd1	 1.01	 0.9780	 1.0000	 1.0000	
152	 PPAR	 NM_007382	 Acadm	 1.00	 0.9859	 1.0000	 1.0000	
153	 LipoproChol	 NM_138672	 Stab1	 1.00	 0.9913	 1.0000	 1.0000	
154	 PPAR	 NM_021272	 Fabp7	 1.00	 0.9935	 1.0000	 1.0000	
155	 LipoproChol	 NM_053272	 Dhcr24	 1.00	 0.9938	 1.0000	 1.0000	
156	 LipoproChol	 NM_026419	 Cela3b	 -10.88	 -	 1.0000	 1.0000	
157	 LipoproChol	 NM_007470	 Apod	 -9.52	 -	 1.0000	 1.0000	
158	 PPAR	 NM_009605	 Adipoq	 3.08	 -	 1.0000	 1.0000	
159	 LipoproChol	 NM_019779	 Cyp11a1	 n.q.	 -	 1.0000	 1.0000	
160	 PPAR	 NM_008375	 Fabp6	 n.q.	 -	 1.0000	 1.0000	
161	 LipoproChol	 NM_008493	 Lep	 n.q.	 -	 1.0000	 1.0000	
162	 LipoproChol	 NM_053011	 Lrp1b	 n.q.	 -	 1.0000	 1.0000	
163	 PPAR	 NM_009463	 Ucp1	 n.q.	 -	 1.0000	 1.0000	
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Appendix C 
Supplemental tables and figures for Ch. 4 
 
 
Figure C.1. 
 
  
 
 
Fig. C.1. Tumor growth curves for individual mice in CON (top left), TP (top right), and TP-I 
(bottom left) groups. Animals TF41, TF45, TF101, and TF86 appear to display divergent “non-
responder” growth behavior compared to other mice in their respective treatment groups.  
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Figure C.2 
 
Figure C.2. Average tumor growth rate curves including (left) and excluding (right) 
“non-responder” tumors putatively identified in Fig. C.1. 
 
0 1 2 3 4 5
0
500
1000
1500
2000
2500
All groups
Week
CON
TP
TP-POST
0 1 2 3 4 5
0
500
1000
1500
2000
2500
All groups
Week
m
m
3
CON
TP
TP-I
